UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 1of 125PROTOCOL  PS001 1AMENDMENT 1
A MUL TICENTER, 48 -WEEK, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, P ARALLEL-GROUP EXTENSION 
STUDY TO A SSESS THE LONG -TERM S AFETY, 
TOLER ABILITY , AND EF FICACY OF BIMEKIZUMA B IN ADULT 
SUBJECTS WITH MODERA TE TO SEVERE CHRONIC
PLAQUE PSORIA SIS
PHA SE 2B
EudraCT Number: 2016-001892- 57
IND Number: 128707
Sponsor:
UCB Biopharma SPRL
Allée de la Recherche 60
B-1070 Brussels
BELGIUM
Protocol/Amendment number Date Type of 
amendment
Final Protocol 01 Jun 2016 Not applicable
Protocol Amendment 1 12Aug 2016 Substantial
Confidential Material
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 2of 125STUDY CONTA CT INFORM ATION
Sponsor
UCB Biopharma SPRL , Allée de la Recherche 60, B -1070 Brussels, Belgium
Sponsor Study  Phy sician
Name:
Address: UCB BioPharma SPRL , Allée de la Recherche, 60, Brussels, 
Belgium, B -1070
Phone:
Fax:
Clinical Project Manager
Name:
Address: UCB BioPharma SPRL , Allée de la Recherche, 60, Brussels, 
Belgium, B -1070
Phone:
Fax:
Clinical Trial Biostatistician
Name:
Address: UCB Biosciences, 8010 Arco Corporation Drive, Raleigh, NC 
27617
Phone:
Fax:
Clinical Monitoring Contract Research Organization
Name: PAREXEL  International (I RL) Limited -Ireland
Address: Ireland Limited at 70 S ir John Rogerson’s Quay , Dublin 2, 
Ireland
Phone: +353 (1) 477 3171
Fax: +353 (1) 477 3308
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 3of 125SERIOUS A DVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax Europe and Rest of the World: +32 2 386 24 21
USA: +1 800 880 6949
or +1 866 890 3175
Canada: +1 877 582 8842
Email Global :DS_ICT@ucb.com (for interventional clinical studies)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 4of 125TABLE OF CONTENTS
LIST OF ABBREVIATION S....................................................................................................9
1 SUMMARY .....................................................................................................................12
2 INTRODUCTION ...........................................................................................................13
2.1 Psoriasis ...........................................................................................................................13
2.1.1 Global epidemiology
 of psoriasis ........................................................................13
2.1.2 Current treatments for psoriasis ...........................................................................14
2.2
Bimekizumab ...................................................................................................................15
2.2.1 Clinical .................................................................................................................15
2.2.2 Nonclinical ...........................................................................................................17
3 STUDY OB JECTIVES ....................................................................................................17
3.1 Primary  objective .............................................................................................................17
3.2 Secondary  objective .........................................................................................................17
3.3 Other objectives ...............................................................................................................17
4 STUDY VARIABLES .....................................................................................................18
4.1 Safety
 variables ................................................................................................................18
4.1.1 Primary  safet y variable ........................................................................................18
4.1.2 Other safety  variables ..........................................................................................18
4.2 Pharmacokinetic variable .................................................................................................18
4.3 Immunological variable ...................................................................................................18
4.4 Efficacy  variables
.............................................................................................................18
4.4.1 Secondary  efficacy  variables ...............................................................................18
4.4.2 Other efficacy  variables
.......................................................................................18
5 STUDY DESIGN .............................................................................................................19
5.1 Study  description .............................................................................................................19
5.1.1 Study  duration per subject ...................................................................................20
5.1.2 Planned number of subjects and sites ..................................................................20
5.1.3 Anticipated regions and countries .......................................................................20
5.2 Schedule of stud y assessments .........................................................................................20
5.3 Schematic diagram ................................ ................................ ................................ ...........23
5.4 Rationale for stud y design and selection of dose .............................................................26
6 SELECTION AND WITHDR AWAL  OF SUBJECTS ...................................................26
6.1 Inclusion criteria ..............................................................................................................26
6.2 Exclusion criteria .............................................................................................................27
6.3 Withdrawal criteria ................................ ................................ ................................ ..........27
6.3.1 PDILI IMP discontinuation criteria ................................ ................................ .....29
7 STUDY TREATMENT ................................ ................................ ................................ ...30
7.1 Description of investigational medicinal product ............................................................30
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 5of 1257.2 Treatments to be administered .........................................................................................30
7.3 Packaging .........................................................................................................................30
7.4 Labeling ...........................................................................................................................31
7.5 Handling and storage requirements
..................................................................................31
7.6 Drug accountability ..........................................................................................................31
7.7 Procedures for monitoring subject compliance ................................................................32
7.8 Concomitant medication(s)/treatment(s) ..........................................................................32
7.8.1 Permitted concomitant treatments (medications 
and therapies) ..........................32
7.8.2 Prohibited concomitant treatments (medications and therapies) .........................33
7.9 Blinding............................................................................................................................33
7.9.1 Procedures for maintaining and breaking the treatment blind .............................
34
7.9.1.1 Maintenance of study  treatment blind .......................................................34
7.9.1.2 Breaking the treatment blind in an emergency  situation ...........................
34
7.10 Randomization and numbering of subjects ......................................................................35
8 STUDY PROCEDURES BY 
VISIT ...............................................................................35
8.1
Baseline Visit ...................................................................................................................35
8.2 Week 4(±3days).............................................................................................................36
8.3 Week 8 (±3 days); Week 16 (±3 days); Week 32 (±3 days); and Week 40 (±3 days)....
37
8.4 Week 12 (±3 days)...........................................................................................................38
8.5 Week 20 (±3 days); Week 28 (±3 days); and Week 44 (±3 days)...................................39
8.6 Week 24 (±3 days)...........................................................................................................39
8.7 Week 36 (±3 days)...........................................................................................................40
8.8 Week 48 (±3 days) Study Exit/Early  Withdrawal ...........................................................41
8.9 SFU Visit (20
weeks after the last dose of bimekizumab or placebo; -3/+7 days)..........42
8.10 Early Withdrawal Visit ....................................................................................................42
8.11 Unscheduled Visit ............................................................................................................42
9 ASSESSMENT OF SAFETY ..........................................................................................43
9.1 Adverse events .................................................................................................................43
9.1.1 Definition of AE ..................................................................................................43
9.1.2
Procedures for reporting and recording AEs .......................................................44
9.1.3 Description of AEs ..............................................................................................44
9.1.4 Follow up of AEs .................................................................................................44
9.1.5 Rule for repetition of an AE ................................................................................44
9.1.6 Pregnancy ............................................................................................................44
9.1.7 Suspected transmission of an infectious agent via a medicinal product ..............
45
9.1.8 Overdose of investigational medicinal product ...................................................45
9.1.9 Safety  signal detection .........................................................................................46
9.2 Serious adverse events ................................ ................................ ................................ .....46
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 6of 1259.2.1 Definition of SAE ................................................................................................46
9.2.2 Procedures for reporting SAEs ............................................................................47
9.2.3 Follow up of SAEs ...............................................................................................48
9.3 Immediate reporting of AEs .............................................................................................48
9.4 Anticipated SAEs .............................................................................................................48
9.5
Adverse events of special interest....................................................................................48
9.6 Adverse events for special monitoring ............................................................................49
9.7 Laboratory  measurements ................................................................................................49
9.7.1 Evaluation of PDILI ............................................................................................50
9.7.1.1 Consultation with Medical Monitor and local hepatologist ......................
54
9.7.1.2 Immediate action: determination of IMP discontinuation .........................54
9.7.1.3 Testing: identification/exclusion of alternative etiology ...........................54
9.7.1.4 Follow -up evaluation .................................................................................56
9.8 Other safety  measurements ..............................................................................................56
9.8.1
Assessment and management of TB and TB risk factors ....................................56
9.8.1.1 TB assessment b y IGRA ...........................................................................58
9.8.1.2 Chest x -ray for TB .....................................................................................59
9.8.1.3 TB questionnaire ................................ ................................ .......................59
9.8.1.4 TB management ........................................................................................59
9.8.2 Pregnancy  testing .................................................................................................60
9.8.3 Vital signs ............................................................................................................60
9.8.4
12-lead ECGs ................................ ................................ ................................ .......60
9.8.5 Physical examination ...........................................................................................60
9.8.6 Assessment of suicidal ideation and behavior .....................................................60
9.8.7 Data Monitoring Committee ................................................................................60
10 ASSESSMENT OF PHARMA COKINETIC VARIABLES ...........................................61
11 ASSESSMENT OF I MMUNO LOGICAL VARIABLES ...............................................61
12 ASSESSMENT OF EFFICA
CY......................................................................................61
12.1 Psoriasis Area and Severity  Index ...................................................................................61
12.2 Investigator’s Global Assessment ....................................................................................62
12.3 Dermatology  Life Quality  Index ......................................................................................63
12.4 BSA affected b y psoriasis ................................................................................................63
12.5 Modified Nail Psoriasis Severity  Index ...........................................................................63
12.6 Psoriasis Scalp Severity  Index ................................ ................................ .........................63
12.7 PGADA for the arthritis VAS ..........................................................................................64
12.8
36-Item Short Form Health Survey ..................................................................................64
12.9 Hospital Anxiety  and Depression Scale ...........................................................................65
13
STUDY MANAGEMENT AND ADMINISTRATION .................................................65
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 7of 12513.1 Adherence to protocol ......................................................................................................65
13.2 Monitoring .......................................................................................................................65
13.2.1 Definition of source data .....................................................................................66
13.2.2 Source data verification .......................................................................................66
13.3 Data handling ...................................................................................................................66
13.3.1 eCRF completion .................................................................................................66
13.3.2 Database entry  and reconciliation ........................................................................67
13.3.3
Subject Enrollment log/Subject Identification Code list .....................................67
13.4 Termination of the stud y
..................................................................................................67
13.5
Archiving and data retention............................................................................................67
13.6 Audit and inspection ........................................................................................................68
13.7 Good Clinical Practices ....................................................................................................68
14 STATI STICS ...................................................................................................................68
14.1 Definition of anal ysis sets ................................................................................................68
14.2 General statistical considerations .....................................................................................69
14.3 Planned safet y anal yses....................................................................................................70
14.3.1 Primary  safet y analysis........................................................................................70
14.3.2 Other safety  anal yses...........................................................................................71
14.4 Planned PK anal yses........................................................................................................71
14.5 Planned immunological analy ses.....................................................................................71
14.6 Planned efficacy  anal yses................................................................................................71
14.7 Planned interim anal ysis and data monitoring
.................................................................72
14.8 Determination of sample size ...........................................................................................72
15 ETHI CS AND REGULATOR Y REQUI REMENTS ......................................................72
15.1 Informed consent .............................................................................................................72
15.2
Subject identification cards ..............................................................................................73
15.3 IRBs and IECs ..................................................................................................................73
15.4 Subject privacy .................................................................................................................74
15.5 Protocol amendments .......................................................................................................74
16 FINANCE, INSURANCE, AND PUBLICATION ................................ .........................74
17 REFERENCES ................................ ................................ ................................ ................74
18 APPENDI CES ................................ ................................ ................................ .................77
18.1 Protocol Amendment 1 ....................................................................................................77
19 DECL ARATION AND SI GNATURE OF INVESTI GATO R
................................ .....124
20 SPONSOR DECLARATION ................................ ................................ ........................125
LIST OF TA BLES
Table 5‒1: Schedule of stud y assessments ................................ ................................ .........21
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 8of 125Table 7‒1: Prohibited psoriasis medications during PS0011.............................................33
Table 9‒1: Anticipated SAEs for the population of subjects with moderate to severe 
chronic plaque psoriasis ...................................................................................48
Table 9‒2: Laboratory  measurements ................................................................................49
Table 9-3: Required investigations and follow -up for PDILI ................................ ...........52
Table 9-4: PDILI laboratory  measurements ................................ ................................ ......55
Table 9-5: PDILI information to be collected ................................ ................................ ...56
Table 12‒1: Body areas for calculation of percent BSA for PASI ................................ ......62
Table 12‒2: Parameters assessed for the PSSI ................................ ................................ .....64
LIST OF FIGURES
Figure 5‒1: Schematic diagram ................................ ................................ ...........................24
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 9of 125LIST OF A BBREVIATION S
AE adverse event
AESM adverse event for special monitoring
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
BSA body  surface area (affected by psoriasis) 
cAMP cyclic adenosine monophosphate
CRO Contract Research Organization
CTCAE Common Terminology  Criteria for Adverse Events
DLQI Dermatology  Life Quality  Index
DMC Data Monitoring Committee
EAER exposure adjusted event rate
EAIR exposure adjusted incidence rate
ECG electrocardiogram
eCRF electronic Case Report Form
eC-SSRS electronic Columbia -Suicide Severit y Rating Scale
EDC electronic data capture
FAS Full Anal ysis Set
FDA Food and Drug Administration
GCP Good Clinical Practice
GI gastrointestinal
GMP Good Manufacturing Practice
HADS Hospital Anxiety  and Depression Scale
HADS -A Hospital Anxiety  and Depression Scale -Anxiety
HADS -D Hospital Anxiety  and Depression Scale -Depression
HLT high level term
IB Investigator’s Brochure
ICH International Council forHarmonisation
IEC Independent Ethics Committee
IGA Investigator’s Global Assessment
IGRA interferon gamma release assay   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 10of 125IL interleukin
IMP investigational medicinal product (s)
IRB Institutional Review Board
iv intravenous
IXRS interactive voice or web response s ystem
LTB latent tuberculosis
mAb monoclonal antibody
MCS Mental Component Summary
mNAPSI modified Nail Psoriasis Severit y Index
NSAID nonsteroidal anti- inflammatory  drug
NTMB nontuberculous my cobacterium
PASI Psoriasis Area and Severity  Index
PCS Physical Component Summary  
PDE4 phosphodiesterase 4
PDILI potential drug -induced liver injury
PGADA Patient’s Global Assessment of Disease Activity
PK pharmacokinetics
PK-PPS Pharmacokinetics Per -Protocol Set
PRO Patient Reported Outcome
PS Patient Safety
PSSI Psoriasis Scalp Severity  Index
PT preferred term
Q4W every  4 weeks
QOL quality  of life
SAE serious adverse event
s
c subcutaneous(l y)
SF-36 36-Item Short Form Health Survey
SFU Safety  Follow -Up
SOC system organ class
SOP Standard Operating Procedure
SS Safety  Set
TB tuberculosis
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 11of 125TEAE treatment -emergent adverse event
TNF tumor necrosis factor
ULN upper limit of normal
VAS visual analog scale
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 12of 1251 SUMM ARY
PS0011 is a multicenter, 48- week, double -blind, placebo -controlled, parallel -group extension 
study  to assess the long -term safet y, tolerability , and efficacy  of bimekizumab in eligible adult 
subjects with moderate to severe chronic plaque psoriasis who complete PS0010. At Week 12 of 
PS0010, all eligible subjects continuing into PS0011 will undergo the PS0010 Week 12 study
assessments and any additional PS0011 Baseline assessments, and will then receive their first 
dose of bimekizumab or placebo in PS0011 .
During the Treatment Period, subjects will attend study  visits at the study  site every  4weeks 
(Q4W) for stud y assessme nts and administration of bimekizumab or placebo by study  site staff 
through Week 48.Any subject who does not achieve a Psoriasis Area and Severity  Index (PASI ) 
75 response (defined as a 75% reduction in the PASI  score from the Baseline of PS0010) at 
Week 12 or later in PS0011 will be withdrawn from study  treatment and will return to complete
the Earl y Withdrawal Visit assessments . Following completion or earl y withdrawal from the 
48-week Treatment Period, subjects will return for a Safet y Follow -Up (SFU) Visit 20weeks 
after their last dose of bimekizumab or 
placebo in PS0011 .
Subjects withdrawing early  from the stud y will undergo the Early Withdrawal Visit assessments 
and will enter the SFU Period.
Subjects who received placebo or bimekizumab 64mg, 160mg ,or 320mg loading dose + 160mg 
Q4W in PS0010 must achieve PASI 90 response at Week 12 in PS0010 to enter the PS0011 
extension study  on the same treatment dose. Subjects who d o not achieve PASI 90 response at 
Week 12 in PS0010 while receiving placebo or bime kizumab 64mg Q4W will be assigned to 
receive bimekizumab 160mg Q4W on entering PS0011. Subjects who do not achieve PASI90 
response at Week 12 in PS0010 while receiving bimekizumab 160mg or 320mg loading dose 
+160mg Q4W will be assigned to receive bimekizu
mab 320mg Q4W on entering PS0011. 
Subjects who receive bimekizumab 320mg or 480mg Q4W in PS0010 will be assigned to receive 
bimekizumab 320mg Q4W on entering PS0011, regardless of their PASI 90 response at Week 12 
in PS0010.
Up to 240 subjects are anticipa ted to enrol l in PS0011 at approximately  40sites in Europe, 
Canada, and the US, with possible extension to other regions and countries as required in 
PS0010.
The primary  objective of the study  is to assess the long -term safet y and tolerability  of 
bimekizu mab. The s econdary  objective of the study  isto assess the efficacy of bimekizumab
administered Q4W over 48 weeks. The other objectives of the study  are to assess the 
pharmacokinetics (PK) and immunogenicit y of bimekizumab.
The primary  safet y variable is t he incidence of treatment-emergent adverse events (TEAEs) 
adjusted by  duration of subject exposure to treatment. The other sa fety variables are change from 
Baseline of PS0010 and PS0011 in clinical laboratory values (chemistry, hematology, and 
urinaly sis), vital sign s, phy sical examination, and 12 -lead electrocardiogram (ECG) results.
The PKvariable is plasma concentration sof bimekizumab and theimmunological variable is 
anti-bimekizumab antibody  levels prior to and following study  treatment. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 13of 125The e fficacy  assessments are PASI , Investigator’s Global Assessment (IGA) Dermatology  Life 
Quality  Index (DLQI), body  surface area (BSA) affected by  psoriasis, modified Nail Psoriasis 
Severity  Index (mNAPSI) score, Psoriasis Scalp Severit y Index (PSSI ), Patient's Global 
Assessment of Disease Activity  (PGADA), 36-item Short Form Health Survey  (SF-36), and the 
Hospital Anxiety  and Depression Scale (HADS) ; a list of the secondary  and other efficacy  
varia bles is presented in Section 4.4.
2 INTRODUCTION
2.1 Psoriasis
Psoriasis is a common, chronic inflammatory  disease characterized by  a series of linked cellular 
changes in the skin: h yperplasia of epidermal keratinocytes, vascular hyperplasia and ectasia, and 
infiltration of T ly mphocy tes, neutrophils, and other ty pes of leukocy tes in affected skin. Though 
the pathophy siology  of psoriasis is not fully  understood, the importance of T -cells and 
inflammatory  cytokines has been demonstr ated by  the clinical benefit provided by  therapies 
directed at these targets (Kr ueger
andEllis, 2005). 
There are a variety  of forms including plaque, guttate, inverse, pustular, and ery throdermic. 
Plaque psoriasis is the most common, comprising approxima tely 80% to 90% of all cases. 
Approximately  17% of those with psoriasis have moderate to severe disease (Kurd etal,2008).
In addition to the impact on skin, psoriasis has a multitude of psy chosocial and emotional effects 
on patients, including increased self-consciousness, frustration, fatigue, depression, and suicidal 
ideation. As a result, patients frequentl y report sleeping problems, difficulties at work, problems 
interacting with family members, disrupted leisure activities, and sexual difficulties 
(Dowlatshahi etal,2014; Gottlieb, 2005; Mukhtar etal,2004; Ortonne, 2004; 
Krueger etal,2001). 
A number of comorbidities have been associated with psoriasis, especiall y with more severe 
psoriasis. Psoriatic arthritis, cardiovascular disease, metabolic syndrome, chronic pulmonary  
disease, peptic ulcer disease, renal disease, and diabetes have all been demonstrated to have an 
increased prevalence in psoriasis patients (Yeung etal,2013; Christophers etal,2010; 
Gisondi etal,2007; Gelfand etal,2006).
2.1.1 Global epidemiology  of psoriasis
Psoriasis affects approximately  3% of the adult US population (Rachakonda etal,2014; 
Kurd andGelfand, 2009) and its onset can begin at any  age (Augustin etal,2010; 
Icen etal,2009). The reported worldwide incidence a nd prevalence of psoriasis varies greatly  
depending on age, gender, ethnicity , and geography  primarily  due to genetic and environmental 
factors. Estimates of incidence and prevalence include all ty pes of psoriasis. Plaque psoriasis is 
the most common form of psoriasis therefore reported estimates of the magnitude of this 
condition are likel y weighted heavil y by this subtype. Both the incidence and prevalence of 
psoriasis are higher among Caucasians and those living in higher latitudes. Psoriasis affects 
approximately  2% to 4% of the population of western countries. Geographical differences are 
also influenced b y case definition, study  design, and the definition of prevalence 
(Parisi etal,2013; Langley etal,2005; Ray chaudhuri andGross, 2000).
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 14of 1252.1.2 Current tre atments for psoriasis
Therap y for patients with psoriasis varies according to the severit y of disease. L imited or mild 
disease is often treated with topical therapies such as corticosteroids and vitamin D analogs. 
Patients with more severe disease are ofte n treated with chemophoto therapy , methotrexate, the 
oral phosphodiesterase 4 (PDE4) inhibitor (apremilast), or biologic agents, such as tumor 
necrosis factor (TNF) antagonists, interleukin (IL) 12/23 inhibitors, and IL -17A inhibitors. The 
effectiveness of 
TNF inhibitors in the treatment of psoriasis has been demonstrated in man y 
Phase 3 clinical studies and has led to the approval of multiple TNF inhibitors for use in patients 
with moderate to severe psoriasis. I nterleukin inhibitors include secukinumab andixekizumab , 
IL-17A inhibitor s approved for treatment of moderate to severe psoriasis. Ustekinumab is an 
IL-12/23 antagonist approved for use in patients with moderate to severe psoriasis, and 
brodalumab, an IL-
17 receptor antagonist, has completed pivotal Phase 3 studies in psoriasis. 
Standard therapies for psoriasis are listed below:
Topical steroids (eg, triamcinolone, mometasone, clobetasol, betamethasone, hy drocortisone) 
are generally  used as first-line treatment of psoriasis. High- strength steroids ar e typicall y 
reserved for use on the arms and legs. Areas such as the face and skin folds (axillary , 
inguinal regions, etc) are usually  treated with a low potency  steroid. Chronic use of topical 
steroids can lead to corticosteroid
-related side effects and i s generally  discouraged.
Vitamin D analogs (eg, calcipotriol and tacalcitol) are commonl y used to treat mild to 
moderate psoriasis, and work best within the mild patients. They  are safe but lack efficacy  
for man y moderate to severe patients.
Chemophoto therap y is a frequent option for moderate to severe patients, but the 
inconvenience of multiple treatment visits and varying efficacy  limits its use in the market. 
Methotrexate is a sy stemic immunosuppressant and is used in moderate to severe patients. 
Toxicity  concerns, particularly  in older patients, are a major drawback.
Apremilast is an oral small-molecule inhibitor of PDE4 that is also approved for treatment of 
adults with moderate to severe plaque psoriasis. Phosphodiesterase 4 inhibitors work 
intrac ellularl y to modulate a network of pro -inflammatory  and anti -inflammatory  mediators. 
Phosphodiesterase 4 is a cy clic adenosine monophosphate (cAMP)- specific PDE and the 
dominant PDE in inflammatory  cells. Phosphodiesterase 4 inhibition elevates intracellul ar 
cAMP levels, which in turn down -regulates the inflammatory  response by  modulating the 
expression of TNFα, IL-23, IL-17, and other inflammatory  cytokines.
Biologics, including TNFα inhibitors (adalimumab, etanercept, and infliximab), 
IL-
12/23 inhibitors (ustekinumab), and IL-17A inhibitors are the treatment options of choice 
for patients with moderate to severe plaque psoriasis who are candidates for sy stemic therapy  
or phototherap y. These products are injected sc or delivered via intravenous (iv) infusio n and 
while effective, TNFα inhibitors come with boxed warnings including the risk of serious 
infections and reports of lymphoma and malignancy  in children and adolescent patients. The 
efficacy  of TNFα inhibitors in treating psoriasis has been attributed t o their inhibition of 
Th17- T cells. Different from the traditional sy stemic drugs that impact the entire immune 
system, biologics target specific parts of the immune sy stem and offer reduced multi -organ 
toxicity  and adverse effects associated with traditio nal treatments.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 15of 125Secukinumab has been approved in the US and the EU for the treatment of moderate to 
severe plaque psoriasis in adult patients who are candidates for s ystemic therap y or 
phototherap y. Secukinumab is a monoclonal antibody (mAb) that inhibits the activity of the 
IL-17A isoform and is the first approved drug in its class. Clinical study  results have shown 
that secukinumab achieves higher efficacy  response levels than other drugs historically , 
demonstrating that IL-
17 is a very  effective target f or the development of drugs for the 
treatment of psoriasis. 
2.2 Bimekizumab
Bimekizumab (also known as UCB4940) is an engineered, humanized, full -length 
immunoglobulin G1 mAb with high affinity  for human IL-
17A and IL- 1 7F, important 
proinflammatory  cytokines of the IL-17 famil y believed to play important roles in autoimmune 
and inflammatory  diseases. Interleukin -17A has been shown to have a role in pathogenesis of 
several autoimmune disorders and IL-17F has been increasingl y recognized to contribute to the 
pathogenesis of a number of inflammatory diseases, including psoriasis, ulcerative colitis, 
asthma, ank ylosing spondy litis, psoriatic arthritis, and rheumatoid arthritis. While anti -IL-17A 
antibodies have demonstrated efficacy  in patients with psoriasis, psor iatic arthritis
,and 
anky losing spondy litis, as y et, no therapeutic approach is available that fully  inhibits the activity  
of IL-17F. Bimekizumab selectivel y and potentl y inhibits the activity  of both IL- 17A and IL- 17F 
isoforms in vitro. Therefore, it perm its an evaluation of the potential for additional efficacy , that 
may be conferred by  dual inhibition of both cy tokines, in patients suffering from diseases in 
which both cy tokines are active.
2.2.1 Clinical
Three clinical studies of bimekizumab have been complet
ed: UP0008 in 39 subjects with mild to 
moderate plaque psoriasis, RA0124 in 30 healthy  volunteers, and PA0007 in 53 subjects with 
psoriatic arthritis. Two studies (RA0123 and UP0031) are ongoing in subjects with moderate to 
severe rheumatoid arthritis and in healthy  subjects, respectivel y. 
UP0008 was a Phase 1, single ascending dose study  in adults with mild to moderate psoriasis 
affecting ≤5% BSA. In this blinded study , single doses of up to 640mg (approximately  8mg/kg 
in an 80kg adult) were evaluated without any safety  concerns. A total of 26 subjects with 
psoriasis with less than 5% of body surface involvement were treated with a range of single iv 
doses from 8 to 640mg. There were no clinicall y relevant safet y findings identified at an y dose 
and all doses were well tolerated. The pre -specified exploratory  assessment of disease activity  
showed clinicall y relevant and statistically significant improvements at the higher doses studied.
RA0124 was a Phase 1, open -label, parallel -group, single -dose study  in healthy  subjects. The 
primary  objective of this study  was to determine the absolute bioavailability  of single sc doses of 
bimekizumab (80mg and 160mg). The secondary objectives were to evaluate the dose 
proportionality  of bimekizumab 80mg and 160mg sc, a nd to evaluate the safety  and tolerability  
of these sc doses and 160mg given b y iv infusion. In RA0124, the absolute bioavailability  was 
similar for the 2 doses tested (0.656 and 0.631 for the bimekizumab 80mg and 160mg sc doses, 
respectivel y). The PK of bimekizumab was linear in the tested dose range and the median t 1/2
following sc administration was similar to that following iv admin istration (27.81 days and 
28.25 days for bimekizumab 160mg sc and 160mg iv, respectivel y).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 16of 125Bimekizumab has also been inve stigated in a Phase 1b, proof of concept, randomized, 
placebo- controlled, multiple dose study  (PA0007). The primary  objective of PA0007 was to 
assess the safety  and PK of multiple dose administration of iv bimekizumab in subjects with 
psoriatic arthritis. Four active doses and a placebo were tested. Drug was administered as a 
loading dose at Week 0, and 2 additional doses were administered at Week 3 and Week 6. In 
each treatment group, subjects received a total of 3 doses of bimekizumab, administered every  
3weeks as shown below:
80mg loading dose followed b y 40mg at Weeks 3 and 6
160mg loading dose followed b y 80mg at Weeks 3 and 6
240mg loading dose followed b y 160 mg at Weeks 3 and 6
560mg loading dose followed b y 320mg at Weeks 3 and 6
The results of thi s study  demonstrated that all doses of bimekizumab were well tolerated and 
there were no unexpected clinically  relevant safety  findings. 
Infections (mostly  nasophary ngitis) were the most commonly  reported events in both the active 
treatment and the placeb o group. None of the infections were considered serious or required 
treatment with antibiotics. Two subjects in the active treatment group experienced 1 local 
candida infection each (oropharh yngitis and vulvovaginitis, respectivel y) that were nonserious 
and resolved with topical therap y. There was a reduction in mean neutrophil count in the active 
treatment group, although this drop was not clinically  relevant and a clear relationship with dose 
or time was not evident. Some increases in liver function tests were reported, but none had a 
convincing relationship to exposure to study  medication. The exploratory  analy sis showed 
clinically  relevant improvement in activity  of psoriatic arthritis and in skin involvement in those 
subjects with concomitant active pso riatic lesions.
Two additional studies of bimekizumab areongoin g. RA0123 is a Phase 2a, double -blind, 
randomized, placebo -controlled, multiple dose study  to evaluate the safet y, PK, 
pharmacod ynamics , and efficacy  of multiple doses of bimekizumab administe red as add -on 
therap y to stable certolizumab pegol therap y in subjects with moderate to severe rheumatoid 
arthritis. UP0031 is a Phase 1 open- label, parallel -group, single -dose study to evaluate the 
relative bioav ailabilit y and tolerability of bimekizumab 160mg sc in healthy subjects.
Additional information on the clinical data for bimekizumab is available in the current version of 
the Investigator’s Brochure (IB).
The current study , PS0011, is a 48- week extension study  for eligible subjects who complete 
PS0010, a Phase 2b, randomized, double -blind, placebo -controlled, parallel -group, dose -ranging 
study  in adult subjects with moderate to severe chronic plaque psoriasis. In PS0010, subjects will 
be randomized 1:1:1:1:1:1 to receive the following blinded study treatment regimens for a 
treatment period of 12 weeks:
Bimekizumab 64mg administered sc Q4W
Bimekizumab 160mg administered sc Q4W
Bimekizumab 320mg loading dose administered sc at Baseline followed b y 160mg dose 
administered sc Q4W.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 17of 125Bimekizumab 320mg administered sc Q4W
Bimekizumab 480mg administered sc Q4W
Placebo administered sc Q4W
2.2.2 Nonclinical
Parallel inhibition of IL-17A and IL- 17F has been shown to be efficacious in a variet y of animal 
models of inflammatory  disease. Intravenousl y administered 
bimekizumab was well tolerated in 
repeat dose toxicology  studies in Cy nomolgus monkey s with a no observed adverse effect level 
of 200mg/kg/week. The findings of note in toxicity studies were diarrhea related to infectious 
enteritis (observed in the single do se study ) and asy mptomatic mild colonic ulceration in a 
proportion of animals (in the repeat dose study ); this latter finding was not associated with 
hematology  abnormalities. Data suggest that bimekizumab has induced primary lesions to the 
mucosa -associat ed lymphoid tissue via a pharmacologicall y-related mechanism. I n a second 
repeat -dose study , none of the minor apoptosis/necrosis findings observed in gut associated 
lymph nodes were revealed. In animals given the highest dose of bimekizumab in the study  
(20mg/kg/week), a slightly  higher number of protozoa ( Balantidium coli ) was observed in the 
cecum and colon as compared to the control animals and low dose animals. Therefore gut 
associated l ymph node lesions observed in the first study are considered to be accidental and/or 
linked to exaggerated pharmacology  and proliferation of Balantidium coli and is considered the 
consequence of a change in local mucosal immunity. To date, similar findings have not been 
seen in studies in humans.
Additional information on the nonclinical data for bimekizumab is available in the current 
version of the IB.
3 STUDY OBJECTIVE S
3.1 Primary  objective
The primary  objective of the study  is to assess the long -term safet y and tolerability  of 
bimekizumab.
3.2 Secondary objective
The secondar yobjective of the study  isto assess the efficacy  of bimekizumab administered Q4W 
over 48 weeks.
3.3 Other objectives
The other objectives of the study  are: 
To assess PK of bimekizumab
To assess the immunogenicity of bimekizumab
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 18of 1254 STUDY VA RIABLES
4.1 Safet y variables
4.1.1 Primary  safety variable
The primary  safet y variable is the incidence of TEAEs adjusted b y duration of subject exposure 
to treatment.
4.1.2 Other safety  variables
Change from Baseline variables will be defined relative to the Baseline measurement sfrom both 
PS0010 and PS0011.
The other safet y variables are:
Change from Baseline in clinical laboratory  values (chemistry, hematology , and urinal ysis) 
Change from Baseline in vital signs
Change from Baseline in phy sical examination
Change from Baseline in 12-lead ECG results
4.2 Pharmacokinetic variable
The PK 
variable is plasma concentrations of bimekizumab .
4.3 Immunological variable
The immunological variable is anti
-bimekizumab antibody  levels prior to and following study  
treatment.
4.4 Efficacy  variables
Change from Baseline variables will be defined relative to the Baseline measurement sfrom both 
PS0010 and PS0011.
4.4.1 Secondary  efficacy  variables
The secondary  efficacy  variables are:
PASI 90 response over time
IGA response (Clear or Almost Clear with at least a 2category  improvement from Baseline 
on a 5- point scale) over time
4.4.2 Other efficacy  variables
The efficacy  variables are listed below and will be evaluated at all scheduled visits in accordance 
with the schedule of assessments in Table 5‒1. 
PASI 75 and PASI100 response
Absolute and percent change from Baseline in PASI  score
Shift from Baseline in IGA score
Change from Baseline in DLQI
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 19of 125Percent of subjects achieving a DLQI score of 0 or 1
Absolute and percent change from Baseline in the BSA affected by  psoriasis
Change from Baseline in mNAPSI  score (in the subgroup of subjects with psoriatic nail 
disease at Baseline)
Change from Baseline in the PSSI  (in the subgroup of subjects with scalp psoriasis at 
Baseline)
Change from Baseline in the PGADA for the arthritis visual analog scale (VAS)
Change from Baseline in SF -36 Phy sical Component Summary  (PCS) score, Mental 
Component Summary  (MCS) score, and individual domains
Change from Baseline in the HADS Anxiety  (HADS -A) and Depression ( HADS -D) scores
Percentage of subjects with scores below 8 in HADS -A and HADS -D (subjects with normal 
scores)
5 STUDY DESIGN
5.1 Stud y description
PS0011 is a multicenter, 48- week, double -blind, placebo -controlled, parallel -group, extension 
study  to assess the long -term safet y, tolerability , and efficacy  of bimekizumab in eligible adult 
subjects with moderate to severe chronic plaque psoriasis who complete PS0010. At Week 12 of 
PS0010, all eligible subjects continuing into PS0011 will undergo the PS0010 Week 12 study  
assessments and an yadditional PS0011 Baseline assessments, and will then receive their first 
dose of bimekizumab or placebo in PS0011 .
During the Treatment Period, subjects will attend study  visits at the study site Q4W for study  
assessments and administration of bimekizumab or placebo by  study  site staff through Week 48. 
Any subject who does not achieve PASI75 response at Week 12 or late r in PS0011 will be 
withdrawn from stud y treatment and will return to complete the Earl y Withdrawal Visit 
assessments. Following completion or earl y withdrawal from the 48 -week Treatment Period, 
subjects wi ll return for a SFU Visit 20 weeks after their last dose of bimekizumab or placebo in 
PS0011 .
Subjects withdrawing early  from the stud y will undergo the Early Withdrawal Visit assessments 
and will enter the SFU Period.
Subjects who received placebo or bimekizumab 64mg, 160mg ,or 320mg loading dose + 160m g 
Q4W in PS0010 must achieve PASI 90 response at Week 12 in PS0010 to enter the PS0011 
extension study  on the same treatment dose. Subjects who do not achieve PASI 90 response at 
Week 12 in PS0010 while receiving placebo or bimek izumab 64mg Q4W will be assig ned to 
receive bimekizumab 160mg Q4W on entering PS0011. Subjects who do not achieve PASI90 
response at Week 12 in PS0010 while receiving bimekizumab 160mg or 320mg loading dose 
+160mg Q4W will be assigned to receive bimekizumab 320mg Q4W on entering PS00 11. 
Subjects who receive bimekizumab 320mg or 480mg Q4W in PS0010 will be assigned to receive 
bimekizumab 320mg Q4W on entering PS0011, regardless of their PASI 90 response at Week 12 
in PS0010.   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 20of 125A schedule of stud y assessments in presented in Table 5‒1.
A study  schematic diagram of PS0011 is presented in Figure 5‒1.
5.1.1 Study duration per subject
The study  duration for each subject is estima ted to be up to a maximum of 64weeks:
Treatment Period: up to 48weeks
SFU Visit: 
20weeks after the last dose of bim ekizumab or placebo
The end of the stud y is defined as the date of the last visit of the last subject in the study .
5.1.2 Planned number of subjects and sites
Up to 240 subjects are anticipated to enroll in PS00 11 at approximately  40sites.
5.1.3 Anticipated regions a nd countries
The regions planned for study  conduct are Europe, Canada, and the US, with possible extension 
to other regions and countries as required in PS0010.
5.2 Schedule of study  assessments
A schedule of stud y assessments is presented in Table 5‒1.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 21of 125Table 5‒1: Schedule of study  assessments
Visit Weeka
Protocol activityPS0011 
BaselineTreatment Period
Wk 
4Wk 
8Wk 
12Wk 
16Wk 
20Wk 
24Wk 
28Wk 
32Wk 
36Wk 
40Wk 
44Wk 48/ 
WD SFUb
Informed consent Xc
Inclusion/exclusion Xd
Physical exam eXfX X
Body  weight XfX X
Vital signsgXfX X X X X X X X X X X X X
Hematology/biochemistry XfX X X X X X X X X X X X X
Urinalysis XfX X X X X
12-lead ECG XfX X X
Pregnancy testinghXfX X X X X X X X X X X X X
eC-SSRS XfX X X X X X X X X X X X X
IGRA TB testi jX
TB questionnaire XfX X X X
Blood sample for bimekizumab plasma 
concentrationskXfX X X X X X X X
Blood sample for anti -bimekizumab 
antibodieskXfX X X X X X X X
PASI XfX X X X X X X X X X X X X
IGA XfX X X X X X X X X X X X X
DLQI XfX X X X X
BSA XfX X X X X X X X X X X X
mNAPSI XfX X X X X
PSSI XfX X X X X
PGADA XfX X X X
SF-36 XfX X X X
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 22of 125Table 5‒1: Schedule of study  assessments
Visit Weeka
Protocol activityPS0011 
BaselineTreatment Period
Wk 
4Wk 
8Wk 
12Wk 
16Wk 
20Wk 
24Wk 
28Wk 
32Wk 
36Wk 
40Wk 
44Wk 48/ 
WD SFUb
HADS XfX X X X X X X X X X X X X
Concomitant medications X X X X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X X l
IXRS X X X X X X X X X X X X X X
Bimekizumab administrationmX X X XmXmXmXmXmXmXmXmXm
BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC -SSRS=electronic Columbia -Suicide Severity Rating Scale; 
HADS=Hospital Anxiety and Depression Scale; IGA=Investigator’s Global Assessment; IGRA=interferon gamma release assay ; IXRS=interactive voice or w eb 
response system; mNAPSI=modified Nail Psoriasis Severity Index; PASI=Psoriasis Area and Severity Index; PGADA=Patient's Globa l Assessment of Disease 
Activity; PSSI=Psoriasis Scalp Severity Index; Q4W=every 4 w eeks; SF -36=36 -item Short Fo rm Health Survey; SFU=Safety Follow -Up; TB=tuberculosis; 
WD=w ithdrawal; Wk=week
aVisit windows of ±3days from the first dose (Baseline) at all visits except SFU , which has a window  of-3 and +7 days from scheduled visit date.
bThe SFU Visit will occur 20weeks after the last dose of bimekizumab or placebo .
cEnsure that the informed consent for PS0011 w as completed by the subject during the Week 8 or Week 12 Visit of PS0010 (must be done before any study 
assessments are performed for PS0011).
dTo be performed prior to the first dose of bimekizumab or placebo in PS0011 .
eIncludes evaluation of signs and symptoms of active TB and risk for exposure to TB.
fThe noted PS0011 Baseline assessments will be obtained at the Week 12 Visit of PS0010 and do not need to be recorded on the case report form for this study.
gVital signs (blood pressure, pulse rate, and temperature) are to be measured prior to blood sampling and prior to dosing, whe re applicable.
hPregnancy testing will be urine testing at all visi ts except SFU, which will be a serum test.
iIt is recommended that the QuantiFERON TB GOLD test be performed.
jEnsure that an IGRA test was performed during the Week 8 Visit of PS0010 and the result was negative.
kAll blood samples are to be taken prior to dosing.
lIncluding assessment for the development of different forms of psoriasis at the SFU visit.
mSubjects who received placebo or bimekizumab 64mg, 160mg ,or 320mg loading dose + 160mg Q4W in PS0010 must achieve PASI90 response at Week 12 in 
PS00 10 to enter the PS0011 extension study on the same treatment dose . Subjects who do not achieve PASI90 response at Week 12 in PS0010 while receiving 
placebo or bimek izumab 64mg will be assigned to receive bimekizumab 160mg on entering PS0011. Subjects who d o not achieve PASI90 response at Week 12 
in PS0010 while receiving bimekizumab 160mg or 
320mg loading dose + 160mg will be assigned to receive bimekizumab 320mg Q4W on entering PS0011. 
Subjects who receive bimekizumab 320mg or 480mg Q4W in PS0010 w ill be a ssigned to receive bimekizumab 320mg Q4W on entering PS0011, regardless of 
their PASI90 response at Week 12 in PS0010. Any subject who does not achieve PASI75 response at Week 12 or later in PS0011 w ill be withdrawn from study 
treatment and will return to complete the Early Withdrawal Visit assessments.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 23of 1255.3 Schematic diagram
A study  schematic diagram of PS0011 is presented in Figure 5‒1.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 24of 125Figure 5‒ 1:Schematic diagram
PASI=Psoriasis Area and Severity Index; Q4W=every 4 w eeks; SFU=Safety Follow -Up
aSubjects who received placebo or bimekizumab 64mg, 160mg ,or 320mg loading dose + 160mg Q4W in PS0010 must achieve PASI90 response at Week 12 in 
PS0010 to enter the PS0011 extension study on the same treatment dose. Subjects who do not achieve PASI90 response at Week 12 in PS0010 while receiving 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 25of 125placebo or bimek izum ab 64mg will be assigned to receive bimekizumab 160mg on entering PS0011. Subjects who do not achieve PASI90 response at Week 12 
in PS0010 while receiving bimekizumab 160mg or 320mg loading dose + 160mg will be assigned to receive bimekizumab 320 mg Q4W on entering PS0011. 
bSubjects who receive bimekizumab 320mg or 480mg Q4W in PS0010 w ill be assigned to receive bimekizumab 320mg Q4W on entering P S0011, regardless of 
their PASI90 response at Week 12 in PS0010.
cAny subject who does not achieve PASI75 response at Week 12 or later in PS0011 w ill be w ithdrawn from study treatment and will return to complete the 
Early Withdrawal Visit assessments .
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 26of 1255.4 Rationale for study  design and selection of dose
PS0011 is a 48- week ,double -blind, placebo -controlled, parallel -group extension study  for 
eligible subjec ts who complete PS0010, a Phase 2b, randomized, double -blind, 
placebo- controlled, parallel -group, dose -ranging study  in adult subjects with moderate to severe 
chronic plaque psoriasis. Because some PS0010 subjects may  have severe disease, the treatment 
in PS0011 provides more time to respond to a potentially efficacious treatment. PS0011 also 
provides an opportunity  for nonresponding PS0010 placebo subjects to receive bimeki zumab.
This study  will allow the collection of further data on the long- term safety , tolerability , and 
efficacy  of bimekizumab in this subject population .
The PS0011 design ( Figure 5‒1) allows PASI90 responders in PS0010 to continue their dose in 
PS0011, thus permitting these subjects to remain on the dose that resulted in this response after 
12 weeks of initial treatment in PS0010. I t also provides an 
opportunity  for an increased dose 
among PS0010 nonresponders (ie, <PASI 90). PASI 90 was selected as the response criterion in 
PS0010 to ensure that a sufficientl y high efficacy response was achieved. This type of dose 
escalation for those who do not achieve a desired response after 12 weeks is common in clinical 
practice. 
Regardless of PASI90 response at Week 12 of PS0010, subjects who received the 2 highest 
doses of bimekizumab (320mg and 480mg Q4W) in PS0010 will begin PS0011 on the 320mg 
Q4W dose. For th ose subjects who do achieve PASI 90 response, this will allow a continuation of 
the PS0010 dose for subjects initially  receiving 320mg Q4W and a dose down for subjects 
originall y randomized to the 480mg Q4W dose. Because bimekizumab 480mg Q4W is the 
highest dose evaluated in PS0010 and because it requires 3 injections, it will be of interest to 
evaluate whether these subjects can maintain response in PS0011 with the lower 320mg dose, 
allowing the blind to be maintained with the use of only  2 injections at ea ch study  administration 
visit.
To protect against the possibility  of exposing subjects to an ineffective treatment for extended 
periods of time, subjects across all treatment groups who have not achieved PASI 75 response at 
Week 12 or later in PS0011 will be withdrawn from study  treatment. Because this withdrawal 
decision is based strictly  on the PASI  response and not on the original study treatment, it can be 
done in such a way  that will not unblind subjects or Investigators .
6 SELECTION A ND WITHDR AWAL  OF SUBJECTS
6.1 Inclusion criteria
To be eligible to participate in this study , all of the following criteria must be met:
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated b y the sub ject.
2. Subject is considered reliable and capable of adhering to the protocol and visit schedule 
according to the judgment of the Investigator.
3.Subje ct complete sall dosing requirements in PS0010 without meeting an y withdrawal 
criteria and completes the st udy.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 27of 1254.Female subjects of childbearing potential and male subjects with a partner of childbearing 
potential must continue to use an acceptable method of contraception (as detailed in PS0010) 
for up to 20 weeks after the last dose of stud y treatment in PS0011 . 
6.2 Exclusion criteria
Subjects are not permitted to enroll in the study  if any  of the following criteria are met:
1.Subject has previously  participated in this study .
2. Female subjects who plan to become pregnant during the stud y or within 20 weeks following 
last dose of study  medication. Male subjects who are planning a partner pregnanc y during the 
study  or within 20 weeks following the last dose.
3.Subject has an y medical or psychiatric condition that, in the opinion of the Investigator, 
could jeopardize or wo uld compromise the subject’s ability to participate in this study . Note: 
For an y subject with an ongoing serious adverse event (SAE), or a history  of serious 
infections (including herpes zoster or hospitalizations) in PS0010, the Medical Monitor must 
be co nsulted prior to the subject’s entry  into PS0011.
4.Subject must have a negative interferon gamma release assay  (IGRA) as measured at Week 8 
of PS0010.
5.Any subject who meets any  withdrawal criteria in the feeder study  (PS0010) is excluded 
from participating in the extension study  (PS0011).
6.3 Withdrawal criteria
Subjects are free to withdraw from the study  at any  time, without prejudice to their continued 
care.
Subjects should be withdrawn from the study  and will be asked to complete the Earl y 
Withdrawal Visit a nd SFU Visit (
20weeks after the last received dose) if any  of the following 
events occur:
1.Subject withdraws his/her consent.
2.There is confirmation of a pregnancy in a female subject during the study , as evidenced by  a 
positive pregnancy  test.
3.The Sponsor or a regulatory  agency  requests withdrawal of the subject.
4.Subject develops an illness that in the opinion of the Investigator would interfere with his/her 
continued participation if the risk of continuing participation outweighs the potential benefit . 
5.Subject develops ery throdermic, guttate, or pustular form of psoriasis.
6. Subjects considered to have either a suspected new latent tuberculosis (LTB) infection or 
who develop an active TB or NTMB infection during the stud y (including but not limited to, 
conve rsion demonstrated by  IGRA or other diagnostic means) must be immediately 
discontinued from study  medication; an Earl y Withdrawal Visit must be scheduled as soon as 
possible, but not later than the next regular visit.
Confirmed active TB is an SAE and must be captured on an SAE Report Form and provided 
to the Sponsor in accordance with SAE reporting requirements. As with all SAEs, periodic 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 28of 125follow -up reports should be completed as per protocol requirements until such time as the TB 
infection resolves. 
Addit ional information on TB policies are provided in Section 9.8.1 .
7.Subject is noncompliant with the study  procedures or medications in the opinion of the 
Investigator.
8.Subject uses prohibited concomitant medications, with the exception of topicals, as defined 
in this protocol ( Section 7.8.2), that may present a risk to the safet y of the subject in the 
opinion of the I nvestigator and/or the Medical Monitor.
9.Subject has a clinical laboratory  value meeting the following criteria:
Common Terminology  Criteria for Adverse Events (CTCAE )Grade 3 and above:
subjects must be withdrawn regardless of relationship to study  drug or duration of event. 
CTCAE Grade 2
◦Subjects may remain in the study  if the event is transient. If a subject has a Grade 2 
laboratory  abnormality , a retest is required within 1 to 2 weeks at a scheduled or 
unscheduled visit. If the repeat value is below Grade 2, the subject may  receive the 
next scheduled study  treatment. I f the value on the repeat is still Grade 2 or above, a 
second repeat test must be performed and results made available prior to the next 
scheduled study treatment. I f this second repeat value is still Grade 2 or above, the 
subject must be withdrawn.
10. Subject has active suicidal ideation as indicated by a positive response (“Yes”) to questions 4
or 5 or to the suicidal behavior question s of the “Since Last Visit” version of the self- rated 
electronic Columbia -Suicide Severit y Rating Scale (eC -SSRS) . The subject should be 
referred immediatel y to a Mental Healthcare Professional and must be withdrawn from the 
study .
11.Subject swith a HADS -D score ≥15 must be withdrawn. An y subject who develops a 
HADS -D score of >10 during the study  should be referred immediatel y to a Mental 
Healthcare Professional for further evaluation and potential withdrawal by the Investigator .
12.
Subject doe s not achieve PASI 75at Week 12 or later following study  treatment in PS0011.
13.
Subject experiences an AE as described below: 
Any CTCAE Grade 3 and above adverse event ( AE)that is assessed as related to study  
drug in the opinion of the I nvestigator 
◦If the event is deemed to be not related to stud y drug b y the Investigator, the subject 
may remain in the study  after approval by  the M edical Monitor. 
Any CTCAE Grade 2 event that is evaluated as related to study  drug in the opinion of the 
Investigator, i s persistent, and falls into any  of the following S ystem Organ Classes 
(SOCs): “Blood and l ymphatic disorders,” “Cardiac disorders,” or “Vascular disorders.” 
◦Persistent is defined as lasting 28 days or more, which spans at least 2 scheduled 
injections.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 29of 125Investigators should attempt to obtain information on subjects in the case of withdrawal. For 
subjects considered as lost to follow- up, the I nvestigator should make an effort (at least 1 phone 
call and 1 written message to the subject), and document his/her effort (date and summary  of the 
phone call and cop y of the written message in the source documents) to complete the final 
evaluation. All results of these evaluations and observations, together with a narrative description 
of the reason(s) for removing the subject, must be recorded in the source documents. The eCRF 
must document the primary reason for withdrawal.
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance.
6.3.1 PDILI IMP discontinuation criteria
Subjects with PDILI must be assessed to determine if investigational medicinal product (IMP) 
must be discontinued. I n addition, all concomitant medications and herbal supplements that are 
not medically  necessary  should also be discontinued. 
The P DILI criteria below require immediate and permanent discontinuation of IMP: 
Subjects with either of the following:
ALT or AST ≥ 5xUL N
ALT or AST ≥3xUL N and coexisting total bilirubin ≥2xUL N 
Subjects with AL T or AST ≥3xULN who exhibit temporally  associated symptoms of 
hepatitis or hy persensitivity . Hepatitis sy mptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hy persensitivity  symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below allows for subjects to continue on I MP at the discretion of the 
Investigator. 
Subjects with AL T or AST ≥3xULN (and ≥2x baseline) and <5xULN, total bilirubin 
<2xUL N, and no eosinophilia (ie, ≤5%), with no fever, rash , or s ymptoms of hepati tis 
(eg,fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Evaluation of PDILI must be initiated as described in Section 9.7.1. I fsubjects are unable to 
comply  with the applicable monitoring schedule, IMP must be discontinued immediately .
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the stud y 
until investigation and monitoring are complete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in th e source documents. The eCRF must document the primary  
reason for IMP discontinuation.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 31of 125such a way  as to protect the product from deterioration during transport and storage. Further 
information regarding storage and transport conditions are provided in the IMP Handling 
Manual.
7.4 Labeling
Clinical drug supplies will be labeled in accordance with the current International Council for 
Harmonisation (IC H) guidelines on Good Clinical Practice (GCP) and GMP and will include an y 
locally  required statements. I f necessary , labels will be translated into the local language.
7.5 Handling and storage requirements
Bimekizumab and placebo must be stored under refriger ated conditions (2ºC to 8ºC) and 
protected from light. The study  drug must not be frozen. 
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored b y the Investigator is to be kept in a secured area with 
limited access according to the storage conditions mentioned on the label .
Appropriate storage conditions must be ensured by controlling the temperature (eg, room, 
refrigeration unit) andby completion of a temperature log in accordance with local requirements 
on a regular basis per study  manuals, showing actual and minimum/ maximum temperatures 
reached over the time interval.
Study  drug will be shipped to the study  sites in temperature controlled containers. Out-of- range 
shipping or storage conditions must be brought to the attention of the Sponsor or designee, as per 
instructions contained in the I MP Handling Manual . Authorization to use any  out-of- range IMP 
must be documented and received prior to dispensing or adminis tering the IMP at the study  site.
7.6 Drug accountability
A Drug Accountability  form will be used to record I MP dispensing and return information on a 
by-subject basis and will serve as source documentation during the course of the study . Details of 
any IMP lo st, damaged (due to breakage or wastage), not used, partially  used, disposed of at the 
study  site, or returned to the Sponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available through out the study  for UCB 
(or designee) to review.
In order to maintain the blind, all IMP documentation (eg, shipping receipts, drug accountability  
logs, interactive web or voice response s ystem [I XRS] treatment assignments ) must be 
maintained and accessed only by trained unblinded site personnel. Designated unblinded site 
personnel must be appropriately  trained and licensed (per country  guidelines) to administer 
injections. 
Blinded study  staff may  be delegated the responsibility  to receive, inventory , and de stroy  the 
used kits. The packaging identifies each kit b y a unique number that does not correlate to the 
contents and does not unblind study  site staff. Unblinded study  staff will be responsible for the
preparation ( eg, breaking tamper proof sticker on kit ) of the IMP, including recording the 
administration information on the source document.
The Investigator (or designee) is responsible for retaining all used, unused, and partiall y used 
containers of IMP until returned or destro yed.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 32of 125The Investigator may  assign some of the Investigator’s duties for drug accountability  at the study  
site to an appropriate pharmacist/designee.
The Investigator must ensure that the IMP is used only  in accordance with the protocol.
Periodically , and/or after completion of the cli nical phase of the stud y, all used (including empty 
containers) , partiall y used, unused, damaged, and/or expired IMP must be reconciled and either 
destroy ed at the site according to local laws, regulations, and UCB SOPs or returned to UCB (or 
designee) . Onsite destruction of used kits only  may  be allowed with prior approval from the 
Sponsor or designee after reconciliation. Investigational medicinal product intended for the stud y 
cannot be used for an y other purpose than that described in this protocol.
7.7 P
rocedures for monitoring subject compliance
During the T reatment Period of this study , study  medication will be administered in the clinic 
and compliance will be determined at the visit by  study  personnel. Drug accountability  must be 
recorded on the Drug A ccountability  Form.
7.8 Concomitant medication(s)/treatment(s)
All concomitant medications, including over the counter products, herbal, traditional remedies, 
vitamin/mineral supplements, other dietary  supplements, “nutraceuticals,” and hormones must be 
record ed in the subj ect’s source documentation (eg, clinical chart) and on the eCRF. This record 
should include the name of the drug, the dose, the route and date(s) of administration, and the 
indication for use.
The Investigator should examine the acceptability of all concomitant procedures, medications, 
topical preparations ,and dietary  supplements not explicitly  prohibited in this study , and if 
necessary , discuss with the Medical Monitor. 
In order to ensure that appropriate concomitant therap y is administered, subjects will be 
instructed to consult with the I nvestigator prior to taking any  medicatio n (either 
self-administered non prescription drugs or prescription therapy  prescribed by another phy sician).
7.8.1 Permitted concomitant treatments (medications and therap ies)
Topical medications
Subjects may  continue to use topical moisturizers or emollients, bath oils, or oatmeal bath 
preparations for skin conditions during the study , as needed. Over- the-counter shampoos for the 
treatment of psoriasis of the scalp are als o permitted. 
Subjects will be allowed to use topical medications (corticosteroids, retinoids, Vitamin D analogs 
coal tar, etc) as needed during this extension study .
Other medications
Subjects who were already  receiving an established nonsteroidal anti-i nflammatory  drug 
(NSAID )regimen during PS0010 may  continue their use during th isstudy . However, initiation 
of, or increase in dosage of, NSAIDs during the study  (especially  in subjects with a history  of 
gastrointestinal [ GI]intolerance to NSAIDs or a hi story  of GI ulceration) should be done with 
caution. Intra -articular injections for arthritis of the knee are allowed.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 33of 125Subjects who were already  receiving an established anti- depressant regimen during PS0010 may  
continue their use during this study .
7.8.2 Prohibited concomitant treatments (medications and therapies)
The list of prohibited concomitant medications is provided Table 7‒1.
Table 7
‒1: Prohibited psoriasis medications during PS0011
Drug
Systemic retinoids
Systemic treatment (non -biological):
systemic immunosuppressant agents (eg, methotrexate, cyclosporine, azathioprine, thioguanine)
systemic fumarate
systemic corticosteroids
phototherapy or chemophototherapy
Anti- TNFs:
infliximab (including biosimilar), golimumab
etanercept (including biosimilar)
certolizumab pegol
adalimumab (including biosimilar)
Other biologics and other systemic therapies:
apremilast
ustekinumab
Anti- IL-17 therapy
Any other antipsoriatic agent (systemic)
Any other antipsoriatic agent (topical) under investigation
IL=interleukin; TNF=tumor necrosis factor
Subjects who take prohibited medications may  be withdrawn from study  treatment but followed 
until the SFU Visit . The decision to withdraw a subject for taking prohibited medications should
be made in consultation with the Medical Monitor. 
Vaccines
Administration of live (including attenuated )vaccines is not allowed during the conduct of the 
study  or for 20 weeks after the last dos e of stud y drug . Administration of inactivated vaccines is
allowed during the stud y at the discretion of the Investigator.
7.9 Blinding
Due to differences in presentation of the IMP (bimekizumab and placebo), special precautions 
will be taken to ensure study  blinding ,and stud y sites will have blinded and unblinded personnel.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 34of 125Bimekizumab and placebo injections will be prepared and administered at the study  sites by  
unblinded dedicated study  personnel who will only  be responsible for dosing and drug 
accountability .
Study  sites will be required to have a written blinding plan in place, signed by  the Principal 
Investigator, which will detail the site’s steps for ensuring that the double -blind nature of the 
study  is maintained. 
During the study , the Sponsor will provide blinded and unblinded site monitors for the purposes 
of verif ying safet y, efficacy ,and drug administration and documentation records. Blinded stud y 
monitors and study  site personnel, blinded to treatment assignment, will not discuss or have 
access to an y drug -related information.
When the feeder (PS0010) study  is unblinded, selected PS0010 study  team members will have 
access to subject -level data. Because treatment assignment in PS0011 is based on PASI 90 
response at Week 12 of PS0010 as opposed to randomization, Sponsor personnel with such 
access to the PS0010 data will know the treatment assignments of all PS0010 subjects including 
those continuing in PS0011. This operational unblinding to PS0011 treatment assignment will 
pertain to selected clinical PS0010 study  team members (some of whom may  be involved in 
PS0011) but will not extend to blinded staff at the investigational sites of PS0011. 
While the blinding of Sponsor clinical study  team members is important for ensuring the 
integrit y of data collection and anal ysis in a controlled study , this unblinding is consi dered 
acceptable because the primary  evaluation of efficacy , upon which sample size calculations were 
based, will be performed in a blinded manner using Week 12 data of PS0010. Additionally , 
because investigational site staff collecting and recording stud y data remain blinded, those data 
will not be impacted by  the unblinding of selected Sponsor clinical study  team members. Finally , 
to ensure that unblinding of study  team members did not impact the primary safet y outcome of 
PS0011, sensitivity  anal yses will be outlined in the SAP to evaluate what, if an y, impact there 
was on the results based on queries that resulted in changes to the AE data following the 
unblinding of PS0010.
Further details are provided in the study  manuals and site blinding plan.
7.9.1 Procedu res for maintaining and breaking the treatment blind
7.9.1.1 Maintenance of study treatment blind
All subject treatment details (bimekizumab or placebo) will be allocated and maintained by  the 
IXRS .
7.9.1.2 Breaking the treatment blind in an emergency  situation
The integr ity of this clinical study  must be maintained by  observing the treatment blind. I n the 
event of an emergency  for which the appropriate treatment for a subject cannot be made without 
knowing the treatment assignment, it will be possible to determine to whic h treatment arm and 
dose the subject has been allocated b y contacting the IXRS . All sites will be provided with 
details of how to contact the sy stem for code breaking at the start of the study . The Medical 
Monitor or equivalent should be consulted prior to unblinding, whenever possible.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 35of 125The Clinical Project Manager will be informed immediately  via the IXRS when a code is broken, 
but will remain blinded to specific treatment information. Any  unblinding of the IMP performed 
by the Investigator must be recorded in the source documents and on the Study  Termination 
eCRF page.
7.10 Randomization and numbering of subje cts
No randomization will be performed in this study. An IXRS will be used for assigning eligible 
subjects to treatment based on a predetermined assignment schedule. An independent 
biostatistician or designee who is not involved in this study  or the feeder study , PS0010 ,will 
produce this assignment schedule. Details of the study  treatments in PS0011 are presented in 
Section
7.2. 
Subjects will continu
e with the 5 -digit subject numbers assigned b y IXRS i n the preceding stud y.
8 STUDY PROCEDURES BY VISIT
Table 5‒1(schedule of study  assessments) provides a general overview of study  assessments. A 
list of procedures to be completed at each visit is provided in the sections that follow. 
Visit windows of ±
3days on either side of the scheduled dosing are permitted for all visits 
other than the SFU Visit (see below) ; however, the Investigator should try  to keep the 
subjects on the original dosing schedule. The window of ± 3daysis relative to the first dose 
(Baseline) and applicable for all subsequent visits. Changes t o the dosing schedule outside of 
the 3- day window must be discussed with the Medical Monitor.
The minimum time between doses should be no less than 24 day s and no more than 32 days 
forQ4W dosing .
For the SFU Visit (20 weeks after the last dose of bimekizu mab or placebo), the visit should 
occur no more than 3days prior to the sc heduled visit date and within 7 days after the 
scheduled visit date ( -3days/+7days).
8.1 Baseline Visit
The Baseline assessments noted with an * will be obtained at the Week 12 Visit of PS0010 and 
do not need to be recorded on the eCRF for this study .
All procedures or assessments will be performed prior to administration of study  drug , unless 
otherwise noted. The following procedures or assessments will be performed:
Ensure t hat a separate Informed Consent Form was completed by  the subject for PS0011 
during the Week 8 or Week 12 Visit of PS0010 (must be done prior to an y PS0011 study  
procedures)
Confirm that a TB test (IGRA) was performed at the Week 8 Visit of PS0010 and the results 
were negative
Assessment of inclusion/exclusion criteria
Vital signs (blood pressure, pulse rate, and temperature)*
Body weight*
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 36of 125Physical examination*
Record 12- lead ECG*
eC-SSRS*
TB questionnaire *
PASI *
IGA*
DLQI*
BSA *
mNAPSI *
PSSI *
PGADA *
SF-36*
HADS*
Obtain blood samples for:
Standard safet y laboratory tests (hematology and biochemistry
)*
Bimekizumab plasma concentration *
Anti- bimekizumab antibodies *
Obtain urine sample for: 
Standard safet y laboratory tests (urinaly sis)*
Urine pregnancy  test for women of childbearing potential*
Concomitant medications
Record AEs
Contact the IXRS
Study  medication administration (after all other visit assessments are completed)
8.2 Week 4 (±3 days)
All procedures or assessments will be performed prior to administration of study drug, unless 
otherwise noted. The following procedures or assessments will be performed:
Vital signs (blood pressure, pulse rate, and temperature)
eC-SSRS
PASI
IGA
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 37of 125DLQI
BSA
mNAPSI
PSSI
HADS
Obtain blood samples for:
Standard safet y laboratory tests (hematology  and biochemistry )
Bimekizumab plasma concentration
Anti- bimekizumab antibodies
Obtain urine sample for: 
Urine pregnancy  test for women of childbearing potential
Concomitant medications
Record AEs
Contact the IXRS
Study  medication administration (after all other visit assessments are completed)
8.3 Week 8 (±3days); Week 16 (±3days); Week 32 (±3days); and 
Week 40 (±3days)
All procedures or assessments will be performed prior to administration of study  drug (if 
applicable), unless oth erwise noted . The following procedures or assessments will be performed:
Vital signs (blood pressure, pulse rate, and temperature)
e
C-SSRS
PASI
IGA
BSA
HADS
Obtain blood samples for:
Standard safet y laboratory tests (hematology and biochemistry)
Bimekizuma b plasma concentration (not collected at Week 32)
Anti- bimekizumab antibodies (not collected at Week 32)
Obtain urine sample for: 
Urine pregnancy  test for women of childbearing potential
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 38of 125Concomitant medications
Record AEs
Contact the IXRS
Study  medication administration ( after all other visit assessments are completed)
8.4 Week 12 (±
3days)
The following procedures or assessments will be performed prior to administration of study  drug
(if applicable) :
Vital signs (blood pressure, pulse rate, and temperature)
eC-SSRS
TB questionnaire
PASI
IGA
DLQI
BSA
mNAPSI
PSSI
PGADA
SF-36
HADS
Obtain blood samples for:
Standard safet y laboratory tests (hematology and biochemistry)
Bimekizumab plasma concentration
Anti- bimekizumab antibodies
Obtain urine sample for: 
Standard safet y laboratory tests (urinalysis)
Urine pregnancy  test for women of childbearing potential
Concomitant medications
Record AEs
Contact the IXRS
Study  medication administration (after all other visit assessments are completed)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 39of 1258.5 Week 20 (±3days); Week 28 (±3days); and Week 44(±3days )
The following procedures or assessments will be performed prior to administration of study  drug 
(if applicable):
Vital signs (blood pressure, pulse rate, and temperature)
eC-SSRS
PASI
IGA
BSA
HADS
Obtain blood sample sfor:
Standard safet y laboratory tests (hematology and biochemistry)
Bimekizumab plasma concentration (collected only  at Week 28)
Anti- bimekizumab antibodies (collected onl y at Week 28)
Obtain urine sample for: 
Urine pregnancy test for women of childbearing pot ential
Concomitant medications
Record AEs
Contact the IXRS
Study  medication administration (after all other visit assessments are completed)
8.6 Week 24 (±3days)
The following procedures or assessments will be performed prior to administration of study  drug 
(if applicable):
Vital signs (blood pressure, pulse rate, and temperature)
Record 12- lead ECG
eC-SSRS
TB questionnaire
PASI
IGA
DLQI
BSA
mNAPSI
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 40of 125PSSI
PGADA
SF-36
HADS
Obtain blood sample for:
Standard safet y laboratory tests (hematology and biochemistry)
Obtain urine sample for: 
Standard safet y laboratory tests (urinalysis)
Urine pregnancy  test for women of childbearing potential
Concomitant medications
Record AEs
Contact the IXRS
Study  medication administration (after all other visit assessments are comple ted)
8.7 Week 36 (±3days)
The following procedures or assessments will be performed prior to administration of study  drug 
(if applicable):
Vital signs (blood pressure, pulse rate, and temperature)
eC-SSRS
TB questionnaire
PASI
IGA
DLQI
BSA
mNAPSI
PSSI
PGADA
SF-36
HADS
Obtain blood sample for:
Standard safet y laboratory tests (hematology and biochemistry)
Obtain urine sample for: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 41of 125Standard safet y laboratory tests (urinalysis)
Urine pregnancy  test for women of childbearing potential
Concomitant medications
Record AEs
Contact the IXRS
Study  medication administration (after all other visit assessments are completed)
8.8 Week 48 (±3days) Study  Exit/Early  Withdrawal
The following procedures or assessments will be performed:
Vital signs (blood pressure, pulse rate, and temperature)
Body weight
Physical examination
Record 12- lead ECG
eC-SSRS
TB questionnaire
PASI
IGA
DLQI
BSA
mNAPSI
PSSI
PGADA
SF-36
HADS
Obtain blood samples for:
TB test (IGRA; QuantiFERON TB GOLD test is recommended)
Standard safet y laboratory tests (hematology and biochemistry )
Bimekizumab plasma concentration
Anti- bimekizumab antibodies
Obtain urine sample for: 
Standard safet y laboratory tests (urinalysis)
Urine pregnancy  test for women of childbearing potential
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 42of 125Concomitant medications
Record AEs
Contact the IXRS
8.9 SFU Visit (20weeks after the last dose of bimekizumab or 
placebo; -3/+7 days)
The following procedures or assessments will be performed:
Vital signs (blood pressure, pulse rate, and temperature)
Body weight
Physical examination
eC-SSRS
Record 12 -lead ECG
PASI
IGA
HADS
Obtain blood samples for:
Standard safet y laboratory tests (hematology and biochemistry)
Serum pregnancy  test for women of childbearing potential
Bimekizumab plasma concentration
Anti- bimekizumab antibodies
Obtain urine sample for: 
Standard safet y laboratory tests (urinalysis)
Concomitant medications
Record AEs (including assessment for development of other forms of psoriasis)
Contact the IXRS
8.10 Earl y Withdrawal Visit
Subjects withdrawing early  from the stud y (see Section 6.3) will undergo the same assessments 
as the Week 48Visit (see Section 8.4) and will enter the SFU Period.
8.11 Unscheduled Visit
At the I nvestigator’s discretion, an Unscheduled Visit may  be completed at any  time during the 
study ,but prior to the SFU Visit, if deemed necessary  for the subject’s safety  and well -being.
If an additional visit ( or unscheduled visit )
is conducted due to safet y or efficacy reasons, an 
eC-SSRS assessment will be performed with the subject during the visit. If an additional visit ( or 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 43of 125unscheduled visit ) is conducted for reasons other than s afety or efficacy concerns 
(eg,replacement of lost medication, repeated collection of a laboratory  specimen due to 
collection or anal ysis issues), an eC -SSRS will not be required at these visits.
At this visit, any  ofthe following assessments may  be performed, depending on the reason for 
the visit:
Vital signs
Physical examination
Record 12- lead ECG 
eC-SSRS
If medicall y indicated, obtain blood sample(s) for:
Standard safet y laboratory tests (hematology and biochemist ry) 
The blood sample may  also be use d for PK assessments, if needed
Obtain urine sample for standard safety laboratory tests ( urinaly sis; including urine 
pregnancy  test)
Concomitant medication s
Record AEs
9 ASSESSMENT OF SA FETY
9.1 Adverse events
9.1.1 Definition of AE
An AE is an y untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product that does not necessaril y have a causal relationship with 
this treatment. An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease temporall y associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product.
In order to ensure complete safety  data collection, all AEs occurring during the study  (ie,after 
the signing of the Informed Consent form), including an y pretreatment and posttreatment periods 
required b y the protocol, must be reported in the eCRF even if no IMP was taken but specific 
study  proce dures were conducted. This includes all AEs not present prior to the initial visit and 
all AEs that recurred or worsened after the initial visit.
Signs or s ymptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs onl y if their nature changes considerabl y or their frequency or intensit y 
increases in a clinicall y significant manner as compared to the clinical profile known to the 
Investigator from the subject’s history
 or the Baseline Period.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 44of 1259.1.2 Procedures for reporting and r ecording AEs
The subject will be given the opportunity  to report AEs spontaneously . A general prompt will 
also be given at each study  visit to detect AEs. For example:
“Did y ou notice any thing unusual about y our health (since y our last visit)?”
In addition, the I nvestigator should review an y self-assessment procedures employ ed in the 
study .
9.1.3 Description of AEs
When recording an AE, the Investigator should use the overall diagnosis or sy ndrome using 
standard medical terminology , rather than recording individual sy mptoms or signs. The eCRF 
and source documents should be consistent. Any  discrepancies between the subject’s own words 
on his/her own records and the corresponding medical terminology  should be clarified in the 
source documentation.
When recor ding the severity  of an AE in the CRF (ie, mild, moderate, or severe), the Investigator 
must refer to the CTCAE Version 4 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm ).Details for 
completion of the AEeCRF (including judgmen t of severit y and relationship to I MP) are 
described in the eCRF Completion Guidelines.
9.1.4 Follow up of AEs
An AE should be followed until it has resolved, has a stable sequelae, the Investigator
determines that it is no longer clinically significant, or the subject is lost to follow up. Further 
details regarding follow up of PDILI events areprovided in Section 9.7.1.4.
If an AE is ongoing at the end of the stud
y for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the Investigator no longer deems that it is 
clinically  significant, or unt il the subject is lost to follow up. If no follow up is provided, the 
Investigator must provide a justification. The follow up will usually  be continued for 20 weeks
after the subject has discontinued his/her I MP.
9.1.5 Rule for repetition of an AE
An increase i n the intensity  of an AE should lead to the repetition of the AE being reported with:
The outcome date of the first AE that is not related to the natural course of the disease being 
the same as the start date of the repeated AE, and the outcome of “worseni ng”
The AE verbatim term being the same for the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one
9.1.6 Pregnancy
If an Investigator is notified that a subject has become pregnant after the first intake of any IMP, 
the Investigator must immediately  notify  UCB’s Patient Safety  (PS) department by  providing the 
completed Pregnancy  Report and Outcome form (for contact details see SAE reporting 
information at the beginning of this protocol). The subject should be withdrawn from the stud y 
as soon as pregnancy  is known (by  positive pregnancy  test), and the following should be 
completed:
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 45of 125The subject should return for an Early Withdrawal Visit .
The subject should immedia tely stop the intake of the I MP. 
A SFU Visit sh ould be scheduled 20 weeks after the subject has discontinued her IMP.
The Investigator must inform the subject of information currently known about potential risks 
and about available treatment alternatives.
The pregnancy  will be documented on the Pregnan cy Report and Outcome form provided to the 
Investigator . The progression of the pregnancy  and the eventual birth (if applicable) must be 
followed up using the Pregnancy  Report and Outcome form in which the Investigator has to 
report on the health of the mo ther and of the child. Every  reasonable attempt should be made to 
follow the health of the child for 30 days after birth for any  significant medical issues. In certain 
circumstances, UCB may request that follow up is contin ued for a period longer than 30 days. If 
the subject is lost to follow up and/or refuses to give information, written documentation of 
attempts to contact the subject needs to be provided by  the Investigator
and filed at the site. 
UCB’s PSdepartment is the primary  contact for any  questions related to the data collection for 
the pregnancy , eventual birth, and follow up.
In cases where the partner of a male subject enrolled in a clinical study  becomes pregnant, the 
Investigator or designee i s asked to contact the subject to request consent of the partner via the 
Partner Pregnancy Consent form that has been approved by  the responsible IRB/IEC and should 
be available in the Investigator site file. In case of questions about the consent process, the 
Investigator may contact the UCB/ Contract R esearch Organization (CRO) contract monitor for 
the study . The Investigator will complete the Pregnancy  Report and Outcome form and send it to 
UCB’s PSdepartment (for contact details see SAE reporting inform ation at the beginning of this 
protocol) only  after the partner has agreed that additional information can be captured and has 
provided the signed Partner Pregnancy  Consent form. UCB’s PS department is also the primary  
contact for an y questions related to the data collection for the partner pregnancy , eventual birth, 
and follow up.
A pregnancy  becomes a n SAE in the following circumstances: miscarriage, abortion (elective or 
spontaneous), unintended pregnancy  after hormonal contraceptive failure (if the horm onal 
contraceptive was correctly  used), ectopic pregnancy , fetal demise, or any  congenital 
anomaly /birth defect of the baby . Those SAEs must be additionally  reported using the 
Investigator SAE Report form.
9.1.7 Suspected transmission of an infectious agent via a medicinal 
product
For the purposes of reporting, an
y suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediatel y, recorded in 
the AE module of the eCRF, and followed as an yother SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy ), pathogenic or 
nonpathogenic, is considered an infectious agent.
9.1.8 Overdose of investigational medicinal product
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the eCRF. Any  SAE or nonserious AE associated with excessive dosing must be 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 46of 125followed as an y other SAE or nonserious AE. These events are onl y considered AEs or SAEs if 
there are associated clinical signs and s ymptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg, suicide attempt).
9.1.9 Safety  signal detection
Selected data from this study  will be reviewed periodically  to detect as earl y as possible an y
safet y concern(s) related to the I MP so that Investigator s, clinical study  subjects, regulatory  
authorities, and IRBs/IECs will be informed appropriately  and as earl y as possible.
In addition, an independent Data Monitoring Committee (DMC) will periodical ly review and 
monitor the safet y data from this study  and advise UCB. Details are provided in the DMC 
Charter. A C ardiovascular Adjudication Committee will also periodicall y review and monitor the 
safet y data from this study and advise UCB. Details are pro vided in the Cardiovascular
Adjudication Committee Charter.
The Study  Physician or medically  qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PSrepresentative.
As approp riate for the stage of development and accumulated experience with the I MP, 
medically  qualified personnel at UCB may  identify  additional safet y measures (eg, AEs, vital 
signs, laboratory , or ECG results) for which data will be periodicall y reviewed during the course 
of the study .
9.2 Serious a dverse events
9.2.1 Definition of SAE
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteria:
Death
Life-threatening
(Life-threa tening does not include a reaction that might have caused death had it occurred in 
a more severe form.)
Significant or persistent disability /incapacit y
Congenital anomal y/birth defect (including that occurring in a fetus)
Important medical event that, base d upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious
(Important medical events may  include , but are not limited to , potential Hy ’s Law [see 
Section 9.5], allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, blood dy scrasias that do not result in inpatient hospitalization, or the development of 
drug dependency  or drug abuse.)
Initial inpatient hospitalization or prolongation of hospitalization
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 47of 125(A patient admitted to a hospital, even if he/she is released on the same day , meets the 
criteria for the initial inpatient hospitalization. An emergency room visit that results in 
admission to the hospital would also qualify  for the initial inpatient hospitalization criteria. 
However, emergency room visits that do not result in admission to the hospital would not 
qualify  for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg, life-threatening adverse experience, important medical event].
Hospitalizations for reasons not associated with th e occurrence of an AE [eg, preplanned 
surgery  or elective surgery  for a pre -existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner] do not qualify for reporting. For example, if a 
subject has a condition recorded on his/her medical history  and later has a preplanned surgery  
for this condition, it is not appropriate to record the surgery or hospitalization as an SAE, 
since there is no AE upon which to assess the serious criteria. Please note that, if the 
pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify  as an AE and, if necessary, the seriousness of the event would need to 
be determined.)
Note: Confirmed active TB is alway s to be considered as an SAE and must be captured on an 
SAE Report Form and provided to the Sponsor in accordance with SAE reporting requirements.
9.2.2 Procedures for reporting SAEs
If an SAE is reported, UCB must be informed within 24 hours of receipt of this information by  
the site (see con tact information for SAE reporting listed in the SAE Reporting section at the 
front of the protocol). The Investigator must forward to UCB (or its representative) a dul y 
completed “Investigator SAE Report Form for Development Drug” (SAE report form) provid ed 
by UCB, even if the data are incomplete, or if it is obvious that more data will be needed in order 
to draw an y conclusions. Information recorded on this form will be entered into the global safet y 
database.
An Investigator SAE report form will be provided to the Investigator . The Investigator SAE 
Report form must be completed in English. 
It is important for the Investigator , when completing the SAE report form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the Investigator is very  important for UCB to consider in assessing the safet y of the IMP 
and in determining whether the SAE requires reporting to the regulatory  authorities in an 
expedit ed manner.
Additional information (eg, autops y or laboratory reports) received b y the Investigator must be 
provided within 24 hours. All documents in the local language must be accompanied by  a 
translation in English, or the relevant information included in the same document must be 
summarized in the I nvestigator SAE report form.
The Investigator is specifically  requested to collect and report to UCB (or its representative) any  
SAEs (even if the Investigator is certain that they  are in no way  associated wit h the I MP), up to 
30daysfrom the end of the study  for each subject, and to also inform participating subjects of 
the need to inform the Investigator of any  SAE within this period. Serious AEs that the 
Investigator thinks may  be associated with the IMP must be reported to UCB regardless of the 
time between the event and the end of the stud y.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 48of 125Upon receipt of the SAE report form, UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the IB.
9.2.3 Follow up of SAEs
An SAE should be followed until it has resolved, has a stable sequelae, the Investigator
determines that it is no longer clinically significant, or the subject is lost to follow up. Further 
details regarding follow up of PDILI events is provided in Section 9.7.1.4.
Information on SAEs obtained after clinical database lock will be captured through the PS
database without limitatio n of time.
9.3 Immediate reporting of AEs
The following AEs must be reported immediately :
SAE: AE that the Investigator classifies as serious by  the definitions in Section
9.2.1
regardless of causality
Suspected transmission of an infectious agent via a medicinal product
AEs of special interest as defined in Section 9.5
9.4 Anticipated SAEs
The following Anticipated SAEs (Table 9‒1) are anticipated to occur in th e population studied in 
this protocol at some frequency  that is independent of drug exposure. This original list will 
remain in effect for the duration of the protocol. Note that listed events will not be regarded as 
anticipated SAEs if they  are life
-threatening or if they  result in the death of the study  subject.
This list does not change the I nvestigator’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section 9.2.2.
Table 9
‒1: Anticipated SAEsfor the population of subjects with moderate to 
severe chronic plaque psoriasis
MedDRA®system order class MedDRA preferred term
Skin and subcutaneous tissue disorders Any psoriatic condition HLT
Musculoskeletal and connective tissue disorders Psoriatic arthropathy
HLT=high level term; MedDRA=Medical Dictionary for Regulatory Activities; SAE=serious adverse event
Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life -threatening or if they result 
in the death of the study subject.
9.5 Adverse events of special interest
An AE of special interest is any  AE that a regulatory  authority  has mandated be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound.
Potential Hy ’s Law, defined as ≥3xUL N ALT or AST with coexisting ≥2xULN total bilirubin in 
the absence of ≥2xUL N AL P, with no alternative explanation for the biochemical abnormalit y, 
must AL WAYS be reported to UCB as an AE of special interest (ie, without waiting for any  
additional etiologic investigations to have been concluded). Follow -up information should then 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 49of 125be reported if an alternative etiology  is identified during investigation and monitoring of the 
subject.
9.6 Adverse events for special monitoring
UCB has identified AEs for special monitoring (AESM). An AESM is a n AE or safet y topic for 
which special monitoring, additional data collection activities, and/or enhanced signal detection 
activities (within UCB), are considered appropriate. Identified AESM can be of particular 
interest based on findings from the IMP clinical program to date, potential risks generall y 
associated with biologic immunomodulators, or comorbidities and risk factors prevalent in the 
study  population.
Adverse events for special monitoring for this study  include: serious infections (including 
opportunistic infections and TB ;see Section 9.8.1), cy topenias, hy persensitivities, suicide 
ideation or behavior (assessed using the eC -
SSRS; see S ection 9.8.6 ), depression and anxiety  
(assessed using the HADS; see Section 12.9), major cardiovascular events, and liver function test 
changes/enz yme elevations (ALT, AST, bilirubin; see Section 9.7.1), malignancies, and 
inflammatory
 bowel diseases.
9.7 Laboratory  measurements
Clinical laboratory  assessments consist of serum chemistry , hematology , and urinaly sis. A 
centralized laboratory  will be used to supply  all laboratory  test supplies and a nalyze all blood 
and urine samples for hematology , biochemistry , and urinal ysis measurements. Any  unscheduled 
laboratory  testing should also be collected using the central laboratory . Laboratory  parameters to 
be measured are listed in Table 9‒2. 
Specific details regarding the handling and processing of serum chemistry , hematology , and 
urinaly sis samples are provided in the study  laboratory  manuals.
Table 9
‒2: Laboratory  measurements
Hematology Chemistry Urinalysis
Basophils Calcium Albumin
Eosinophils Chloride Bacteria
Lymphocytes CRP Crystals
Atypical lymphocytes Magnesium Glucose
Monocytes Potassium pH
Neutrophils Sodium RBC
Hematocrit Glucose WBC
Hemoglobin BUN Urine dipstick for pregnancy testinga
MCH Creatinine
MCHC ALP
MCV AST
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 50of 125Table 9‒2: Laboratory  measurements
Hematology Chemistry Urinalysis
Platelet count ALT
RBC count GGT
WBC count Total bilirubin
LDH
Total cholesterol
Serum pregnancy testing a
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; CRP=C -reactive protein; GGT=gamma glutamyltransferase; LDH=lactate dehydrogenase; MCH=mean 
corpuscular hemoglobin; MCHC=mean corpuscular hemoglobin concentration; MCV=mean corpuscular volume; 
RBC=red blood cell; W BC=white blood cell
aPregnancy testing will be done in all w omen of childbearing potential and will consist of serum testing at the 
Safety Follow -Up Visit and urine testing at all other visits .
Assessments of PK variables are described in Section 10. Assessments of immunological
variables are described in Section
11.
9.7.1 Evaluation of PDILI
The PDILI IMP discontinuation criteria for this study  are provided in Section
6.3.1 , with the 
accompan ying required follow -up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study  site and S ponsor within 24 hours of learning 
of their occurrence. An y PDILI event that meets the criterion for potential Hy ’s Law must be 
reported as an AE of special interest (see Section 9.5), and, if applicable, also reported as an SAE 
(see Section
9.2.1). 
Evaluation of PDILI consists of the diagnostic testing and continued mon itoring included in 
Table 9-3(specific tests dependent on laboratory  results and corresponding s ymptoms) and 
consultation with a local hepatologist (i f applicable; discussed in Section
9.7.1.1). The local 
hepatologist is the expert usually  consulted b y the treating ph ysician for assessment and 
management of potential hepatic disease. This would usually  be a hepatologist, but may  bea 
gastroenterologist. Additional investigation and monitoring may  be required and adapted based 
on the diagnosis after the cause of the liver injury /abnormality  is confirmed (details in 
Section
9.7.1.4). 
The results of all monitoring, including laboratory  testing and other testing, should be made 
available to the stud y site and sponsor.
All initial tests resulting in abnormal hepatic laboratory  valu es need to be repeated, but 
appropriate medical action must not be delay
ed waiting for the repeat result.
If tests are done locall y for more rapid results, a concurrent sample should also be sent to the 
central laboratory  whenever possible. Medical care de cisions are to be made initially  using the 
most rapidly  available results and a conservative approach must be taken if the results from the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 51of 1252laboratory  tests are significantly  different. Data from the local and central laboratory  are to be 
recorded on the applicable eCRF pages.
When I MP is discontinued, all concomitant medications and herbal supplements that are not 
medically  necessary  should also be discontinued. In these cases, the investigator should also 
consider dose reduction for medicall y necessary concomitant medication and consider changing 
any medicall y required concomitant medication known to be hepatotoxic to a suitable 
alternative.
When I MP is stopped due to PDILI (as described in Section 6.3.1), I MP must be permanentl y 
discontinued even if 
a subsequent alternative diagnosis fully  explains the hepatic findings. 
Rechallenge with a substance potentiall y causing drug -induced liver injury is d angerous, may  be 
fatal, and must not occur.
Table 9-3summarizes the approach to investigate PDILI.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 52of 125Table 9-3: Required investigations and follow- up for PDILI
Laboratory valueSymptomsaof 
hepatitis or 
hypersensitivityImmediate Follow up
ALT or 
ASTTotal 
bilirubinConsultation 
requirementsActions Testing Evaluation
≥3xULN ≥2xULNbNA Hepatology consult.c
Medical Monitor 
must be notified 
within 24 hours 
(eg,by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.Immediate, permanent 
IMP discontinuation.Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section 9.7.1.3 ); 
recommended to 
occur at the site 
with HCP.Monitoring of liver 
chemistry values at least 
twice per week until values 
normalize, stabilize, or 
return to within baseline 
values. d≥3xULN NA Yes
≥5xULN NA NA Need for hepatology 
consult to be 
discussed (required if 
ALT or AST 
≥8xULN).
Medical Monitor 
must be notified 
within 24 hours 
(eg,by laboratory 
alert) and subject 
discussed with 
Medical Monitor
ASAP.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 53of 125Table 9-3: Required investigations and follow- up for PDILI
Laboratory valueSymptomsaof 
hepatitis or 
hypersensitivityImmediate Follow up
ALT or 
ASTTotal 
bilirubinConsultation 
requirementsActions Testing Evaluation
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN
(and ≥2x 
baseline)<2xULN No Discussion with 
Medical Monitor 
required.
Consider need for 
hepatology consult if 
there is no evidence 
of resolution (see 
Follow up 
requirements).cFurther investigation –
immediate IMP 
discontinuation not 
required (see 
Section 9.7.1.2 ).
IMP discontinuation 
required if any of the 
following occur:
Subject cannot com ply 
with monitoring 
schedule.
Liver chemistry values 
continue to increase.
Liver chemistry values 
remain ≥3 xULN (and 
≥2xbaseline) after 
2weeks of monitoring 
without evidence of 
resolution.Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48 hours at 
the site with HCP 
(see 
Section 9.7.1.3 ).Monitoring of liver 
chemistry value s at least 
twice per week for 
2weeks.d
Immediate IMP 
discontinuation required if 
liver chemistry values 
continue to in crease.
After 2 weeks of 
monitoring liver chemistry 
values:
Discontinue IMP if levels 
remain ≥3xULN (and 
≥2xbaseline) without 
evidence of resolutiond
Continue to monitor until 
values normalize, 
stabilize, or return to 
within baseline values .d
ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; IMP=inve stigational medicinal 
product; NA=not applicable; PDILI=potential drug -induced liver injury; ULN=upper limit of normal 
aHepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
bIf the subject also has ≥2xULN alkaline phosphatase , the possibility of an indication of biliary obstruction should be discussed w ith the Medical Monitor.
cDetails provided in Section 9.7.1.1 . The local hepatologist is the expert usually consulted by the treating physician for assessment and management of potential 
hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
dUnless an alternative monitoring schedule is agreed by the Investigator and UCB responsible physician. Determination of stabilizati on is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 54of 1259.7.1.1 Consultation with Medical Monitor and local hepatologist 
Potential drug -induced liver injury  events require notification of the Medical Monitor within 
24hours (eg, b y laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject m ust also be discussed with the local hepatologist. The 
local hepatologist is the expert usually  consulted by  the treating phy sician for assessment and 
management of potential hepatic disease. This would usually  be a hepatologist, but may  be a 
gastroenterol ogist. If determined necessary , this discussion should be followed by  a full 
hepatology  assessment (see Section 9.7.1.3) and SAE report (if applicabl e).
9.7.1.2 Immediate action: determination of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the laboratory  values and s ymptoms of hepatitis or 
hypersensitivity  and ranges from continuation of IMP (followed by immediate investigation) to 
immediate and permanent discontinuation (see Section 6.3.1 and Table 9-3for details).
When I MP is discontinued, all concomitant medications and herbal supplements that are not 
medically  necessary  should also be discontinued. The investigator should also consider dose 
reduction for medicall y necessary  concomitant medication and consider changing an y medicall y 
required concomitant medication known to be hepatotoxic to a suitable alternative.
9.7.1.3 Testing: identification/exclusion of alternative etiology
The measurements and additional information required for the assessment of PDILI events when 
there is a 
reasonable possibility that they  may  have been caused by  the IMP include, but are not 
limited to, those listed in Table 9-4(laboratory  measurements) and Table 9-5(additional 
information). Results of the laboratory  measurements and information collected are to be 
submitted to the sponsor on the corresponding eCRF. If the medical history of the subject 
indicates a requirement for other assessments not included below, these additional assessments 
should be completed and submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locall y for more rapid results, a 
concurrent sample must also be sent to the central laboratory .
Thelaboratory measurements to be assessed are presented in Table 9-4.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 55of 125Table 9-4: PDILI laboratory  measurements
Virology-
relatedHepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb -IgM
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein -Barr viral capsid antigen IgM antibod y (if unavailable, obtain 
heterophile antibod y or monospot testing)
Immunology Anti- nuclear antibody  (qualitative and quantitative)
Anti- smooth muscle antibody  (qualitative and quantitative)
Type 1 anti -liver kidney  microsomal antibodies (qualitative and /or quantitative )
Hematology Eosinophil count
Urinalysis Toxicology  screena
Chemistry Amy lase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin
Serum CPK and L DH to evaluate possible muscle injury  causing transaminase 
elevation
Additional Prothrombin time/INRb
Serum pregnancy  test
PK sample
ALT=alanine aminotransferase; CPK=creatine phosphokinase; HBcAb -IgM=hepatitis B core antibody -IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; LDH=lactate 
dehydrogenase; PDILI=potential drug -induced liver injury; PK=pharmacokinetic; RNA=ribonucleic acid; 
ULN=upper limit of normal
aFor detecting substances (ie, amphetamines, benzodiazepines, opioids, marijuana, cocaine, phencyclidine, and 
tricyclic antidepressants), additional tests may be performe d based on the Investigator’s medical judgment and 
patient’s history.
bMeasured only for subjects w ith ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and righ t upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (w ithout clear alternative 
cause).
Additional information to be collected is presented in Table 9-5.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 56of 125Table 9-5: PDILI information to be collected
New  or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.
Pertinent medical history, including the following:
History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty liver 
disease”)
Adverse reactions to drugs
Allergies
Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha- 1 antitrypsin 
deficiency)
Recent travel 
Progression of malignancy involving the liver (Note: Metastatic disea se to the liver, by itself, should 
not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or ten derness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Alcohol and illicit drug use
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug -induced liver injury
9.7.1.4 Follow -up evaluation
Potential drug -induced liver injury  events require follow -up monitoring as described in 
Table 9-3. Monitoring should continue until liver chemistry  val ues normalize, stabilize, or return 
to baseline. Determination of stabilization is at the discretion of the investigator in consultation 
with the hepatologist (as applicable) and UCB responsible physician, as needed.
9.8 Other safety  measurements
9.8.1 Assessment an d management of TB and TB risk factors
All subjects will be assessed for TB through ph ysical examination for si gns and sy mptoms of 
TB, laboratory  testing ( Section 9.8.1.1), and subject questionnaire ( Section 9.8.1.3). A chest 
x
-ray can be performed in PS0 011, if warranted ,to confirm or exclude TB ( Section 9.8.1.2).
At the Baseline Visit of PS0011
, all subjects will undergo ph ysical examination for signs and 
symptoms of TB and must be confirmed to have undergone an IGRA test (QuantiFERON TB 
GOLD is recommended) at the Week 8 Visit of PS0010 with negative results .In addition, each 
subject will complete a TB questionnaire with questions directed at s ymptoms of TB and 
potential exposure to TB. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 57of 125Exclusion criteria at Baseline of PS0011
Subjects with known TB infection, at high risk of acquiring TB infection, or latent TB infection 
are excluded. 
a.Known TB infection whether present or past is defined as:
Active TB infection or clinical signs and s ymptoms suspicious for TB (pulmonary  or 
extra -pulmonary )
History  of active TB infection involving any  organ sy stem or findings in other organ 
systems consistent with TB infection, unless adequately  treated and pro ven to be fully  
recovered upon consult with a TB specialist
Any evidence by  radiography  or other imaging modalities consistent with previously  
active TB infection that is not reported in the subject’s medical history
b. High risk of acquiring TB infection is defined as:
Known exposure to another person with a ctive TB infection within the 3
months prior to 
enrollment
Time spent in a healthcare delivery  setting or institution where individuals infected with 
TB are housed and where the risk of transmission of infection is high
c.Latent TB infection is defined as:
The absence of signs, s ymptoms (ie, evidence of organ -specific involvement), or phy sical 
findings suggestive of TB infection with a positive IGRA test (or 2 indeterminate I GRA 
test results) and a chest x -ray (or other imaging) without evidence of TB infection. If the 
result of the IGRA test is indeterminate, the particular IGRA test previously  performed 
may be repeated once; if positive or indeterminate on retest, the subject may  not be 
enrolled in the st udy. The retest m ust be done prior to entry  in PS0011 .
Note: If available, respiratory  or other specimens must also be smear and culture 
negative for TB (Centers for Disease Control diagnosis of L TB infection) 
http://www.cdc.gov/TB/topic /testing/default.h tm)
d.Current or history  of NTMB infection
Signs and Sy mptoms
The Investigator should consider all potential sites of infection when assessing for TB during the 
physical examination and other evaluations, and based on the subject’s medical or social history .
The most common primary  focus of TB is the lung. Other sites may  include GI system, 
bone/joints, ly mph glands and meninges
,etc. However, in immune compromised patients and/or 
patients tre ated with TNF inhibitors, extra pulmonary  manifestations of TB arecommon 
compared to the normal population.
Some common sy mptoms that the subject may  present are dependent on the primary  focus of 
infection and may  include cough, blood in sputum, night sweats, ly mphadenitis, joint 
pain/swelling, spinal deformity , headache /confusion, abdominal pain (mimicking inflammatory  
bowel disease), etc. Unusual presentations should alway s be considered.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 58of 125Latent TBinfection is defined in the “Exclusion Criteria” above. If the result of the IGRA is 
indeterminate, the particular IGRA pre viously  performed may  be repeated once; if positive or 
indeterminate on retest, the subject may  not be enrolled in the study without further evaluation 
by a TB specialist .In the event of an indeterminate test result , the retest must be done prior to the 
next visit .If LTB infection or active TB is identified, subject must undergo appropriate study  
specified withdrawal procedures. Laboratory  diagnosis should be undertaken via my cobacteria 
culture media (or if available b y preferred nucleic acid amplificatio n test such as the Xpert MTB 
RIF test) and 
the result must be negative for TB inducing pathogens.
Test Conversion
Tuberculosis test conversion is defined as a positive IGRA result for the current test when 
previous IGRA test results were negative. All subjects with TB test conversion must immediately  
stop study  drug administration. I n case of a TB test conversion, the subject must be considered as 
having either a suspected new latent or an active TB infection and be promptly  referred to an 
appropriate speci alist (eg, pulmonologist, infectious disease specialist) for further evaluation. If 
test conversion indicates LTB infection , active TB, or NTMB then, per UCB TB working 
instructions, TB test conversion (confirmed) should be classified adequately , either as due to 
LTB infection , active TB infection, or NTMB, respectivel y. Additional assessme nts (eg, blood 
tests or IGRA, chest x -rays, or other imaging) should be performed where medically  relevant and 
documented. Such conversions should be reported to the UCB PSfunction.
LTB
In case the evaluation by  the appropriate specialist indicates a new LTB infection during the 
study , a proph ylactic TB treatment should be initiated and the subject must be withdrawn from 
the study . Every  related action should be discussed in advance with the Medical Monitor. 
Once withdrawn from study  treatment, subjects should return for the Week 48/Withdrawal Visit, 
complete all Earl
y Withdrawal Visit assessment s, and complete a SFU Visit ( 20weeks after the 
last dose of study  medication).
Active TB or NTMB infection 
Subjects who develop active TB or NTMB infection during the stud y must be withdrawn from 
the study . The subject must be immediately  discontinued from study  medication and an Earl y 
Withdrawal Visit must be scheduled as soon as possible, but no later than the next scheduled 
visit. The subject should be encouraged to keep th e SFU Visit as specified by  the protocol. 
Treatment should be started immediately .
Note that subjects with history  of NTMB or active NTMB infection are excluded from the study  
regardless of prior or current therap y for this condition. 
9.8.1.1 TBassessment by  IGRA
During conduct of the study , the TB assessment by IGRA (QuantiFERON TB GOLD is 
recommended) will be performed at Week 8 of PS0010 and should be repeated at Week 48/Earl y 
Withdrawal Visit for all subjects. The test results will be reported as positive, ne gative, or 
indeterminate. UCB also recommends that a TB specialist be consulted where TB (latent or 
active) is suspected or if there are doubts regarding test results. If latent or active TB is 
identified, the 
subject must undergo appropriate study -specifi ed withdrawal procedures. In the 
event of an indeterminate test result, t he retest must be done prior to the next visit .
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 60of 1259.8.2 Pregnancy  testing
Pregnancy  testing will consist of serum testing at the SFU Visit and urine testing at all other 
visits. 
The Baseline Visit urine pregnancy  test result must be negative prior to enrollment of the subject. 
A negative urine pregnancy  test result should be o btained immediately  prior to each 
administration of study  drug and at all subsequent visits. Pregnancy  tests should be administered 
to all female subjects of childbearing potential, regardless of their use of birth control.
9.8.3 Vital signs
Vital signs will be collected at every  visit and will include sy stolic and diastolic blood pressure , 
pulse rate, and bod y temperature (oral , axillary , or otic). Subjects should be sitting for 5 minutes 
before and during vital signs assessments. 
Vital signs are to be measured prior to blood sampling, and prior to dosing, where applicable. 
Body weight will be measured at the time points specified in the schedule of study  assessments 
(Table 5‒1).
9.8.4 12
-lead ECGs
Twelve -lead standard ECGs will be recorded at the visits specified in Table 5‒1, and read b y a 
central ECG laboratory . 
Full details of ECG recording will be provided in the ECG Manual. 
9.8.5 Physical examination
The phy sical examination will include general appearance; ear, nose, and throat; ey es, hair, and 
skin; respiratory ; cardiovascular ; GI; musculoskeletal; hepatic; neurological (including limb 
reflexes); and mental status. Phy sical examination will be performed at the at the time points 
specified in the schedule of stud y assessments ( Table 5‒1). Findings considered clinically  
significant changes since the phy sical examination at the Screening Visit of PS0010 will be 
recorded as AEs.
9.8.6 Assessment of suicidal ideation and behavior
Suicidal ideation and behavior will be assessed b y trained study  personnel using the e
C-SSRS. 
This scale will be used to assess suicidal ideation and behavior that may  occur during the study . 
The visits at which the eC-SSRS assessments will be performed are specified in the schedule of 
study  assessments ( Table 5‒1).
The eC -SSRS is a standardized and validated instrument developed for the assessment of the 
severit y and frequency of suicidal ideation and behavior (Mundt et al, 2010; Posner et al, 2 011). 
Subjects respond to standardized clinical questions that are presented in a uniform fashion. The 
eC-SSRS defines five subty pes of suicidal ideation and behavior in addition to self -injurious 
behavior with no suicidal intent. The eC
-SSRS takes approxi mately  3 to 10 minutes to complete.
Refer to Section 6.3 for eCSSR S-related withdrawal criteria.
9.8.7 Data Monitoring Committee
The DMC membership includes clinicians knowledgeable about the disease or the treatment. The 
DMC will include a statistician, and at a minimum, specialists in dermatology  and infectious 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 61of 125disease. All members have experience and expertise in clinical trials. Board members may  not 
participate in the stud y as principal or co-Investigators, or as study  subject care phy sicians. The 
duration of membership for the DMC will be inclusive of planned anal yses for PS0011. The 
DMC may  also be asked to provide a review of final study  results, as deemed appropriate.
The detailed role, scope, responsibilities, and complete procedures, as well as the identity  of the 
DMC members, will be described in a separate charter document.
The DMC procedures will ensure that data remain blind to the study  team and I nvestigators at all 
times throughout the conduct of the study .
A Cardiovascular Adjudication Committee will also periodicall y review the safet y data from this 
study . Details will be described in a separate charter document.
10 ASSESSMENT OF PHA RMACOK INETIC VA RIABLES
Blood samples for measurement of PK ( Section 4.2) will be collected at the time points specified 
in the schedule of study  assessments ( Table 5‒1). 
At dosing visits, blood samples will be drawn prior to dosing, and will be drawn at the same time 
of the sampling fo r clinical laboratory  tests. The time and date of collection will be recorded in 
the eCRF. 
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study . Detailed information
on sample anal ysis will be 
provided in a bioanal ytical report.
11 ASSESSMENT OF IMMUNOLOGIC AL VARIABLE S
Blood samples for measurement of antibodies to bimekizumab will be collected at the visits 
specified in Table 5‒1. The threshold for antibody positivity  will be defined prior to anal ysis.
At dosing visits, blood samples will be drawn prior to dosing, and will be drawn at the same time 
of the sampling for clinical laboratory  tests. The time and date of collection will be recorded in 
the eCRF. 
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study . The presence of antibodies to bimekizumab will 
be determined using a validated bioanal ytical method. Detailed information on sample anal ysis 
will be provided in a bioanal ytical report.
12 ASSESSMENT OF EFFICA CY
12.1 Psoriasis A rea and Severity Index
The PASI  is the most commonly  used and validated assessment for grading the severit y of 
psoriasis in clinical studies (Feldman, 2004). The PASI  quantifies the severity  and extent of the 
disease and weighs these with the percentage of BSA involvement. 
The degree of involveme nt is estimated across 4 body  areas; head, upper limbs, trunk, and lower 
limbs and then transferred into a grade ( Table 12‒1). 
The Investigator assesses the average re dness, thickness, and scaliness of lesions in each body  
area (each on a 5 -point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very  marked. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 62of 125The PASI  score ranges from 0 to 72 with a higher score indicating increased disease severity . 
Table 12‒1:Body areas for calculation of percent BSA  for PA SI
Body area Details of area BSA Degree of involvement of 
body areaa
Head Face, back of head 10% 0 to 6
Upper limbs Left, right, upper lower, flexor surface, 
extensor surface20% 0 to 6
Trunk Front, back, groin 30% 0 to 6
Lower limbs Left, right, upper lower, flexor surface, 
extensor surface, including buttocks40% 0 to6
Total 100% 
BSA=body surface area; PASI=Psoriasis Area and Severity Index
aWhere 0=none; 1=1% to <10% affected, 2=10% to <30% affected, 3=30% to <50% affected, 4=50% to <70% 
affected, 5=70% to <90% affected, 6=90% to 100% affected .
The PASI 50, PASI75, PASI 90, and PASI 100 responses are based on at least 50%, 75%, 90%, 
and 100% improvement in the PASI  score. The improvement will be based on changes from the 
PASI  score at the Baseline of P S0010.
The PASI  will be completed at the visits specified in Table 5‒1.
12.2 Investigator’s Global A ssessment
A static IGA for 
psoriasis will be used to assess disease severit y in all subjects during the stud y. 
The IGA will be completed at the visits specified in Table 5‒1. 
The Investi gator will assess the overall severit y of psoriasis using the following 5 -point scale:
5 point Investigator’s Global Assessment
Score Short Descriptor Detailed Descriptor
0 ClearNo signs of psoriasis; post -inflammatory hyperpigmentation may be 
present
1 Almost clear No thickening; normal to pink coloration; no to minimal focal scaling
2 MildJust detectable to mild thickening; pink to light red coloration; 
predominately fine scaling
3 ModerateClearly distinguishable to moderate thickening; dull to bright red, 
clearly distinguishable to moderate thickening; moderate scaling
4 SevereSevere thickening with hard edges; bright to deep dark red coloration; 
severe/coarse scaling covering almost all or all lesions
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 63of 12512.3 Dermatology  Life Quality  Index
The DLQI is a questionnaire designed for use in adult subjects with psoriasis. The DLQI is a skin 
disease -specific questionnaire aimed at the evaluation of how sy mptoms and treatment affect 
patients’ health related quality  of life ( QOL ). This instrument as ks subjects about sy mptoms and 
feelings, dail y activities, leisure, work and school, personal relationships and treatment. It has 
been shown to be valid and reproducible in psoriasis patient s. The DLQI score ranges from 
0to30 with higher scores indicatin g lower health related QOL. A 5 -point change in the DLQI 
score (DLQI response) has been reported to be meaningful for the patient (within -patient 
minimal important difference); while a DLQI absolute score of 0 or 1 indicates no or small 
impact of the disease on health related QOL . Subjects will be asked to complete the DLQI as 
outlined in the Schedule of Study  Assessments ( Table 5‒1). Study  site personne l should ensure 
that each subject completes the instrument prior to leaving the study  site. 
12.4 BSA  affected by  psoriasis
The BSA palm method will be used for the evaluation of BSA as follows:
Body surface area estimation uses the palm (subject’s flat hand an d thumb together, fingers 
included) as representing around 1% of the total BSA.
Subject’s palm=1%
Head and neck=10% (10 palms)
Upper extremities=20 % (20 palms)
Trunk=30% (30 palms)
Lower extremities=40 % (40 palms) 
Total BSA=100%
Evaluation of BSA will be completed at the visits specified in Table 5‒1.
12.5 Modified Nail Psoriasis Severity  Index
Psoriatic nail disease will be evaluated at the Baseline Visit of PS0010 using the mNAPSI. All 
affected nails will be scored (0 to 3) for ony cholysis/oil drop dy schromia, nail plate crumbling, 
and pitting and will be scored (0 for “no” or 1 for “yes”) for leukon ychia, nail bed 
hyperkeratosis, splinter haemorrhages and red spots in the lunula. The score for a n individual 
nail ranges from 0 to13 with higher scores indicative of more severe nail disease. The total 
mNAPSI  score is the sum of the scores for each individual nail. I f a nail is unaffected, it will be 
recorded as such and will not contribute to the total mNAPSI  score. Subjects with nail disease at 
Baseline are defined as those with an mNAPSI  score >0 at Baseline of PS0010.
The mNAPSI  will be assessed at the visits specified in Table 5‒1. 
12.6 Psoriasis Scalp Severity  Index
The PSSI  considers both the extent of the area of involvement and the severity  based on the 
scoring scales outlined in 
Table 12‒2. The assessment considers ery thema, induration ,and 
desquamation on the scalp. For each of these 3 elements, the scores of the area and severit y are 
multiplied. Th en, the score from each element is totaled to obtain the PSSI
 score. As with the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 64of 125PASI , the PSSI  score ranges from 0 to 72 with a higher score indicating increased scalp disease 
severit y.
The PSSI  will be assessed at the visits specified in Table 5‒1. 
Table 12‒
2:Parameters assessed for the PSSI
Assessment of extent of scalp psoriasis
Score Definition
1 <10%
2 10-29%
3 30-49%
4 50-69%
5 70-89%
6 90-100%
Assessment of clinical symptoms 
(erythema, induration, and desquamation)
Score Definition
0 Absent
1 Slight
2 Moderate
3 Severe
4 Severest possible
PSSI=Psoriasis Scalp Severity Index
12.7 PGADA for the arthritis VA S
The PGADA for the arthritis VAS will be used to provide an overall evaluation of arthritis 
disease s ymptoms. Subjects will respond to the question, “Considering all the way s your arthritis 
affects y ou, please mark a vertical line on the scale below to show how y ou are feeling today ,” 
using a VAS where 0 is “very  good, no s ymptoms” and 100 is “very  poor, severe s ymptoms. ”
Each subject will complete the PGADA at the visits specified in Table 5‒1.
12.8 36
-Item Short Form Health Survey
The SF -36 (Version 2, standard recall) is a 36 -item generic health -related QOL instrument that 
uses a recall period of 4 weeks. Items are grouped into 8 domains as follows: Phy sical 
Functioning (10 items), Role Phy sical (4 items), Bodily  Pain (2 items), Ge neral Health (5 items), 
Vitality  (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health 
(5items), and 1 item for perceived stability  or change in health (Health Transition) during the 
last y ear. The concepts represented b y these domains contribute to phy sical, mental, and social 
aspects of health -related QOL. In addition to domain scores, the PCS and MCS scores are 
calculated from the 8 domains (excluding the Health Transition item). Component scores 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 65of 125appreciate the impact of each domain on phy sical and mental health status (Maruish, 2011). Each 
of the 8 domain scores and the component summary  scores range from 0 to 100, with a higher 
score indicating a better health status. The domains and the 2 component summary  scores are 
standar dized with a mean of 50 and a standard deviation of 10 in the general USA population. 
The minimally  important differences, in terms of T- score points, for SF -36 domains and 
component summaries are as follows: PCS, 2; MCS, 3; Phy sical Functioning, 3; Role -
Physical, 3; Bodily Pain, 3; General Health, 2; Vitality, 2; Social Functioning, 3; Role -
Emotional, 4; and Mental Health, 3 (Maruish, 2011).
The SF -36 will be completed by  the subject the visits specified in Table 5‒1. 
12.9 Hospital A nxiety  and Depression Scale
The HADS was chosen for its well -established psy chometric properties and its use in clinical 
research on biological therap y in subjects with chronic pl aque psorias is (Dauden etal,2009; 
Langley etal,2010). The HADS scores for anxiety  
and for depression range from 0 to21 with 
higher scores indicating worse state. A score below 8 is considered to be normal 
(Snaith andZigmond, 1994).
13 STUDY M ANAG EMENT A ND A DMINISTRA TION 
13.1 Adherence to protocol
The Investigator should not deviate from the protocol. However, the Investigator should take any  
measure necessary  in deviation from or not defined by  the protocol in order to protect clinical 
study  subjects from an y immediate hazard to their health and safet y. In this case, this action 
should be taken immediately , without prior notification of the regulatory  authority , IRB/IEC, or 
Sponsor.
After implementation of such measure, the Investigator must notify  the C linical Project Manager 
of the Sponsor within 24 hours and follow an y local regulatory requirements.
13.2 Monitoring
UCB (or designee) will monitor the study  to meet the Sponsor’s monitoring Standard Operating 
Procedures (SOPs), I CH-GCP guideline, and applicable regulatory  requirements, and to ensure 
that study  initiation, conduct, and closure are adequate. Monitoring of the study  may  be 
delegated b y UC B to a CRO or a contract monitor.
The Investigator and his/her staff are expected to cooperate with UCB (or desig nee) and to be 
available during the monitoring visits to answer questions sufficiently  and to provide any  
missing information. The I nvestigator(s)/institution(s) will permit direct access to source 
data/documents for stud y-related monitoring, audits, I RB/IEC review, and regulatory  
inspection(s).
The Investigator will allow UCB (or designee) to periodicall y review all eCRFs and 
corresponding source documents (eg, hospital and laboratory  records for each study  participant). 
Monitoring visits will provide UCB (or designee) with the opportunity  to evaluate the progress 
of the study , verify  the accuracy  and completeness of eCRFs, ensure that all protocol 
requirements, applicable authorities regulations, and I nvestigator’s obligations are being 
fulfilled, and reso lve any inconsistencies in the study  records.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 66of 12513.2.1 Definition of source data 
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. Source documentation should be made using some permanent form of recording (ink, 
typing, printing, optical disc). They  should not be obscured by  correction fluid or have temporary  
attachments (such as removable self -stick notes). Photocopies of eCRFs are not considered 
acceptable source documents. Source documents are original records in which raw data are first 
recorded. These may  include hospital/clinic/general practitioner records, charts, diaries, x -rays, 
laboratory  results, printouts, pharmacy  records, care records, ECG or other printouts, completed 
scales, or QOL questionnaires, f or example. Source documents should be kept in a secure, 
limited access area.
The Sponsor or designee will review to ensure that computerized source documents produced b y 
the site are compliant with Food and Drug Administration ( FDA ) Part 11 requirements and 
document appropriatel y. Source documents that are computer generated and stored elect ronicall y 
that are not FDA Part 11 compliant, must be printed for review by  the monitor (eg, ECG reports). 
Once printed, these copies should be signed and dated b y the Investigator and become a 
permanent part of the subject’s source documents. The Investigator will facilitate the process for 
enabling the monitor to compare the content of the printout and the data stored in the computer 
to ensure all data are consistent.
Electronic data records, such as Holter monitor records or electroencephalogram records, must 
be saved and stored as instructed b y the Sponsor or designee. 
Patient Reported Outcome (PRO) measures (eg, DLQI, SF -36, and PGADA) will be completed 
by each subj ect utilizing electronic data capture.
13.2.2 Source data verification
Source data verification ensures accuracy  and credibility  of the data obtained. During monitoring 
visits, reported data are reviewed with regard to being accurate, complete, and verifiable fro m 
source documents (eg, subject files, recordings from automated instruments, tracings [ECG], 
x-ray films, laboratory  notes). All data reported on the eCRF should be supported by  source 
documents, unless otherwise specified in Section 13.2.1.
13.3 Data handling
13.3.1 eCRF completion
This study  will use electronic data capture (EDC); the I nvestigator is responsible for prompt 
reporting of accurate, complete, and l egible data in the eCRF and in all required reports.
This study  will use an electronic device to capture patient reported outcomes (see 
Section
13.2.1).
Serious 
AEreporting will be done using the SAE Form (see Section 9.2.2) while also entering 
the event in the appropriate eCRF section. The safety  database and the clinical database will be 
reconciled during the study  and discrepancies will be corrected as needed.
The Investigator should maintain a list of personnel authorized to enter data into the eCRF. 
Access to the EDC will be given after training has been received. A training certificate will be 
provided and filed.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 67of 125Detailed instructions on the use of the EDC will be provided in the eCRF Completion 
Guidelines.
Corrections made after the Investigator’s review and approval (b y means of a 
password/electronic signature) will be re -approved by  the Investigator. Any  change or correction 
to the eCRF after saving must be accompanied b y a reason for the change.
13.3.2 Database entry  and reconciliation
Case Report Forms/external electronic data will be enter ed/loaded into a validated electronic 
database using a clinical data management sy stem. Computerized data cleaning checks will be 
used in addition to manual review to check for discrepancies and to ensure consistency  of the 
data. This study  is performed us ing EDC: the data are entered into the eCRFs once and are 
subsequently  verified.
An electronic audit trail system will be maintained to track all data changes in the database once 
the data have been saved initially  into the s ystem or electronically  loaded. Regular backups of 
the electronic data will be performed.
13.3.3 Subject Enrollment l og/Subject Identification Code list
The subject’s enrollment will be recorded in the Su bject Enrollment L og.
The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject.
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify  the study  and document the dates o f the subject’s 
participation.
13.4 Termination of the study
UCB reserves the right to temporaril y suspend or prematurel y discontinue this study  either at a 
single site, multiple sites, or at all sites at an y time for reasons including, but not limited to, 
safety or ethical issues, inaccurate or incomplete data recording, noncompliance, or 
unsatisfactory  enrollment with respect to qualit y or quantity.
If the stud y is prematurely terminated or suspended, UCB (or its representative) will inform the 
Investigators/i nstitutions and the regulatory  authority (ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory  
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by  the Sponsor or b y the Investigator/institution, as specified b y the 
applicable regulatory  requirement(s). In addition, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB pr ocedures for the study .
13.5 Archiving and data retention
The Investigator will maintain adequate records for the study , including eCRFs, medical records, 
laboratory  results, I nformed Consent documents, drug dispensing and disposition records, safety  
reports, i nformation regarding participants who discontinued, and other pertinent data.
All essential documents are to be retained b y the Investigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no p ending or 
contemplated marketing applications in an I CH region, or at least 2 years have elapsed since the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 68of 125formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by the applic able regulatory  requirement(s) or by  an 
agreement with UCB ( Committee for Proprietary  Medicinal Products [ CPMP ]/ICH/135/95, 2002 
[Section 4.9.5]). The I nvestigator will contact UCB for authorization prior to the destruction of 
any study  records or in the e vent of accidental loss or destruction of an y study  records. The 
Investigator will also notify  UCB should he/she relocate or move the study -related files to a 
location other than that specified in the Sponsor’s study  master file.
13.6 Audit and inspection
The Investigator will permit study -related audits mandated b y UCB, after reasonable notice, and 
inspections by  domestic or foreign regulatory  authorities.
The main purposes of an audit or inspection are to confirm that the rights and well -being of the 
subjects enrolled have been protected, that enrolled subjects (ie, signing consent and undergoing 
study  procedures) are appropriate for the study , and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the plan ned arrangements, the 
protocol, investigational site, and I RB/IEC SOPs, ICH GCP, and applicable regulatory  
requirements.
The Investigator will provide direct access to all study  documents, source records, and source 
data. If an inspection b y a regulatory  authority  is announced, the Investigator will immediately  
inform UCB (or designee).
13.7 Good Clinical Practices
Noncompliance with the protocol, I CH-GCP, or local regulatory  requirements by  the 
Investigator, institution, institution staff, or designees of the S ponsor will lead to prompt action 
by UCB to secure compliance. Continued noncompliance may  result in the termination of the 
site’s involvement in the study .
14 STATISTICS
A description of statistical methods is presented below and will be described in more de tail in the 
Statistical Analy sis Plan (SAP) .
14.1 Definition of analy sis sets
The Enrolled Set (ES) will consist of all subjects who have given informed consent for PS0011.
The Safet y Set (SS) will consist of all subjects who receive at least 1 dose of the stud y 
medication in PS0011.
The Full Anal ysis Set (FAS) will consist of all enrolled subjects who receive at least 1 dose of 
the study  medication in PS0011 and have a valid efficacy  measurement for PASI  at Baseline of 
PS0011. 
The Pharmacokinetics Per -Protocol Set (PK -PPS) will consist of all enrolled subjects who 
receive at least 1 dose of the study  medication in PS0011 andprovide at least 1 quantifiable 
plasma concentration postdose in PS0011.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 69of 12514.2 General statistical considerations
No inferential statistical anal yses are planned for this extension study . Instead, all variables will 
be presented using summary  statistics. For categorical variables, counts and percentages will be 
display ed. For continuous variables, summary  statistics w ill consist of the number of available 
observations, arithmetic mean, standard deviation, median, minimum, and maximum unless 
stated otherwise. 
Because subjects entering PS0011 may  or may  not be continuing on the same dose as that 
received in PS0010, there are various combinations of treatment that could be received when 
considering both PS0010 and PS0011 together. For describing the summaries to be produced, 
treatment groups will be categorized as either the PS0011 treatment groups or PS0010/PS0011 
treatm ent groups. These categorizations are outlined below.
PS0011 treatment groups
This refers to the stud y treatment assigned to the subject at the beginning of PS0011 and does not 
account for the treatment received in PS0010. The PS0011 treatment groups are a s follows:
Placebo
Bimekizumab 64mg Q4W
Bimekizumab 160mg Q4W
Bimekizumab 320mg Q4W
All Bimekizumab (optional – to be used only  if specified)
PS0010/PS0011 treatment groups
This refers to the combination of the randomized treatment in PS0010 and the treatment assigned 
at the beginning of PS0011. Some groups have been combined where it is considered appropriate 
to do so. The PS0010/PS0011 treatment groups with descriptions are as follows:
Placebo to Placebo –Subjects randomized to placebo in PS0010 wh o achieve PASI 90 
response at Week 12 of PS0010 and continue to receive placebo in PS0011.
Placebo to Bimekizumab 160mg Q4W –Subjects randomized to placebo in PS0010 who do 
not achieve PASI90 response at Week 12 of PS0010 and are treated with bimekizumab 
160mg Q4W in PS0011.
Bimekizumab 64mg to Bimekizumab 64mg –
Subjects randomized to bimekizumab 64mg 
Q4W in PS0010 who achieve PASI 90 response at Week 12 of PS0010 and continue to 
receive bimekizumab 64mg Q4W in PS0011.
Bimekizumab 64mg to Bimekizumab 160mg – Subjects randomized to bimekizumab 64mg 
Q4W in PS0010 who do not achieve PASI90 response at Week 12 of PS0010 and are treated 
with bimekizumab 160mg Q4W in PS0011.
Bimekizumab 160mg Q4W to Bimekizumab 160mg Q4W –Subjects randomized to 
bimekizumab 160mg Q4W or bimekizumab 320mg loading dose + 160mg Q4W in PS0010 
who achieve PASI 90 response at Week 12 of PS0010 and continue to receive bimekizumab 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 70of 125160mg Q4W in PS0011. Note that the PS0010 160mg Q4W groups with and without the 
loading dose are combined here.
Bimekizumab 160mg Q4W to Bimekizumab 320mg Q4W –Subjects randomized to 
bimekizumab 160mg Q4W or bimekizumab 320mg loading dose + 160mg Q4W in PS0010 
who do not achieve PASI90 response at Week 12 of PS0010 and are treated with 
bimekizumab 320mg Q4W in PS0011. Note that the PS0010 160mg Q4W groups with and 
without the loading dose are combined here.
Bimekizumab 320mg Q4W to Bimekizumab 320mg Q4W –Subjects randomized to 
bimekizumab 320mg Q4W in PS0010 and continue on 320mg Q4W in PS0011. No 
distinction will be made between subjects that were or were not PASI90 responders at 
Week 12 of PS0010.
Bimekizumab 480mg Q4W to Bimekizumab 320mg Q4W –Subjects randomized to 
bimekizumab 480mg Q4W in PS0010 and continue on 320mg Q4W in PS0011. No 
distinction will be made between subjects that were or were not PASI90 responders at 
Week 12 of PS0010.
The treatment groups to be used in the presentations of safet y and efficacy will depend on the 
objective of the summaries and will be specified accordingl y.
14.3 Planned safety  anal yses
Safety  variables will be analy zed for all subjects in the SS.
Adverse events will be coded according to the Medical Dictionary  for Regulatory  Activities 
(MedDRA®). Treatment -emergent AEs will be defined as events that have a start date on or 
following the first administration of study  treatment in PS0011 through the final administration 
of study  treatment + 140days (covering the 20-week SFU P eriod). Treatment -emergent AEs will 
be categorized by PS0011 treatment group. Tables will include columns for pl acebo, 
bimekizumab 64mg Q4W, bimekizumab 160mg Q4W, bimekizumab 320mg, and All 
bimekizumab (ie, any  dose of bimekizumab) . 
14.3.1 Primary  safety analysis
All TEAEs will be summarized descriptivel y by PS0011 treatment group, primary  SOC , high 
level term (HLT), an d preferred term (PT). This summary  will include the exposure adjusted 
incidence rate (EAIR) with associated 95% confidence interval and the exposure adjusted event 
rate (EAER). 
For EAI R, the numerator will be the total number of subjects experiencing the AE. The 
denominator will be 100 subject -years; that is, the total summation of individual subject -years at 
risk up to the first occurrence of the AE for subjects with that AE, and the total subject -years at 
risk for those subjects not experiencing that AE, divided by  100. Exposure adjusted incidence 
rates will be presented with a 95% exact confide nce interval based upon the Chi -Square 
distribution (Ulm, 1990). 
For EAERs, the numerator will be the number of AEs including repeat occurrences in individual 
subjects; the denominator will be 100 subject
-years. That is, the total summation of individual 
subject -years at risk divided by 100. No confidence interval will be computed for EAER. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 71of 125Patient exposure at risk in day s will be defined as date of last admini stration of study medication 
–date of first administration of study  medication in PS0011 + 140 day s(ie, the duration of the 
SFU P eriod). If a subject dies, patient exposure at risk is censored at the date of death. The sum 
of these exposure day s at risk across subjects is converted to years for the EAI R and EAER 
calculations described above.
14.3.2 Other safety  analy ses
Additional tables will summarize TEAEs by  intensity  and relationship to study  medication, 
TEAEs leading to withdrawal from the stud y, treatment -emergent SAEs, and deaths. 
Other AE 
summaries to be included will be specified in the SAP. All AEtables will be presented b y 
PS0011 treatment group (including the All bimekizumab group).
Extent of exposure to study  medication in PS0011 will be summarized using descriptive statistics
by PS0011 treatment group. 
Change from Baseline in laboratory  values, ECGs, and vital signs will be presented using 
descriptive statistics by PS0010 /PS0011 treatment group. As these variables are summarized 
over time and the initial values can be impacted by  the randomized treatment in PS0010, the 
presentation by  PS0010 /PS0011 treatment group is intended to provide perspective on the 
change in these values starting with the initial PS0010 randomization through the 48 -week 
Treat ment Period of PS0011. The table presentations will display  descriptive statistics for the 
PS0010 Baseline followed by  descriptive statistics for the observed, change from PS0010 
Baseline ,and change from PS0011 results by  scheduled visit for PS0011.
14.4 Planned PKanaly ses
Pharmacokinetic variables will be analy zed for all subjects in the PK -PPS. 
Bimekizumab plasma concentrations will be summarized by PS0010/PS0011 treatment group at 
each scheduled visit. Descriptive statistics for the plasma concentrations at PS0010 Baseline will 
be presented followed b y descriptive statistics for the observed , change from PS0010 Baseline , 
and change from PS0011 Baseline results for scheduled visits in PS0011. Summarizing in this 
manner based on the PS0010/PS0011 treatment group will allow for an evaluation of how 
changing doses (where applicable) impacted plasma concentrations relative to both the original 
(PS0010) Baseline as well as the new (PS0011) Baseline . For the descriptive statistics, geometric 
mean, geometric coefficient of variation, and 95% confidence interval for the geometric mean 
will be used instead of the arithmetic mean and standard deviation.
14.5 Planned immunological analy ses
Immunological variables will be a nalyzed for all subjects in the PK -PPS. 
Anti- bimekizumab antibody  data will be summarized by PS0010/PS0011 treatment group at 
each scheduled visit. The summary  of anti -bimekizumab antibody  levels will follow a similar 
approach to that used for the summary of bimekizumab plasma concentrations. Additional 
analyses related to antibody  positivity  will be performed and will be described in greater detail in 
the SAP.
14.6 Planned efficacy  analy ses
Efficacy  variables will be summarized based on the FAS. The summaries described in this 
section will provide data on maintenance of effect of study  treatment over 48 weeks. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 72of 125Responder efficacy  variables (PASI 75, PASI90, PASI 100, IGA, and DLQI score of 0 or1) will 
be summarized descriptively  using counts and percentages b y scheduled visit and 
PS0010 /PS0011 treatment group. The PASI  responder variables will be derived relative to both 
the PS0010 Baseline and the PS0011 Baseline with responder rates being presented side -by-side 
in applicable summary  tables . Missing data will be handled b y using nonresponder imputation 
(NRI), meaning that subjects that discontinue early
 or who have missing data at a given time 
point are imputed as though they  did not achieve the given response. Supportive summaries will 
be based on observed case data.
Continuous efficacy  variables based on the change from Baseline (PASI, DLQI, BSA, mNAPSI , 
PSSI , PGADA, SF - 36, and HADS ) will be summarized using descriptive statistics by  scheduled 
visit and PS0010/PS0011 treatment group .The table presentations will display  descriptive 
statistics for the PS0010 Baseline , followed by  descriptive statistics for the observed , change 
from PS0010 Baseline , and change from PS0011 Baseline results by  scheduled visit for PS0011.
Figures for selected variables will also be ge
nerated in order to demonstrate the kinetics of 
response over time. Missing data will be handled by  using multiple imputation (MI ) via the 
Markov -Chain Monte Carlo (MCMC) method. Supportive summaries will be based on observed 
case data.
14.7 Planned interim ana lysis and data monitoring
A DMC will review the safet y data on a recurring basis as outlined in the DMC charter. In 
addition to these ongoing reviews, an anal ysis combining safet y data from PS0010 and PS0011 
will be performed when the PS0010 study  database is locked. This analysiswill account for data 
in PS0010 as well as the accrued safety data in PS0011 available at the time of the PS0010 
database lock. At the time of the interim analy sis, the DMC will be unblinded; however, the 
Sponsor study  team will remain blind. The details of this combined safet y analysisof PS0010 
and PS0011, including the events of interest to be considered, will be outlined in the DMC 
charter.
14.8 Determination of sample size
Up to 240 subjects are anticipated to enroll in PS0011. Th is number is based on the fact that 
240 subjects are planned to be randomized in the feeder stud y, PS0010. The calculations to reach 
that sample size are outlined in the PS0010 protocol. As the primary  objective of this study is to 
assess the long- term saf ety and tolerability  of bimekizumab 320mg Q4W, the number of subjects 
anticipated is based on the number of subjects completing PS0010 and meeting eligibility  
requirements for PS0011.
15 ETHICS A ND REGULA TOR Y REQUIREMENTS
15.1 Informed consent
Subject’s informed c onsent must be obtained and documented in accordance with local 
regulations, I CH-GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information should b e given in a language and at a level of 
complexity  understandable to the subject in both oral and written form by  the Investigator (or 
designee). Each subject will have the opportunity to discuss the study  and its alternatives with 
the Investigator.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 73of 125Prior to participation in the study , the written Informed Consent Form should be signed and 
personall y dated b y the subject and b y the person who conducted the informed consent 
discussion (I nvestigator or designee). The subject must receive a copy  of the signed 
and dated 
Informed Consent Form. As part of the consent process, each subject must consent to direct 
access to his/her medical records for stud y-related monitoring, auditing, IRB/IEC review, and 
regulatory  inspection.
If the Informed Consent Form is amende d during the study , the Investigator (or the Sponsor, if 
applicable) must follow all applicable regulatory  requirements pertaining to the approval of the 
amended Informed Consent Form b y the IRB/IEC and use of the amended form.
All studies conducted at cen ters in the United States must include the use of a Health Insurance 
Portability  and Accountability  Act Authorization form.
The subject may  withdraw his/her consent to participate in the study  at any  time. A subject is 
considered as enrolled in the study  when he/she has signed the Informed Consent Form. An 
eCRF must not be started, nor may  any study  specific procedure be performed for a given 
subject, without having obtained his/her written consent to participate in the study .
15.2 Subject identification cards
Upon signing the Informed Consent, the subject will be provided with a subject identification 
card in the language of the subject. The Investigator will fill in the subject identify ing 
information and medical emergency  contact information. The Investigator will instruct the 
subject to keep the card with him/her at all times.
15.3 IRBs and IECs
The study  will be conducted under the auspices of an I RB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.
The Investigator/UCB will ensure that an appropriately  constituted I RB/IEC that complies with 
the requirements of the current ICH -GCP version or applicable country -specific regulations will 
be responsible for the initial an d continuing review and approval of the clinical study . Prior to 
initiation of the study , the Investigator/UCB will forward copies of the protocol, I nformed 
Consent Form, IB, Investigator’s curriculum vitae (if applicable), advertisement (if applicable), 
and all other subject-related documents to be used for the stud y to the I RB/IEC for its review and 
approval.
Before initiating a study , the I nvestigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.
The Investigator will also promptly  report to the IRB/IEC all changes in the study , all 
unanticipated problems involving risks to human subjects or others, and any  protocol deviations, 
to eliminate immediate hazards to subjects.
The Investigator will not make any changes in the study  or study  conduct without I RB/IEC 
approval, except where necessary  to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously  approved protocol during the period covered by  the original 
approval, it m ay be possible for the Investigator to obtain an expedited review by  the IRB/IEC as 
allowed.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 74of 125As part of the IRB/IEC requirements for continuing review of approved studies, the Investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The Investigator should provide a final report to the IRB/IEC following study  
completion.
UCB (or its representative) will communicate safety  information to the appropriate regulatory  
authorities and all active Investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will also be informed b y the I nvestigator or the Sponsor, as specifie d 
by the applicable regulatory  requirements in each concerned country . Where applicable, 
Investigators are to provide the Sponsor (or its representative) with evidence of such IRB/IEC 
notification.
15.4 Subject privacy
UCB staff (or designee) will affirm and up hold the subject’s confidentiality . Throughout this 
study , all data forwarded to UCB (or designee) will be identified only  by the subject number 
assigned at Screening.
The Investigator agrees that representatives of UCB, its designee, representatives of th e relevant 
IRB/IEC, or representatives of regulatory  authorities will be allowed to review that portion of the 
subject’s primary  medical records that directl y concerns this study (including, but not limited to, 
laboratory  test result reports, ECG reports, admission/discharge summaries for hospital 
admissions occurring during a subject’s study  participation, and autopsy  reports for deaths 
occurring during the study).
15.5 Protocol amendments
Protocol changes may affect the legal and ethical status of the study  and may  also affect the 
statistical evaluations of sample size and the likelihood of the study  fulfilling its primary  
objective.
Significant changes to the protocol will only  be made as an amendment to the protocol and must 
be approved b y UCB, the I RB/IEC, a nd the regulatory  authorities (if required), prior to being 
implemented.
16 FINA NCE, INSURANCE, AND PUBLICA TION
Insurance coverage will be handled according to local requirements.
Finance, insurance, and publication rights are addressed in the Investigator an d/or CRO 
agreements, as applicable.
17 REFERENCES
Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology  and 
comorbidity  of psoriasis in children. Br J Dermatol. 2010;162:633 -6.
Christophers E, Barker JN, Griffiths CE, Daudén E, Milligan G, Molta C, et al. The risk of 
psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in 
European dermatology  clinics. J Eur Acad Dermatol Venereol. 2010;24:548 -54.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 75of 125Common Terminology Criteria for Adverse E vents (CTCAE), Version 4.0. National Institutes of 
Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis. 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . Updated 
26Jul2016.
CPMP/I CH/135/95 Note for guid ance on Good Clinical Practice (EMEA) Jul 2002.
Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. Improvements 
in patient -reported outcomes in moderate- to-severe psoriasis patients receiving continuous or 
paused etanercept trea tment over 54 weeks: the CRYSTEL  study . J Eur Acad Dermatol 
Venereol. 2009;23(12):1374 -82.
Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive 
symptoms and clinical depression in psoriasis patient s: a sy stematic review and meta -analysis. 
JInvest Dermatol. 2014;134:1542-51.
Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog 
Treat. 2004;15(1):27
-9.
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of my ocardial 
infarction in patients with psoriasis . JAMA. 2006;296:1735-41.
Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of 
metabolic sy ndrome in patients with psoriasis: a hospit al-based case -control study . 
BrJDermatol. 2007;157:68 -73.
Gottlieb AB. Psoriasis: Emerging therapeutic strategies. Nat Rev Drug Discov. 2005;4:19-34.
Icen M, Crowson CS, McEvoy  MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in 
incidence of adult -onset psoriasis over three decades: a population- based study . 
JAmAcad Dermatol. 2009;60:394-401.
Krueger G, Ellis CN. Psoriasis–recent advances in understanding its pathogenesis and treatment. 
J Am Acad Dermatol. 2005;53(1 Suppl 1):S94 -
100.
Krueger G, Koo J, L ebwohl M, Menter A, Stern RS, Ro lstad T. The impact of psoriasis on 
quality  of Life. Results of a 1998 National Psoriasis Foundation patient -membership survey . 
Arch Dermatol. 2001;137:280-4. 
Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, et al. Oral curcumin 
in the t reatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. J Am Acad 
Dermatol. 2008;58:625 -31.
Kurd SK, Gelfand JM. The prevalence of previously  diagnosed and undiagnosed psoriasis in US 
adults: results from NHANES 2003- 2004. J Am Aca d Dermatol. 2009;60:218 -24.
Langley  RG, Krueger GG, Griffiths CEM. Psoriasis: epidemiology , clinical features, and qualit y 
of life. Ann Rheum Dis. 2005;64(Suppl II):ii18–ii23.
Langley  RG, Feldman SR, Han C, Schenkel B, Szapary  P, Hsu MC, et al. Ustekinumab
significantl y improves s ymptoms of anxiety , depression, and skin -related quality  of life in 
patients with moderate -to-severe psoriasis: Results from a ra ndomized, double -blind, 
placebo- controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457 -65.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 76of 125Maruish ME, editor . User’s manua l for the SF -36v2 Health Survey . 3rd ed. Lincoln, RI: 
Quality Metric Incorporated; 2011.
Mukhtar R, Choi J, Koo JY. Quality  of life issues in psoria sis. Dermatol Clin. 2004;22:389-95. 
Mundt JC, Greist JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Model JG. Feasibility  and 
validation of a c omputer-a utomated Columbia -Suicide S everit y Rating Scale using Interactive 
Voice Response Technology . J Psy chiatric Res. 2010;44:1224 -
1228.
Ortonne JP. Redefining clinical response in psoriasis: targeting the p athological basis of disease. 
JDrugs Dermatol. 2004;3:13 -
20.
Parisi R, Sy mmons DP, Griffiths CE, Ashcroft DM .Identification and Management of Psoriasis 
and Associated ComorbidiTy  (IMPACT) project team. Global epidemiology  of psoriasis: A 
systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377 –385.
Posner K, Brown GK, Stanley  B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia -
Suicide Severity
 Rating Scale: Initial validity  and internal consistency  findings from t hree 
multisite studies w ith adolescents and a dults. Am J Psy chiatry . 2011;168:1266 - 1277.
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United 
States. J Am Acad Dermatol. 2014;70:512 -6. 
Raychaudhuri SP, Gross J. A co mparative study  of pediatric onset psoriasis with adult onset 
psoriasi s. Pediatric Dermatology . 2000; 17(3):174–178.
Snaith RP, Zigmond AS. The Hospital Anxiety  and Depression Scale Manual. NFER: Nelson, 
Windsor; 1994.
Ulm K. A simple method to calculate th e confidence interval of a s tandardized mortality  ratio. 
AmJEpidemiol. 1990;131(2):373 -375.
Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity  
and the prevalence of major medical comorbidity :a population -based study . JAMA Dermatol. 
2013;149:1173-9.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 77of 12518 APPENDICES
18.1 Protocol A mendment 1
This purpose of this substantial amendment is to revise the study  design of PS0011 to allow 
subjects who were responding to placebo or the lowest dose of bimekizumab (64mg Q4W ) in 
PS0010 to continue into PS0011 with no change in treatment, while protecting the study blind.
Thus, the s tudy design changed from an open -label to a double -blind, placebo -controlled, 
parallel -group extension study  with additional treatment groups included to be c onsistent with 
the feeder stud y, PS0010. 
The other changes in this amendment are as follows:
Provide details of the revised PS0011 study  including the study  type and description 
Clarify  the treatments to be administered and the criteria for assigning su bjects to treatment
in PS0011   
Reduce the number of secondary  objective s to reflect the revised study  design
Reassign the PK and immunological variables from secondary  objectives to other objectives
Reassign the secondary  safet y variables to other safet y variables
Remove severit y and frequency of TEAE sas a safety  variable
Remove the population PK from PS
0011
Classify  the efficacy  variables into secondary  efficacy  variables and other efficacy  variables 
Extend the timing of the SFU Visit to 20 weeks after the last dose of stud y medication
Extend the maximum duration of subject participation to 64 weeks
Increase the frequency  of safet y laboratory  testing (hematology /biochemistry )
Clarify  the frequency  of safet y laboratory  testing (urinal ysis) 
Revise the fre quency  of blood sampling for bimekizumab plasma concentrations and 
anti-bimekizumab antibody  levels after Week 16
Revise the frequency  of completion of HADS
Provide a rationale for the revised study  design 
Remove references to legal representatives being able to provide consent on behalf of 
subjects. Subjects who lack the capacit y to consent wi ll not be included in the study
Remove specific details on contraception but clarify  that continued use of an acc eptable 
forms of contraception (as specified in PS0 010) is required in PS0011 for up to 20 weeks 
after the last dose of study  treatment 
Remove reference to subjects who may  have a clinically  active infection or medicall y 
significant infection as being excluded from the study    
Include the requirement that su bjects must have a negative IGRA to be eligible for PS0011
(obtained in PS0010)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 78of 125Clarify  that subject must complete PS0010 to be eligible to participate in PS0011 
Provide more detail in the Withdrawal Criterion regarding subjects that develop illnes ses that 
would interfere with study participation
Clarify  that subjects who develop any  form of pustular psoriasis (ie, localized or generalized) 
during the stud y will be withdrawn from the study
Clarify  that topicals are not considered prohibited concomit ant medication that would result 
in subject withdrawal in the Withdrawal Criteria 
Clarify  the HADS thresholds for withdrawal of a subject in the Withdrawal Criteria
Provide more detail in the Withdrawal Criteria regarding the withdrawal of subjects due to
AEs and clinical laboratory  values
Clarify  the PASI threshold for withdrawal of a subject in the Withdrawal Criteria
Revised I MP description to include bimekizumab and placebo
Provide details on maintaining the blind during the study  (eg, drug accountabil ity, drug 
preparation and administration, and study  monitoring )even though some clinical study  team 
members will be unblinded to treatment assignments in PS0011
Provide details on the procedures for breaking the blind in an emergency  situation
Provide fur ther details on the assignment of subject to treatment by  the IXRS
Provide additional detail and a reference for recording the severit y of AEs
Extend the follow up of AE to 20 weeks after the last dose of IMP
Clarify  the adverse events for special monitoring
Remove the requirement to test for alcohol in the PDILI urine toxicology  screen
Remove reference to Screening Log for PS0011
Clarif yin FAS and PK -PPS that 1 dose of study  medication refers to the PS0011 to avoid 
confusion with study medication in PS0010
Add section (General statistical considerations) to provide details on what constitutes 
descriptive statistics and to define 2 different sets of treatment groups that will be used when 
summarizing the data
Update treatment emergent definition in the planned safet y analyses to match with the 
revised 20-week SFU period and provide details on treatment groups used for summaries of 
AEs
Remove other safet y analysis based on adjuster status as this is no longer applicable given 
the revised stud y design
Provide additional details to specify  what t ypes of summaries will be done for PK and 
immunogenicit y data
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 79of 125Modifications and changes
Global changes
The following changes were made throughout the protocol
The study  design was changed from a n open- label to a double -blind, placebo -controlled, 
parallel -group design to maintain the study  blind
A detailed description of the revised stud y design was included (schematic diagram and 
scheduled of stud y assessments were updated)
Treatment groups were added to be consistent with the feeder stud y PS0010 (with the 
exception of the bimekizumab 480mg Q4W treatment group) 
Secondary  objectives were reduced to just 1 efficacy  objective
PK and 
immunological variables were assigned to oth er objectives
Secondary  safet y variables were designated as other safety variables 
The timing of the S FUVisit was changed from 17 weeks after the last dose of study  
medication to 20 weeks after the last dose of stud y medication
The maximum study  duration for subjects was changed from 61 weeks to 64 weeks
The frequency  of safety  laboratory  testing ( hematology /biochemistry ) was increased from 
every  8 weeks to every  4 weeks (at every  visit), including the 
SFU Visit
The frequency  of safety  laboratory  testing (urinalysis) was decreased from every  8 weeks to 
every  12 weeks, including the SFU Visit 
After the Week 16 Visit, the timing of blood samples for the measurement of PK and 
antibodies to bimekizumab was changed from every  8 weeks, followed by  the SFU Visit to 
every  12 weeks (up to Week 40), followed by  Week 48 and the SFU Visit
The frequency of the H ADS assessment w as changed from every  12 weeks to every  4 weeks 
(at every  visit) and the SFU Visit
The term “photochemotherap y” was changed to “chemophototherapy ” throughout for 
consistency
Changes made throughout the statistics section to clarify which treatment groups would be 
used when summarizing data.
Multiple changes made to account for the fact that summaries of change from Baseline 
variab les would be calculated relative to the PS0010 Baseline and PS0011 Baseline, with 
both being presented in summary  tables.
The L ist of Abbreviations was revised
Minor editorial revisions were made
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 80of 125Change #1
TITLE
A MULTICENTER, 48- WEEK, OPEN -LABEL EXTENSION STUDY TO ASSESS THE 
LONG- TERM SAFETY, TOL ERABILITY, AND EFFI CACY OF BIMEKIZUMAB IN 
ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONI C PLAQUE PSORI ASIS
Has been changed to: 
A MULTICENTER, 48- WEEK, OPEN LABEL DOUBLE -BLIND, 
PLACEBO -CONTROLLED, PARALLEL- GROUP EXTENSION STUDY TO ASSESS 
THE LONG -TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN 
ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONI C PLAQUE PSORI ASIS
Change #2
LIST OFABBREVIATIONS
The following abbreviation has been added
CTCAE Common Termi nology Criteria for Adverse Events
Change #3
LIST OFABBREVIATIONS
ICH International Council on Harmonisation
Has been changed to:
ICH International Council foronHarmonisation
Change # 4
LIST OFABBREVIATIONS
IMP investigational medicinal product
Has been changed to:
IMP investigational medicinal product (s)
Change # 5
Section 1 S ummary
PS0011 is a multicenter, 48- week, open- label extension study  to assess the long -term safet y, 
tolerability , and efficacy  of bimekizumab in eligible adult subjects with moderate to severe 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 81of 125chronic plaque psoriasis who complete PS0010. At Week 12 of PS0010, all eligible subjects 
continuing into PS0011 will undergo the PS0010 Week 12 study  assessments and PS0011 
Baseline assessments, and will then receive their first open- label dose of bimekizumab.
Has been changed to: 
PS0011 is a multicenter, 48- week, double -blind, placebo- controlled, parallel -group
open label extension study  to assess the long- term safet y, tolerability, and efficacy of 
bimekizumab in eligible adult subjects with moderate to severe chronic plaque psoriasis who 
complete PS0010. At Week 12 of PS0010, all eligible subjects continuing into PS0011 will 
undergo the PS0010 Week 12 study assessments and any additional PS0011 Baseline 
assessments, and will then receive their first open label dose of bimekizumab or placebo in 
PS0011.
Change # 6
Section 1 S ummary
During the Open- Label Treatment Period, subjects will attend study  visits at th e site every  
4weeks (Q4W) for study assessments and administration of bimekizumab (if applicable) b y 
study  site staff through Week 48. Following completion or earl y withdrawal from the 48 -week 
Open -Label Treatment Period, subjects will return for a Safety Follow -Up (SFU) Visit at 
17 weeks after their last dose of bimekizumab. Subjects withdrawing earl y from the study  will 
undergo the Early  Withdrawal Visit assessments and will enter the SFU Period.
Has been changed to: 
During the Open Label Treatment Period, subjects will attend study  visits at the study site
every  4weeks (Q4W) for study  assessments and administration of bimekizumab or placebo (if 
applicable) by study  site staff through Week 48. Any subject who does not achieve a Psoriasis 
Area and Severity Index (PASI) 75 response (defined as a 75% reduction in the PASI score 
from the Baseline of PS0010) at Week 12 or later in PS0011 will be withdrawn from study 
treatment and will return to complete the Early Withdrawal Visit assessments. Following 
completion or earl y withdrawal from the 48 -week Open Label Treatment Period, subjects will 
return for a Safet y Follow -Up (SFU) Visit at 17 20weeks after their last dose of bimekizumab
or placebo in PS0011.
Subjects withdrawing early  from the study  will undergo the Early  Withdrawal Visit assessments 
and will enter the SFU Period.
Change # 7
Section 1 S ummary
The following text has been deleted
Bimekizumab will initially be administered at a dose of 320mg Q4W subcutaneously (sc) 
during the 48 week Open Label Treatment Period, with an option to reduce the dose to 
160mg Q4W at the discretion of the Investigator if the subject achieves a Psoriasis Area 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 82of 125and Severity Index (PASI) 90 response (defined as a 90% reduction in the PASI score from 
the Bas eline of PS0010) for at least 2 consecutive visits (not including the PS0011 Baseline 
Visit). If the subject’s disease is not adequately controlled on the 160mg Q4W dose, they 
may return to 320mg Q4W. The decision to return to 320mg Q4W dosing should be ba sed 
upon treatment response, tolerability, and Investigator discretion, with the aim to use the 
dosing regimen that achieves the optimal benefit risk for each subject.
Change # 8
Section 1 S ummary
The following text has been added
Subjects who received pla cebo or bimekizumab 64mg, 160mg, or 320mg loading dose + 
160mg Q4W in PS0010 must achieve PASI90 response at Week 12 in PS0010 to enter the 
PS0011 extension study on the same treatment dose. Subjects who do not achieve PASI90 
response at Week 12 in PS0010 while receiving placebo or bimek izumab 64mg Q4W will be 
assigned to receive bimekizumab 160mg Q4W on entering PS0011. Subjects who do not 
achieve PASI90 response at Week 12 in PS0010 while receiving bimekizumab 160mg or 
320mg loading dose + 160mg Q4W will be assigned to receive bimekizumab 320mg Q4W 
on entering PS0011. Subjects who receive bimekizumab 320mg or 480mg Q4W in PS0010 
will be assigned to receive bimekizumab 320mg Q4W on entering PS0011, regardless of 
their PASI90 response at Week 12 in PS0010.
Change # 9
Section 1 S ummary
The primary  objective of the study  is to assess the long -term safet y and tolerability  of 
bimekizumab. Secondary objectives of the stud y are to assess the safet y and tolerability of 
reduction of the dose of bimekizumab from 320mg Q4W to 160mg Q4W; to assess the 
pharmacokinetics (PK) of bimekizumab; to assess the immunogenicit y of bimekizumab; and to 
assess the efficacy  of open- label bimekizumab 320mg Q4W administered over 48 weeks with 
and without dose reduction.
Has been changed to: 
The primary  objective of the study  is to assess the long -term safet y and tolerability  of 
bimekizumab. The Ssecondar y objective sof the study  isare to assess the safety and 
tolerability of reduction of the dose of bimekizumab from 320mg Q4W to 160mg Q4W; to 
assess the pharmacokinetics (PK) of bimekizumab; to assess the pharmacokinetics (PK) of 
bimekizumab; to assess the immunogenicity of bimekizumab; and to assess the efficacy  of 
open label bimekizumab 320mg Q4W administered Q4W over 48 weeks. with and without 
dose reduction . The other objectives of the study are to assess the pharmacokinetics (PK) 
and immunogenicity of bimekizumab.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 83of 125Change # 10
Section 1 S ummary
The primary  safet y variable is the incidence of treatment -emergent adverse events (TEAEs) 
adjusted by  duration of subject exposure to treatment. The secondary  safet y variables are severit y 
and frequency  of TEAEs and change from Baseline of PS0010 in clinical laboratory  values 
(chemistry , hematology , and urinal ysis), vital signs, phy sical examin ation, and 12 -lead 
electrocardiogram (ECG) results.
Has been changed to: 
The primary  safet y variable is the incidence of treatment -emergent adverse events (TEAEs) 
adjusted by  duration of subject exposure to treatment. The other secondary safet y variables are 
severity and frequency of TEAEs and change from Baseline of PS0010 and PS0011 in clinical 
laboratory  values (chemistry , hematology , and urinaly sis), vital signs, phy sical examination, and 
12-lead electrocardiogram (ECG) results.
Change #1 1
Section 1 S ummary
Pharmacokinetic variables are plasma concentrations of bimekizumab and population PK (CL /F, 
V/F). The immunological variable is anti -bimekizumab antibody  levels prior to and following 
study  treatment.
Has been changed to: 
The Pharmacokinetic PKvariable s are isplasma concentrations of bimekizumab and
population PK (CL/F, V/F). Ttheimmunological variable is anti -bimekizumab antibody  levels 
prior to and following study  treatment.
Change #12
Section 1 S ummary
The efficacy  assessments are PASI, I nvestigator’s Global Assessment (IGA), Dermatology  Life 
Quality  Index (DLQI), body  surface area (BSA) affected by  psoriasis, modified Nail Psoriasis 
Severity  Index (mNAPSI) score, Psoriasis Scalp Severit y Index (PSSI ), Patient's Global 
Assessment of Diseas e Activity  (PGADA), 36 -item Short Form Health Survey  (SF-36), and the 
Hospital Anxiety  and Depression Scale (HADS); a detailed list of efficacy  variables is presented 
in Section 4.4.
Has been changed to: 
The efficacy  assessments are PASI , Investigator’s G lobal Assessment (IGA) Dermatology  Life 
Quality  Index (DLQI), body  surface area (BSA) affected by  psoriasis, modified Nail Psoriasis 
Severity  Index (mNAPSI) score, Psoriasis Scalp Severit y Index (PSSI ), Patient's Global 
Assessment of Disease Activity  (PGADA), 36 -item Short Form Health Survey  (SF-36), and the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 84of 125Hospital Anxiety  and Depression Scale (HADS); a detailed list of the secondary and other
efficacy  variables is presented in Section 4.4.
Change # 13
Section 2.1.2 Current treatments for psoriasis
Therap y for patients with psoriasis varies according to the severit y of disease. L imited or mild 
disease is often treated with topical therapies such as corticosteroids and vitamin D analogs. 
Patients with more severe disease are often treated with photoche motherapy
, methotrexate, the 
oral phosphodiesterase 4 (PDE4) inhibitor (apremilast), or biologic agents, such as tumor 
necrosis factor (TNF) antagonists, interleukin (IL) 12/23 inhibitors, and IL -17A inhibitors. The 
effectiveness of TNF inhibitors in the t reatment of psoriasis has been demonstrated in man y 
Phase 3 clinical studies and has led to the approval of multiple TNF inhibitors for use in patients 
with moderate to severe psoriasis. I nterleukin inhibitors include secukinumab and ixekizumab, 
IL-17A inhibitors approved for treatment of moderate to severe psoriasis. Ustekinumab is an 
IL-
12/23 antagonist approved for use in patients with moderate to severe psoriasis, and 
brodalumab, an IL -17 receptor antagonist, has completed pivotal Phase 3 studies in psoriasis. 
Standard therapies for psoriasis are listed below:
Has been changed to: 
Therap y for patients with psoriasis varies according to the severit y of disease. L imited or mild 
disease is often treated with topical therapies such as corticosteroids and vi tamin D analogs. 
Patients with more severe disease are often treated with photochemophototherapy, 
methotrexate, the oral phosphodiesterase 4 (PDE4) inhibitor (apremilast), or biologic agents, 
such as tumor necrosis factor (TNF) antagonists, interleukin (IL ) 12/23 inhibitors, and IL -17A 
inhibitors. The effectiveness of TNF inhibitors in the treatment of psoriasis has been 
demonstrated in man y Phase 3 clinical studies and has led to the approval of multiple TNF 
inhibitors for use in patients with moderate to severe psoriasis. Interleukin inhibitors include 
secukinumab and ixekizumab, IL-17A inhibitors approved for treatment of moderate to severe 
psoriasis. Ustekinumab is an IL -12/23 antagonist approved for use in patients with moderate to 
severe psoriasis, and brodalumab, an IL -17 receptor antagonist, has completed pivotal Phase 3 
studies in psoriasis. Standard therapies for psoriasis are listed below:
Change # 14
Section 2.1.2 Current treatments for psoriasis
Photochemotherap y is a frequent option for moderate to severe patients, but the 
inconvenience of multiple treatment visits and varying efficacy  limits its use in the market.
Has been changed to: 
Photoc Chemophototherapy is a frequent option for moderate to severe patients, but the 
inconvenience of multiple treatment visits and vary ing efficacy  limits its use in the market. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 85of 125Change #1 5
Section 2.2.1 C linical
The current study , PS0011, is a 48- week open -label extension study for eligible subjects who 
complete PS0010, a Phase 2b, randomized, double- blind, placebo -controlled, parallel -group, 
dose-ranging stud y in adult subjects with moderate to severe chronic plaque psoriasis. In 
PS0010, subjects will be randomized 1:1:1:1:1:1 to receive the following blinded study  treatment 
regimens for a treatment period of 12 weeks:
Has been changed to: 
The current study , PS0011, is a 48- week open label extension study  for eligible subjects who 
complete PS0010, a Phase 2b, randomized, double- blind, placebo -controlled, parallel -group, 
dose-ranging stud y in adult subjects with moderate to severe chronic plaque psoriasis. In 
PS0010, subjects will be randomized 1:1:1:1:1:1 to receive the following blinded study  treatment 
regimens for a treatment period of 12 weeks:
Change # 16
Section 3.2 Secondary objectives
Secondary  objectives of the study  are:
To assess the safety and tolerability of reduction of the dose of bimekizumab from 320mg 
Q4W to 160mg Q4W
To assess PK of bimekizumab
To assess the immu nogenicity  of bimekizumab
To assess the efficacy  of open-label bimekizumab 320mg Q4W administered over 48 weeks 
with and without dose reduction 
Has been changed to: 
Section 3.2 Secondary objective s
The Ssecondary  objective sof the study  isare:
To assess the safety and tolerability of reduction of the dose of bimekizumab from 
320mg Q4W to 160mg Q4W
To assess PK of bimekizumab
To assess the immunogenicity of bimekizumab
tTo assess the efficacy  of open label bimekizumab 320mg Q4W administered Q4W over 
48weeks.with and without dose reduction
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 86of 125Change #1 7
Section 3.3 Other objectives (new section)
The other objectives of the study are: 
To assess PK of bimekizumab
To assess the immunogenicity of bimekizumab
Change # 18
Section 4.1.2 Secondary safety variables
Change from Baseline variables will be defined relative to the Baseline measurement from 
PS0010. 
The secondary safet y variables are:
Severity  and frequency  of TEAEs 
Change from Baseline in clinical laboratory  values (chemistry, hematology , and urinal ysis) 
Change from Baseline in vital signs
Change from Baseline in phy sical examination
Change from Baseline in 12- lead ECG results
Has been changed to: 
Section 4.1.2 Other Secondary safety variables
Change from Baseline variables will be defined relative to the Baseline measurement sfrom both
PS0010 and PS0011 .
The secondary other safety variables are:
Severity and frequency of TEAEs 
Change from Baseline in clinical laboratory  values (chemistry , hem atology , and urinal ysis) 
Change from Baseline in vital signs
Change from Baseline in phy sical examination
Change from Baseline in 12- lead ECG results
Change # 19
Section 4.2 Pharmacokinetic variables
The PK variables are:
Plasma concentrations of bimekizumab and population PK (CL /F, V/F)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 87of 125Has been changed to:
Section 4.2 Pharmacokinetic variable s
The PK variable sare: isPplasma concentrations of bimekizumab and population PK (CL/F, 
V/F).
Change # 20
Section 4.4 Efficacy variables
Change from Baseline variables will be defined relative to the Baseline measurement from 
PS0010.
Has been changed to:
Change from Baseline variables will be defined relative to the Baseline measurement sfrom both
PS0010 and PS0011 .
Change # 21
Section 4.4.1 Secondary efficacy variables (new section)
The secondary efficacy variables are:
PASI90 response over time
IGA response (Clear or Almost Clear with at least a 2 category improvement from 
Baseline on a 5 -point scale) over time
Change # 22
Section 4.4.2 Other efficacy variables (new section; text previously under Section 4.4 
Efficacy variables)
The following variables have been designated as secondary efficacy variables and have 
been deleted from th elist of other efficacy variables
PASI 75, PASI90, andPASI 100 response
IGA response (Clear or Almost Clear with at least a 2 category improvement from 
Baseline on a 5 -point scale)
Change # 23
Section 5.1 Study description
PS0011 is a multicenter, 48- week, open- label extension study  to assess the long -term safet y, 
tolerabilit y, and efficacy of bimekizumab in eligible adult subjects with moderate to severe 
chronic plaque psoriasis who complete PS0010. At Week 12 of PS0010, all eligible subjects 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 88of 125continuing into PS0011 will undergo the PS0010 Week 12 study  assessments and PS0011 
Baseline assessments, and will then receive their first open- label dose of bimekizumab.
Has been changed to:
PS0011 is a multicenter, 48- week, double -blind, placebo- controlled, parallel -group
open label extension study  to assess the long- term safet y, tolerability, and efficacy of 
bimekizumab in eligible adult subjects with moderate to severe chronic plaque psoriasis who 
complete PS0010. At Week 12 of PS0010, all eligible subjects continuing into PS0011 will 
undergo the PS0010 Week 12 study assessments and any additional PS0011 Baseline 
assessments, and will then receive their first open label dose of bimekizumab or placebo in 
PS0011.
Change # 24
Section 5.1 Study description
During the Open- Label Treatment Period, subjects will attend study visits at the site Q4W for 
study  assessments and administration of bimekizumab (if applicable) by  study  site staff through 
Week 48. Following completion or earl y withdrawal from the 48 -week Open -Label Treatment 
Period, subjects will return for a SFU Visit at 17 weeks after their last dose of bimekizumab. 
Subjects withdrawing early  from the stud y will undergo the Early Withdrawal Visit assessments 
and will enter the SFU Period.
Has been changed to:
During the Open Label Treatment Period, subjects will atten d study  visits at the study site
every  4weeks (Q4W) for study  assessments and administration of bimekizumab or placebo (if 
applicable) by study  site staff through Week 48. Any s ubject who does not achieve PASI75 
response at Week 12 or later in PS0011 will be withdrawn from study treatment and will 
return tocomplete the Early Withdrawal Visit assessments. Following completion or earl y 
withdrawal from the 48 -week Open
Label Treatment Period, subjects will return for a Safet y 
Follow -Up (SFU) Visit at 17 20 weeks after their last dose of bimekizumab or placebo in 
PS0011 .
Subjects withdrawing early  from the stud y will undergo the Early Withdrawal Visit assessments 
and will enter the SFU Period.
Change # 25
Section 5.1 Study description
The following text has been deleted
Bimekizumab will initially be administered at a dose of 320mg Q4W sc during the 48 week 
Open Label Treatment Period, with an option to reduce the dose to 160mg Q4W at the 
discretion of the Investigator if the subject achieves a PASI90 respons e (90% reduction in 
the PASI score from the Baseline of PS0010) for at least 2 consecutive visits (not including 
the PS0011 Baseline Visit). If the subject’s disease is not adequately controlled on the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 89of 125160mg Q4W dose, they may return to 320mg Q4W. The deci sion to return to 320mg Q4W 
dosing should be based upon treatment response, tolerability, and Investigator discretion, 
with the aim to use the dosing regimen that achieves the optimal benefit risk for each 
subject.
Change #2 6
Section 5.1 Study description
The following text has been added
Subjects who received placebo or bimekizumab 64mg, 160mg ,or 320mg loading dose + 
160mg Q4W in PS0010 must achieve PASI90 response at Week 12 in PS0010 to enter the 
PS0011 extension study on the same treatment dose. Subje cts who do not achieve PASI90 
response at Week 12 in PS0010 while receiving placebo or bimek izumab 64mg Q4W will be 
assigned to receive bimekizumab 160mg Q4W on entering PS0011. Subjects who do not 
achieve PASI90 response at Week 12 in PS0010 while receiving bimekizumab 160mg or 
320mg loading dose + 160mg Q4W will be assigned to receive bimekizumab 320mg Q4W 
on entering PS0011. Subjects who receive bimekizumab 320mg or 480mg Q4W in PS0010 
will be assigned to receive bimekizumab 320mg Q4W on entering PS0011, regardless of 
their PASI90 response at Week 12 in PS0010.
Change # 27
Section 5.1.1 Study duration per subject
The study  duration for each subject is estimated to be up to a maximum of 61 weeks:
Open -Label Treatment Period: up to 48 weeks
SFU Visit: 17 weeks after the last dose of bimekizumab
The end of the stud y is defined as the date of the last visit of the last subject in the study .
Has been changed to:
The study  duration for each subject is estimated to be up to a maximum of 6164 weeks:
Open Label Treatment Period: up to 48 weeks
SFU Visit: 2017 weeks after the last dose of bimekizumab or placebo
The end of the stud y is defined as the date of the last visit of the last subject in the study .
Change # 28
Table 5 -1 Schedule of study assessments
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 90of 125Table 5 -1: Schedule of study  assessments
Visit Weeka
Protocol activityPS0011 
BaselineOpen -Label Treatment Period
Wk 
4Wk 
8Wk 
12Wk 
16Wk 
20Wk 
24Wk 
28Wk 
32Wk 
36Wk 
40Wk 
44Wk 48/ 
WD SFUb
Hematology/biochemistry/urinalysis XfX X X X X X X
Blood sample for bimekizumab plasma 
concentrationskXfX X X X X X X X X
Blood sample for anti -bimekizumab
antibodieskXfX X X X X X X X X
HADS XfX X X X
Has been changed to:
Table 5 -1: Schedule of study  assessments
Visit Weeka
Protocol activityPS0011 
BaselineOpen Label Treatment Period
Wk 
4Wk 
8Wk 
12Wk 
16Wk 
20Wk 
24Wk 
28Wk 
32Wk 
36Wk 
40Wk 
44Wk 48/ 
WD SFUb
Hematology/ biochemistry /urinalysis XfX X X X X X X X X X X X X
Urinalysis XfX X X X X
Blood sample for bimekizumab plasma 
concentrationskXfX X X X X X X X X X
Blood sample for anti -bimekizumab
antibodieskXfX X X X X X X X X X
HADS XfX X X X X X X X X X X X X
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 91of 125Change # 29
Table 5 -1 Schedule of study assessments
bThe SFU Visit will occur 17 weeks after the last dose.
Has been changed to:
bThe SFU Visit will occur 2017 weeks after the last dose of bimekizumab or placebo .
Change # 30
Table 5 -1 Schedule of study assessments
dTo be performed 
prior to the first dose of open -label bimekizumab.
Has been changed to:
dTo be performed prior to the first dose of open label bimekizumab or placebo in PS0011.
Change # 31
Table 5 -1 Schedule of study assessments
The following footnote has been deleted
mBimekizumab will be administered at a dose of 320mg Q4W with an option to reduce the 
dose to 160mg Q4W at the discretion of the Investigator if the subject achieves a PASI90 
response (90% reduction in the PASI score from the Baseline of PS0010) for at lea st 2 
consecutive visits (not including the PS0011 Baseline Visit). If the subject’s disease is not 
adequately controlled on the 160mg Q4W dose, they may return to 320mg Q4W based on 
treatment response, tolerability, and Investigator discretion, with the ai m to use the 
dosing regimen that achieves the optimal benefit risk for each subject.
Change # 32
Table 5 -1 Schedule of study assessments
The following footnote has been added
mSubjects who received placebo or bimekizumab 64mg, 160mg
,or 320mg loading dose + 
160mg Q4W in PS0010 must achieve PASI90 response at Week 12 in PS0010 to enter the 
PS0011 extension study on the same treatment dose . Subjects who do not achieve PASI90 
response at Week 12 in PS0010 while receiving placebo or bimek izumab 64mg Q4W will 
be assigned to receive bimekizumab 160mg Q4W on entering PS0011. Subjects who do 
not achieve PASI90 response at Week 12 in PS0010 while receiving bimekizumab 160mg 
or 320mg 
loading dose + 160mg Q4W will be assigned to receive bimekizumab 320mg 
Q4W on enteri ng PS0011. Subjects who receive bimekizumab 320mg or 480mg Q4W in 
PS0010 will be assigned to receive bimekizumab 320mg Q4W on entering PS0011, 
regardless of their PASI90 response at Week 12 in PS0010. Any subject who does not 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 92of 125achieve PASI75 response at Wee k12 or later in PS0011 will be withdrawn from study 
treatment and will return to complete the Early Withdrawal Visit assessments.
Change # 33
Figure 5 -1 Schematic diagram
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 94of 125Has been changed to:
PASI=Psoriasis Area and Severity Index; Q4W=every 4 weeks; SFU=Safety Follow -Up
aSubjects who received placebo or bim ekizum ab 64m g, 160m g,or 320m g loading dose + 160m g Q4W in PS0010 must achieve PASI90 response at 
Week 12 in PS0010 to enter the PS0011 extension study on the sam e treatment dose . Subjects who do n ot achieve PASI90 response at Week 12 in 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 95of 125PS0010 while receiving placebo or bim ekizumab 64m g will be assigned to receive bimekizum ab 160m g on entering PS0011. Subjects who do not 
achieve PASI90 response at Week 12 in PS0010 while receiving bimekizumab 160m gor 320mg loading dose + 160m g will be assigned to receive 
bimekizumab 320m g Q4W on entering PS0011. 
bSubjects who receive bim ekizumab 320m g or 480m g Q4W in PS0010 will be assigned to receive bim ekizumab 320m g Q4W on entering P S0011, 
regardless of their PASI90 response at Week 12 in PS0010.
cAny subject who does not achieve PASI75 response at Week 12 or later in PS0011 will be withdrawn from  study treatm ent and will return to com plete 
the Early Withdrawal Visit assessments.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 96of 125Change # 34
Secti on 5.4 Rationale for study design and dose selection
PS0011 is a 48- week open- label extension study  for eligible subjec ts who complete PS0010, a 
Phase 2b, randomized, double -blind, placebo -controlled, parallel -group, dose -ranging stud y in 
adult subjects wi th moderate to severe chronic plaque psoriasis. This study  will allow the 
collection of further data on the long- term safety , tolerability , and efficacy  of bimekizumab in 
this subject population and access/continued access to bimekizumab for subjects who r eceived 
either bimekizumab or placebo in the lead -in study .
Has been changed to:
PS0011 is a 48- week ,double -blind, placebo- controlled, parallel -group open label extension 
study  for eligible subjec ts who complete PS0010, a Phase 2b, randomized, double -blind, 
placebo- controlled, parallel -group, dose -ranging study  in adult subjects with moderate to severe 
chronic plaque psoriasis. Because some PS0010 subjects may have severe disease, the 
treatment in PS0011 provides more time to respond to a potentially efficacious treatment. 
PS0011 also provides an opportunity for nonresponding PS0010 placebo subjects to receive 
bimekizumab. This study  will allow the collection of further data on the long -term safety , 
tolerability , and efficacy  of bimekizumab in this subject population. and access/continued 
access to bimekizumab for subjects who received either bimekizumab or placebo in the 
lead in study .
Change # 35
Section 5.4 Rationale for s tudy design and dose selection
The following rationale has been deleted
In this study, bimekizumab will initially be administered at a dose of 320mg Q4W sc, with 
an option to reduce the dose to 160mg Q4W at the discretion of the Investigator if the 
subject achieves a PASI90 response (90% reduction in the PASI score from the Baseline of 
PS0010) for at least 2 consecutive visits (not including the PS0011 Baseline Visit). If the 
subject’s disease is not adequately controlled on the 160mg Q4W dose, they may return to 
320mg Q4W. The decision to return to 320mg Q4W dosing should be b ased upon treatment 
response, tolerability, and Investigator discretion, with the aim to use the dosing regimen 
that achieves the optimal benefit risk for each subject. This will allow the assessment of 
safety, tolerability, and efficacy following a reduct ion in the bimekizumab dose to 160mg 
Q4W.
The rationale for the selection of the 320mg Q4W dose for this study is based on the 
following: 
The optimal therapeutic dose of bimekizumab will not yet be known at the time subjects 
begin entering PS0011 from PS0010.
Stratification of dosing in PS0011 based on prior dose in PS0010 would result in 
unblinding of PS0010. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 97of 125The 320mg Q4W dose is within the range of doses that have already been explored by iv 
administration. This dose was selected based on modeling usin g the currently available 
data and may be modified, if appropriate, as further data are collected on the optimal 
dose of bimekizumab. 
Based on currently available data and modeling, few subjects are expected to have a 
robust response to bimekizumab 64mg Q 4W in PS0010. The 320mg Q4W dose allows 
subjects who received placebo or bimekizumab 64mg Q4W in PS0010 to receive a 
potentially effective dose in this extension study. Although some subjects may have had 
some response to a lower dose in PS0010 (eg, 64mg o r 160mg), the increased dose in 
PS0011 could provide additional benefit, resulting in an improved response or 
remission. 
The 320mg Q4W dose decreases the risk that subjects who responded to treatment in 
PS0010 experience a loss of efficacy due to a dose r eduction upon entry into PS0011. 
Importantly, subjects who are nonresponders after 12 weeks of treatment in PS0011 
will be withdrawn. This minimizes exposure to a possibly noneffective treatment.
Change #3 6
Section 5.4 Rationale for s tudy design and dose selection
The following rationale has been added
The PS0011 design ( Figure 5-1) allows PASI90 responders in PS0010 to continue their dose 
in PS0011, thus permitting these subjects to remain on the dose that resulted in this 
response after 12 weeks of initial treatment in PS0010. It also provides an opportunity for 
an increased dose among PS0010 nonresponders (ie, <PASI90). PASI90 was selected as the 
response criterion in PS0010 to ensure that a sufficiently high efficacy response was 
achieved. This type of dose escalation for those who do not achieve a desired response after 
12 weeks is common in clinical practice. 
Regardless of PASI90 response at Week 12 of PS0010, subjects who received the 2 highest 
doses of bimekizumab (320mg and 480mg Q4W) in PS0010 will begin PS0011 on the 320mg 
Q4W dose. For those subjects who do achieve PASI90 response, this will allow a 
continuation of the PS0010 dose for subjects initially receiving 320mg Q4W and a dose 
down for subjects originally randomized to the 480mg Q4W dose. Because bimekizumab 
480mg Q4W is the highest dose evaluated in PS0010 and beca use it requires 3 injections, it 
will be of interest to evaluate whether these subjects can maintain response in PS0011 with 
the lower 320mg dose, allowing the blind to be maintained with the use of only 2 injections 
at each study administration visit.
To protect against the possibility of exposing subjects to an ineffective treatment for 
extended periods of time, subjects across all treatment groups who have not achieved 
PASI75 response at Week 12 or later in PS0011 will be withdrawn from study treatment. 
Because this withdrawal decision is based strictly on the PASI response and not on the 
original study treatment, it can be done in such a way that will not unblind subjects or 
Investigators.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 98of 125Change # 37
Section 6.1 Inclusion criteria 
1. An Institutional Re view Board (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated b y the subject or b y the parent(s) or legal 
representative.
Has been changed to:
1. An Institutional Review Board (IRB)/Independent Ethics Commit tee (I EC) approved written 
Informed Consent form is signed and dated b y the subject .or by the parent(s) or legal 
representative .
Change # 38
Section 6.1 Inclusion criteria
2. Subject/legal representative is considered reliable and capable of adhering to the protocol and 
visit schedule according to the judgment of the Investigator.
Has been changed to:
2. Subject /legal representative is considered reliable and capable of adhering to the protocol and 
visit schedule according to the judgment of the Investiga tor.
Change #3 9
Section 6.1 Inclusion criteria
3. Subje ct completes all dosing requirements in PS0010 without meeting any  withdrawal criteria .
Has been changed to:
3. Subje ct completes all dosing requirements in PS0010 without meeting any  withdrawal criteria
and completes the study.
Change # 40
Section 6.1 Inclusion criteria
4. Female subjects must be postmenopausal (at least 1 year; to be confirmed hormonally at 
the PS0011 Baseline Visit, if less than 2 years since last menstrual period), permanently
sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy) or, if of 
childbearing potential, must be willing to use a highly effective method of contraception 
up until 20 weeks after last administration of study medication (anticipated 5 half lives), 
and have a negative pregnancy test at Visit 1 (Baseline) and immediately prior to first 
dose. The following methods are considered highly effective when used consistently and 
correctly:
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 99of 125combined (estrogen and progestogen) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal, or transdermal) 
progestogen only hormonal contraception associated with inhibition of ovulation 
(oral, injectable, or implantable)
intrauterine device 
intrauterine hormone releasing system 
bilateral tubal occlusion
vasectomized partner (where postvasectomy testing had demonstrated sperm 
clearance).
sexual abstinence if it is in accordance with a subject’s preferred and common 
lifestyle. Subjects who use abstinence as a form of birth control must agree to 
abstain from heterosexual intercourse until 20 weeks after the last dose of study 
medication. Study personnel must confirm the continued use of abstinence is still in 
accordance with the subject’s lifestyle at regular intervals during the study.
Male subjects with a partner of childbearing potential must be willing to use a condom 
when sexually active, up till 20 weeks after the last administration of study medication 
(anticipated 5 half lives).
Has been changed to:
4. Female subjects of child bearing potential and male subjects with a partner of 
childbearing potential must continue to use an acceptable method of contraception (as 
detailed in PS0010) for up to 20 weeks after the last dose of study treatment in PS0011.
Change # 41
Section 6.2 Exc lusion criteria
E
xclusion criterion #4 has been deleted
4. Subject has any current sign or symptom that may indicate a medically significant 
infection.
Change # 42
Section 6.2 Exclusion criteria
Exclusion criterion #5 has been deleted
5. Subject has 
current clinically active infection with Histoplasma, Coccidiodes, 
Paracoccidioides, Pneumocystis, tuberculosis (TB), nontuberculous mycobacteria 
(NTMB), Blastomyces, Aspergillus, or Candidiasis (systemic). Any subject diagnosed 
with Histoplasmosis, Coccid iodes, Paracoccidiodes, Pneumocystis, TB, NTMB, 
Blastomyces, Aspergillus, or Candidiasis (systemic) during PS0010 is excluded from 
PS0011 even if treatment has been completed.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 100of 125Change # 43
Section 6.2 Exclusion criteria
The following e xclusion criterion has been added 
4. Subject must have a negative interferon gamma release assay (IGRA) as measured at 
Week 8 of PS0010.
Change # 44
Section 6.2 Exclusion criteria (now exclusion criterion #5; previously exclusion criterion #6)
6. Any  subj ect who meets any  withdrawal criteria in the feeder study  (PS0010) is excluded from 
participating in the open -label 
extension study  (PS0011).
Has been changed to:
5. Any  subject who meets any  withdrawal criteria in the feeder study  (PS0010) is excluded from 
participating in the open label extension study  (PS0011).
Change # 45
Section 6.3 Withdrawal criteria
Subjects should be withdrawn from the study  and will be asked to complete the Earl y 
Withdrawal Visit and SFU Visit (17 weeks after the last received dose) if any  of the following 
events occur:
Has been changed to:
Subjects should be withdrawn from the study  and will be asked to complete the Earl y 
Withdrawal Visit and SFU Visit ( 17 20 weeks after the last received dose) if any  of the following 
events occur:
Change # 46
Section 6.3 Withdrawal criteria
4. Subject develops an illness that would interfere with his/her continued participation.
Has been changed to:
4. Subject develops an illness that in the opinion of the Investigator would interfere with 
his/her continued participation if the risk of continuing participation outweighs the 
potential benefit.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 101of 125Change # 47
Section 6.3 Withdrawal criteria
5. Subject devel ops ery throdermic, guttate, or generalized pustular form of psoriasis.
Has been changed to:
5. Subject develops ery throdermic, guttate, or generalized pustular form of psoriasis.
Change # 48
Section 6.3 Withdrawal criteria
The following text has been added to withdrawal criterion #6
Additional information on TB policies are provided in 
Section 9.8.1. 
Change # 49
Section 6.3 Withdrawal criteria
8. Subject uses prohibited concomitant medications that may  present a risk to the safet y of the 
subject in the opinion of the I nvestigator and/or the Medical Monitor
Has been changed to:
8. Subject uses prohibited concomitant medications , with the exception of topicals , as defined 
in this protocol ( Section 7.8.2), that may  present a risk to the safet y of the subject in the 
opinion of the I nvestigator and/or the Medical Monitor .
Change # 50
Section 6.3 Withdrawal criteria
9. Subject develops laboratory abnormalities (with or without clinical symptoms) of 
neutropenia <1.0x109/L, lymphopenia < 0.5x109/L, or other clinically relevant laboratory 
abnormalities consistent with rheumatology Common Terminology Criteria (CTC) 
Grade 3 or higher. (Refer to Section 6.3.1 for withdrawal criteria in relation to potential 
drug induced liver injury [PDILI]).
Has been changed to:
9. Subject has a clinical laboratory value meeting the following criteria:
CTCAE Grade 3 and above: subjects must be withdrawn regardless of relationship 
to study drug or duration of event. 
CTCAE Grade 2
◦Subjects may remain in the stu dy if the event is transient. If a subject has a 
Grade 2 laboratory abnormality, a retest is required within 1 to 2 weeks at a 
scheduled or unscheduled visit. If the repeat value is below Grade 2, the subject 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 102of 125may receive the next scheduled study treatment. If the value on the repeat is still 
Grade 2 or above, a second repeat test must be performed and results made 
available prior to the next scheduled study treatment. If this second repeat value 
is still Grade 2 or above, the subject must be withdrawn. 
Change # 51
Section 6.3 Withdrawal criteria
11. Subjects with a HADS -D score ≥15 must be withdrawn. Any  subject who has a HADS -D 
score of ≥10 should be referred immediatel y to a Mental Healthcare Professional for further 
evaluation and potential withdrawal b ythe Investigator.
Has been changed to:
11. Subjects with a HADS -D score ≥15 must be withdrawn. Any  subject who develops has a 
HADS -D score of ≥10 >10 during the study should be referred immediately to a Mental 
Healthcare Professional for further evaluation and potential withdrawal b y the Investigator.
Change # 52
Section 6.3 Withdrawal criteria
12. Subject does not achieve a PASI 50 at Week 12 or later following open -label treatment in 
PS0011.
Has been changed to:
12. Subject does not achieve aPASI50 PASI75 at Week 12 or later following open label study
treatment in PS0011.
Change # 53
Section 6.3 Withdrawal criteria
The following withdrawal criterion for AEs has been added
13. Subject experiences an AE as described below: 
Any CTCAE Grade 3 and above adverse event ( AE)that is assessed as related to study  
drug in the opinion of the I nvestigator 
◦If the event is deemed to be not related to stud y drug b y the Investigator, the subject 
may remain in the study  after approval by  the Medical Monitor. 
Any CTCAE Grade 2 event that is evaluated as related to study  drug in the opinion of the 
Investigator, is persistent, and falls into any  of the following S ystem Organ Classes 
(SOCs): “Blood and l ymphatic disorders,” “Cardiac disorders, ” or “Vascular disorders.” 
◦Persistent is defined as lasting 28 day
s or more, which spans at least 2 scheduled 
injections.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 103of 125Change # 54
Section 7.1 Description of investigational medicinal product
The IMP used in this study  is bimekizumab. 
Has been changed to:
The IMP used in this study  isarebimekizumab and placebo .
Change # 55
Section 7.1 Description of investigational medicinal product
The following description of placebo has been added
Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia (USP/Ph.Eur) quality appropriate for injection .
Change # 56
Section 7.2 Treatments to be administered
During the Treatment Period, all subjects will receive bimekizumab 320mg Q4W sc 
administered for up to 48 weeks in an open -label manner. At the discretion of the Investigator, 
and if the subject achieves PASI 90 response (90% reduction in the PASI  score from the Baseline 
of PS0010) for at least for at least 2 consecutive visits (not including the PS0011 Baseline Visit), 
the bimekizumab dose may  be reduced to 160mg Q4W sc. If the subject’s disease is not 
adequatel y controlled on the 160mg Q4W dose, they  may  return to 320mg Q4W. The decision to 
return to 320mg Q4W dosing should be based upon treatment r esponse, tolerability , and 
Investigator discretion, with the aim to use the dosing regimen that achieves the optimal benefit -
risk for each subject.
Has been changed to:
During the Treatment Period, all subjects will receive bimekizumab or placebo 320mg Q4W sc
administered scfor up to 48 weeks in an open label manner. (refer to Figure 5 -1for further 
details). At the discretion of the Investigator, and if the subject achieves a PASI90 response 
(90% reduction in the PASI score from the Baseline of PS0010) for at least for at least 
2consecutive visits (not including the PS0011 Baseline Visit), the bimekizumab dose may 
be reduced to 160mg Q4W sc. If the subject’s disease is not adequately controlled on the 
160mg Q4W dose, they may return to 320mg Q4W. The decision to return to 320mg Q4W 
dosing should be based upon treatment response, tolerability, and Investigator discretion, 
with the aim to use the dosing regimen that achieves the optimal benefit risk for each 
subject.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 104of 125Change # 57
Section 7.2 Treatments to b e administered
The following text has been added
Subjects who received placebo or bimekizumab 64mg, 160mg ,or 320mg loading dose + 
160mg Q4W in PS0010 must achieve PASI90 response at Week 12 in PS0010 to enter the 
PS0011 extension study on the same treatment dose. Subjects who do not achieve PASI90 
response at Week 12 in PS0010 while on these treatments will be assigned to receive 
bimekizumab 160mg or 320mg Q4W at Baseline in PS0011 as follows:
Subjects receiving placebo and bimekizumab 64mg Q4W in P S0010 will be assigned to 
bimekizumab 160mg Q4W in PS0011.
Subjects receiving bimekizumab 160mg Q4W and 320mg loading dose + 160mg Q4W in 
PS0010 will be assigned to bimekizumab 320mg Q4W in PS0011.
Subjects who receive bimekizumab 320mg or 480mg Q4W in PS0010 will be assigned to 
receive bimekizumab 320mg Q4W on entering PS0011, regardless of their PASI90 response 
at Week 12 in PS0010.
Change # 58
Section 7.2 Treatments to be administered
The study  medication is to be administered in the clinic by  study  site staff as 2 sc injections for 
the 320mg dose or 1 sc injection for the 160mg dose. Suitable areas for sc injections are the 
lateral abdominal wall and upper outer thigh. Injection sites should be rotated and injections 
should not be given into areas where the skin is tender, bruised, red, or hard.
Has been changed to:
The study  medication is to be administered in the clinic by  study  site staff as 2 sc injections for 
the 320mg dose or 1 sc injection for the 160mg dose for all study treatments in PS0011.
Suitable areas for sc injections are the lateral abdominal wall and upper outer thigh. Injection 
sites should be rotated , and injections should not be given into areas where the skin is tender, 
bruised, red, or hard.
Change # 59
Section 7.3 Packaging
Bimekizumab will be packaged and labeled according to Good Manufacturing Practice (GMP) 
guidelines and applicable laws or regulations. I t will be suitably  packaged in such a way  as to 
protect the product from deterioration during transport and storage. Fur ther information 
regarding storage and transport conditions are provided in the I MP Handling Manual.
Has been changed to:
Bimekizumab and placebo will be packaged and labeled according to Good Manufacturing 
Practice (GMP) guidelines and applicable laws or regulations. I t will be suitably  packaged in 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 105of 125such a way  as to protect the product from deterioration during transport and storage. Further 
informa tion regarding storage and transport conditions are provided in the IMP Handling 
Manual.
Change # 60
Section 7.4 Labeling
Clinical drug supplies will be labeled in accordance with the current International Council on 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and GMP and will include an y 
locally  required statements. I f necessary , labels will be translated into the local language.
Has been changed to:
Clinical drug supplies will be labeled in accordance with the current International Coun cil on for
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and GMP and will include an y 
locally  required statements. I f necessary , labels will be translated into the local language.
Change # 61
Section 7.5 Handling and storage requirements
The IMP must be stored under refrigerated conditions (2ºC to 8ºC) and protected from light. The 
study  drug must not be frozen.
Has been changed to:
The IMP Bimekizumab and placebo must be stored under refrigerated conditions (2ºC to 8ºC) 
and protected from light. The study  drug must not be frozen.
Change # 62
Section 7.6 Drug Accountability
The following text has been ad ded
In order to maintain the blind, all IMP documentation (eg, shipping receipts, drug 
accountability logs, interactive web or voice respon se system [IXRS] treatment 
assignments) must be maintained and accessed only by trained unblinded site personnel. 
Designated unblinded site personnel must be appropriately trained and licensed (per 
country guidelines) to administer injections. 
Blinded stu dy staff may be delegated the responsibility to receive, inventory, and destroy 
the used kits. The packaging identifies each kit by a unique number that does not correlate 
to the contents and does not unblind study site staff. Unblinded study staff will be
responsible for the preparation (eg, breaking tamper proof sticker on kit) of the IMP, 
including recording the administration information on the source document.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 106of 125Change # 63
Section 7.8.1 Permitted concomitant treatments (medications and therapies)
Topical medications
Subjects will be allowed to use topical medications (corticosteroids, retinoids, Vitamin D analogs 
coal tar, etc) as needed during this open -label extension.
Has been changed to:
Topical medications
Subjects will be allowed to use topic al medications (corticosteroids, retinoids, Vitamin D analogs 
coal tar, etc) as needed during this open label extension study .
Change # 64
Section 7.9 Prohibited concomitant treatments (medications and therapies)
The following text has been deleted
Subjects who use prohibited medications will be withdrawn from study treatment but 
followed until the SFU Visit.
Change # 65
Table 7 -1 Prohibited psoriasis medications during PS0011
phototherap y or photochemotherap y
Has been changed to:
phototherap y or chemophototherapy photochemotherapy
Change # 66
Section 7.9 Blinding
The following text has been deleted
This is an open label extension study  and no blinding will be performed. All subjects’ treatment 
assignments during PS0010 will remain blinded until database lock of PS0010.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 107of 125Change # 67
Section 7.9 Blinding
The following text has been added
Due to differences in presentation of the IMP (bimekizumab and placebo), special 
precautions will be taken to ensure study blinding, and study sites will have blinded and 
unblinded personnel.
Bimekizumab and placebo injections will be prepared and administered at the study sites 
by unblinded dedicated study personnel who will only have responsibility for dosing and 
drug accountability.
Study sites will be requir ed to have a written blinding plan in place, signed by the Principal 
Investigator, which will detail the site’s steps for ensuring that the double -blind nature of 
the study is maintained. 
During the study, the Sponsor will provide blinded and unblinded si te monitors for the 
purposes of verifying safety, efficacy, and drug administration and documentation records. 
Blinded study monitors and study site personnel, blinded to treatment assignment, will not 
discuss or have access to any drug -related information .
When the feeder (PS0010) study is unblinded, selected PS0010 study team members will 
have access to subject -level data. Because treatment assignment in PS0011 is based on 
PASI90 response at Week 12 of PS0010 as opposed to randomization, Sponsor personnel
with such access to the PS0010 data will know the treatment assignments of all PS0010 
subjects including those continuing in PS0011. This operational unblinding to PS0011 
treatment assignment will pertain to selected clinical PS0010 study team members (so me of 
whom may be involved in PS0011) but will not extend to blinded staff at the investigational 
sites of PS0011. 
While the blinding of Sponsor clinical study team members is important for ensuring the 
integrity of data collection and analysis in a contr olled study, this unblinding is considered 
acceptable because the primary evaluation of efficacy, upon which sample size calculations 
were based, will be performed in a blinded manner using Week 12 data of PS0010. 
Additionally, because investigational site staff collecting and recording study data remain 
blinded, those data will not be impacted by the unblinding of selected Sponsor clinical 
study team members. Finally, to ensure that unblinding of study team members did not 
impact the primary safety outcome of PS0011, sensitivity analyses will be outlined in the 
SAP to evaluate what, if any, impact there was on the results based on queries that resulted 
in changes to the AE data following the unblinding of PS0010.
Further details are provided in the study ma nuals and site blinding plan.
Change # 68
Section 7.9.1 Procedures for maintaining and breaking the treatment blind (new section)
This new section has been added and subdivided ( see Change #69 and Change #70)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 108of 125Change # 69
Section 7.9.1.1 Maintenance of study treatment blind (new subsection)
The following text has been added
All subject treatment details (bimekizumab or placebo) will be allocated and maintained by 
the IXRS.
Change # 70
Section 7.9.1.2 Breaking the treatment blind in an emergency situation (new subsection)
The following text has been added
The integrity of this clinical study must be maintained by observing the treatment blind. In 
the event of an emergency for which the appropriate treatment for a subject cannot be 
made without knowing the treatment assignment, it will be possible to determine to which 
treatment arm and dose the subject has been allocated by contacting the IXRS. All sites 
will be provided with details of how to contact the system for code breaking at the start of 
the study. The Medical Monitor or equivalent should be consulted prior to unblinding, 
whenever possible.
The Clinical Project Manager will be informed immediately via the IXRS when a code is 
broken, but will remain blinded to specific treatment information. Any unbli nding of the 
IMP performed by the Investigator must be recorded in the source documents and on the 
Study Termination eCRF page.
Change # 71
Section 7.10 Randomization and numbering of subjects
This is an open -label extension study and no randomization will be performed. All subjects will 
receive bimekizumab 320mg Q4W sc with an option to reduce the dose to 160mg Q4W at the 
discretion of the Investigator (see Section 7.2for further details).
Subjects will continue with the 5- digit subject numbers assigned b y the interactive web or voice 
response s ystem (IXRS) in the preceding stud y. The randomization number must be incorporated 
into the eCRF.
Has been changed to:
This is an open label extension study and n No randomization will be performed in this study. 
An IXRS will be used for assigning eligible subjects to study treatment based on a 
predetermined assignment schedule. A n independent biostatistician or designee w ho is not 
involved in this study or the feeder study, PS0010 , will produce this assignment sch edule . 
Details of the study treatments in PS0011 are presented in Section 7.2. Allsubjects will 
receive bimekizumab 320mg Q4W sc with an option to reduce the dose to 160mg Q4W at 
the discretion of the Investigator (see Section 7.2 for further details).
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 109of 125Subjects will continue with the 5- digit subject numbers assigned b y the interactive web or voice 
response system ( IXRS )in the preceding stud y. The randomization number must be 
incorporated into the eCRF.
Change # 72
Section 8 Study procedures by visit
For the SFU Visit ( 17weeks after the last dose), the visit should occur no more than 3 days 
prior to the scheduled visit date and within 7 days after the scheduled visit date 
(-3days/+7 days).
Has been changed to:
For the SFU Visit ( 2017 weeks after the last dose of bi mekizumab or placebo), the visit 
should occur no more than 3 days prior to the scheduled visit date and within 7 days after the 
scheduled visit date ( -3days/+7 days).
Change # 73
Section 8.2 Week 4 (±3 days)
The following assessment has been added
HADS
Change #74
Section 8.2 Week 4 (±3 days)
A blood sample for safety laboratory test inghas been added
Obtain blood samples for:
Standard safety laboratory tests (hematology and biochemistry)
Change # 75
Section 8.3 
Week 8 (±3 days); Week 16 (±3 days); Week 32 (±3 days); and Week 40 
(±3days)
The following assessment has been added
HADS
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 110of 125Change #7 6
Section 8.3 Week 8 (±3 days); Week 16 (±3 days); Week 32 (±3 days); and Week 40 
(±3days)
Obtain blood samples for:
Bimekizumab plasma concentratio n
Anti
-bimekizumab antibodies
Has been changed to:
Obtain blood samples for:
Bimekizumab plasma concentration (not collected at Week 32)
Anti- bimekizumab antibodies (not collected at Week 32)
Change # 77
Section 8.3 Week 8 (±3 days); Week 16 (±3 days); Week 32 (±3 days); and Week 40 
(±3days)
A urine sample for safety laboratory test inghas been deleted
Obtain a urine sample for:
Standard safety laboratory tests (urinalysis)
Change # 78
Section 8.4 Week 12 (±3 days)
A blood sample f or safety laboratory testing has been added
Obtain blood samples for: 
Standard safety laboratory tests (hematology and biochemistry)
Change # 79
Section 8.
4Week 12 (±3 days)
A urine sample for safety laboratory test inghas been added
Obtain urine sample for: 
Standard safety laboratory tests (urinalysis)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 111of 125Change # 80
Section 8.5 Week 20 (±3 days); Week 28 (±3 days); and Week 44 (±3 days)
The following assessment has been added
HADS
Change # 81
Section 8.5 Week 20 (±3 days); Week 28 (±3 days); and Week 44 (±3 days)
Blood samples for safety laboratory test ing and for measuring PK and antibodies to 
bimekizumab have been added 
Obtain blood samples for:
Standard safety laboratory tests (hematology and biochemistry)
Bimekizumab plasma concentration (collected only at Week 28)
Anti -bimekizumab antibodies (collected only at Week 28)
Change # 82
Section 8.6 Week 24 (±3 days)
A blood sample for measuring PK and antibodies to bimekizumab has been deleted 
Obtain blood sample sfor:
Bimekizumab plasma concentration
Anti bimekizumab antibodies
Change # 83
Section 8.7 Week 36(±3 days)
A blood sample for safety laboratory test ing has been added
Obtain blood sample for:
Standard safety laboratory tests (hematology and biochemistry)
Change # 84
Section 8.7 Week 36(±3 days)
A urine sample for safety laboratory test ing has been added
Obtain a urine sample for:
Standard safety laboratory tests (urinalysis)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 112of 125Change # 85
Section 8.9 SFU Visit (17 weeks after the last dose; -3/+7 days)
Has been changed to:
Section 8.9 SFU Visit ( 1720 weeks after the last dose of bimekizumab or 
placebo; -3/+7 days)
Change # 86
Section 8.9 SFU Visit (17 weeks after the last dose; -3/+7 days)
The following assessment has been added
HADS
Change # 87
Section 9.1.3 Description of AEs
Details for completion of the AE eCRF (including judgment of relationship to I MP) are 
described in the eCRF Completion Guidelines.
Has been changed to:
When recording the severity of an AE in the CRF (ie, mild, moderate, or severe), the 
Investigator must refer to the CTCAE Version 4 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm ).Details for 
completion of the AE eCRF (including judgment of severity and relationship to I MP) are 
described in the eCRF Completion Guidelines.
Change # 88
Section 9.1.4 Follow up of AEs
If an AE is ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the I nvestigator no longer deems that it is 
clinically  significant, or until the subject is lost to follow up. If no follow up is provided, the 
Investigator must provide a justification. The follow up will usually  be continued for 17 weeks 
after the subject has discontinued his/her I MP.
Has been changed to:
If an AE is ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the I nvestigator no longer deems that it is 
clinically  significant, or until the subject is lost to follow up. If no follow up is provided, the 
Investigator must provide a justification. The follow up will usually  be continued for 1720 weeks 
after the subject has discontinued his/her I MP.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 113of 125Change # 89
Section 9.1.6 Pregnancy
A SFU Visit should be scheduled 17 weeks after the subject has discontinued her IMP.
Has been changed to:
A SFU Visit should be scheduled 1720 weeks after the subject has discontinued her IMP.
Change # 90
Section 9.6 Adverse events for special monitoring
Adverse events for special monitoring for this study  include: serious infections (including 
opportunistic infections and TB; see Section 9.8.1 ), cytopenias, hy persensitivities, suicide 
ideation or behavior (assessed using the eC -SSRS; see Section 9.8.6), depression and anxiety  
(assessed using the HADS; see 
Section 12.9), major cardiac events, and liver function test 
changes/enz yme elevations (ALT, AST, bilirubin; see Section 9.7.1), malignancies, and 
inflammatory
 bowel diseases.
Has been changed to:
Adverse events for special monitoring for this study  include: serious infections (including 
opportunistic infections and TB; see Section 9.8.1), cy topenias, hy persensitivities, suicide 
ideation or behavior (assessed using the eC -
SSRS; see Section 9.8.6), depr ession and anxiety  
(assessed using the HADS; see 
Section 12.9), major cardiac cardiovascular events, and liver 
function test changes/enzy me elevations (ALT, AST, bilirubin; see Section 9.7.1) , malignancies, 
and inflammatory  bowel diseases.
Change # 91
Table 9 -4 PDILI laboratory measurements
aFor detecting substances (ie, alcohol, amphetamines, benzodiazepines, opioids, marijuana, 
cocaine, phency clidine, and tricy clic antidepressants), additional tests may  be performed based 
on the Investigator’s medical judgment and patient’s history .
Has been changed to:
aFor detecting substances (ie, alcohol amphetamines, benzodiazepines, opioids, marijuana, 
cocaine, phency clidine, and tricy clic antidepressants), additional tests may  be performed based 
on the Investigator’s medical judgment and patient’s history .
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 114of 125Change # 92
Section 9.8.1 Assessment and management of TB and TB risk factors
LTB
Once withdrawn from study  treatment, subjects should return for the Week 48/Withdrawal Visit, 
complete all Earl y Withdrawal Visit assessments, and complete a SFU Visit ( 17weeks after the 
last dose of study  medication).
Has been changed to:
Once withdrawn from study  treatment, subjects should return for the Week 48/Withdrawal Visit, 
complete all Earl y Withdrawal Visi t assessments, and complete a SFU Visit ( 2017 weeks after 
the last dose of study  medication).
Change # 93
Section 9.8.1.4 TB management
LTB infection and active TB identified during study
The subject should be encouraged to complete a SFU Visit (17 weeks a fter the last dose of study  
medication).
Has been changed to:
The subject should be encouraged to complete a SFU Visit ( 2017 weeks after the last dose of 
study  medication).
Change # 94
Section 13.3.3 Subject Screening and Enrollment log/Subject Identification Code list
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
Log.
Has been changed to:
Section 13.3.3 Subject Screening and Enrollment log/Subject Identification Code list
The subject’s screening andenrollment will be recorded in the Subject Screening and
Enrollment L og.
Change # 95
Section 14.1 Definition of analysis sets
The Full Anal ysis Set (FAS) will consist of all enrolled subjects who receive at least 1 dose of 
the study  medication and have a valid efficacy  measurement for PASI  at Baseline of PS0011.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 115of 125Has been changed to:
The Full Anal ysis Set (FAS) will consist of all enrolled subjects who receive at least 1 dose of 
the study  medication in PS0011 andhave a valid efficacy  measurement for PAS I at Baseline of 
PS0011 .
Change # 96
Section 14.1 Definition of analysis sets
The Pharmacokinetics Per -Protocol Set (PK -PPS) will consist of all enrolled subjects who 
receive at least 1 dose of the study  medication and provide at least 1 quantifiable plasma 
concentration postdose in PS0011.
Has been changed to:
The Pharmacokinetics Per -Protocol Set (PK -PPS) will consist of all enrolled subjects who 
receive at least 1 dose of the study  medication in PS0011 and provide at least 1 quantifiable 
plasma conc entration postdose in PS0011.
Change # 97
Section 14.2 General statistical considerations (new section)
The following text has been added
No inferential statistical analyses are planned for this extension study. Instead, all variables 
will be presented usi ng summary statistics. For categorical variables, counts and 
percentages will be displayed. For continuous variables, summary statistics will consist of 
the number of available observations, arithmetic mean, standard deviation, median, 
minimum, and maximum unless stated otherwise. 
Because subjects entering PS0011 may or may not be continuing on the same dose as that 
received in PS0010, there are various combinations of treatment that could be received 
when considering both PS0010 and PS0011 together. For d escribing the summaries to be 
produced, treatment groups will be categorized as either the PS0011 treatment groups or 
PS0010/PS0011 treatment groups. These categorizations are outlined below.
PS0011 treatment groups
This refers to the study treatment assigned to the subject at the beginning of PS0011 and 
does not account for the treatment received in PS0010. The PS0011 treatment groups are 
as follows:
Placebo
Bimekizumab 64mg Q4W
Bimekizumab 160mg Q4W
Bimekizumab 320mg Q4W
All Bimekizumab (optional –to be used only if specified)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 116of 125PS0010/PS0011 treatment groups
This refers to the combination of the randomized treatment in PS0010 and the treatment 
assigned at the beginning of PS0011. Some groups have been combined where it is 
considered appropriate to do so. The PS0010/PS0011 treatment groups with descriptions 
are as follows:
Placebo to Placebo – Subjects randomized to placebo in PS0010 who achieve PASI90 
response at Week 12 of PS0010 and continue to receive placebo in PS0011.
Placebo to Bimekizumab 160mg Q4W –Subjects randomized to placebo in PS0010 who 
do not achieve PASI90 response at Week 12 of PS0010 and are treated with 
bimekizumab 160mg Q4W in PS0011.
Bimekizumab 64mg to Bimekizumab 64mg – Subjects randomized to bimekizumab 
64mg Q4W in PS0010 who achieve PASI90 response at Week 12 of PS0010 and 
continue to receive bimekizumab 64mg Q4W in PS0011.
Bimekizumab 64mg to Bimekizumab 160mg – Subjects randomized to bimekizumab 
64mg Q4W in PS0010 who do not achieve PASI90 response at Week 12 of PS0010 and 
are treated with bimekizumab 160mg Q4W in PS0011.
Bimekizumab 160mg Q4W to Bimekizumab 160mg Q4W –Subjects randomized to 
bimekizumab 160mg Q4W or bimekizumab 320mg loading dose + 160mg Q4W in 
PS0010 who achieve PASI90 response at Week 12 of PS0010 and conti nue to receive 
bimekizumab 160mg Q4W in PS0011. Note that the PS0010 160mg Q4W groups with 
and without the loading dose are combined here.
Bimekizumab 160mg Q4W to Bimekizumab 320mg Q4W –Subjects randomized to 
bimekizumab 160mg Q4W or bimekizumab 320mg loading dose + 160mg Q4W in 
PS0010 who do not achieve PASI90 response at Week 12 of PS0010 and are treated 
with bimekizumab 320mg Q4W in PS0011. Note that the PS0010 160mg Q4W groups 
with and without the loading dose are combined here.
Bimekizumab 320mg Q4W to Bimekizumab 320mg Q4W – Subjects randomized to 
bimekizumab 320mg Q4W in PS0010 and continue on 320mg Q4W in PS0011. No 
distinction will be made between subjects that were or were not PASI90 responders at 
Week 12 of PS0010.
Bimekizumab 480mg Q4W to Bimek izumab 320mg Q4W –Subjects randomized to 
bimekizumab 480mg Q4W in PS0010 and continue on 320mg Q4W in PS0011. No 
distinction will be made between subjects that were or were not PASI90 responders at 
Week 12 of PS0010.
The treatment groups to be used in the presentations of safety and efficacy will depend on 
the objective of the summaries and will be specified accordingly.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 117of 125Change # 98
Section 14.2 Planned safety analyses (now Section 14.3)
Adverse events will be coded according to the Medical Dictionary  for Regulatory  Activities 
(MedDRA®). Treatment -emergent AEs will be defined as events that have a start date on or 
following the first administration of study  treatment in PS0011 through the final administration 
of study  treatment +119 days (covering the 17 -week SFU Period). Treatment- emergent AEs will 
be categorized to treatment group based on the dose being received at the time of onset of the 
event. Tables will include columns for bimekizumab 320mg Q4W, bimekizumab 160mg Q4W, 
and All bimekizumab (ie, either dose of bimekizumab). 
Change from Baseline va riables will be defined relative to the Bas eline measurement f rom 
PS0010.
Has been changed to: 
Adverse events will be coded according to the Medical Dictionary  for Regulatory  Activities 
(MedDRA®). Treatment -emergent AEs will be defined as events that have a start date on or 
following the first administration of study  treatment in PS0011 through the final administration 
of study  treatment + 119 140days (covering the 1720-week SFU Period). Treatme nt -emergent 
AEs will be categorized toby PS0011 treatment group based on the dose being received at the 
time of onset of the event . Tables will include columns for placebo, bimekizumab 64mg 
Q4W, bimekizumab 160mg Q4W, bimekizumab 320mg, and All bimekizuma b (ie, any dose 
of bimekizumab) bimekizumab 320mg Q4W, bimekizumab 160mg Q4W, and All 
bimekizumab (ie, either dose of bimekizumab) .
Change from Baseline variables will be defined relative to the Baseline measurement from 
PS0010.
Change # 99
Section 14.2.1 Primary safety analysis (now Section 14.3.1)
All TEAEs will be summarized descriptivel y by treatment group, primary system organ class 
(SOC), high level term (HL T), and preferred term (PT). This summary  will include the exposure 
adjusted incidence rate (E AIR) with associated 95% confidence interval and the exposure 
adjusted event rate (EAER). 
Has been changed to:
All TEAEs will be summarized descriptivel y by PS0011 treatment group, primary  SOC system 
organ class (SOC) , high level term (HLT), and preferred term (PT). This summary  will include 
the exposure adjusted incidence rate (EAI R) with associated 95% confidence interval and the 
exposure adjusted event rate (EAER). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 118of 125Change # 100
Section 14.2.1 Primary safety analysis (now Section 14.3.1)
Patient exposur e at risk in day s will be defined as date of last administration of study  medication 
–date of first administration of study  medication + 119 day s (ie, the duration of the SFU Period). 
If a subject dies, patient exposure at risk is censored at the date of death. The sum of these 
exposure day s at risk across subjects is converted to y ears for the EAIR and EAER calculations 
described above.
Has been changed to:
Patient exposure at risk in days will be defined as date of last administration of study  medication
–date of first administration of study  medication in PS0011 +119 140days (ie, the duration of 
the SFU Period). If a subject dies, patient exposure at risk is censored at the date of death. The 
sum of these exposure day s at risk across subjects is converted to y ears for the EAIR and EAER 
calculations described above.
Change # 101
Section 14.2.2 Other safety analyses (now Section 14.3.2)
Additional tables will summarize TEAEs by  intensity  and relationship to study  medication, 
TEAEs leading to withdrawal from the stud y, treatment -emergent SAEs, and deaths. 
Has been changed to:
Additional tables will summarize TEAEs by  intensity  and relationship to study  medication, 
TEAEs leading to w ithdrawal from the study , treatment- emergent SAEs, and deaths. Other AE 
summaries to be included will be specified in the SAP. All AE tables will be presented by 
PS0011 treatment group (including the All bimekizumab group).
Change # 102
Section 14.2.2 Other safety analyses (now Section 14.3.2)
The following text has been deleted
In order to evaluate if there is any difference in the TEAE profile of subjects who have dose 
adjustments, additional summaries will be generated and are described further here. With 
respect to dose adjustments, subjects will be classified into 1 of the following 3 groups:
Nonadjusters This group consists of subjects who do not experience a dose adjustment 
during the study.
Single adjusters This group consists of subjects who experience just one dose 
adjustment during the study. Per the protocol, if just a single adjustment occurs, then 
that adjustment must be to go from bimekizumab 320mg Q4W to 160mg Q4W.
Multiple adjusters This group c onsists of subjects who experience more than 1 dose 
adjustment during the study. This means that the subjects in this group dose adjust 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 119of 125from bimekizumab 320mg Q4W to 160mg Q4W and then adjust back to 320mg Q4W 
(with further dose adjustments possible).
Summ aries based on these 3 groups will be done for the TEAE overview, incidence of 
TEAEs (by SOC, HLT, and PT), and incidence of treatment emergent SAEs.
Change # 103
Section 14.2.2 Other safety analyses (now Section 14.3.2)
Extent of exposure to study  medicat ion in PS0011 will be summarized using descriptive 
statistics. As with the primary  summaries of TEAEs, extent of exposure will be presented with 
columns for bimekizumab 320mg Q4W, bimekizumab 160mg Q4W, and All bimekizumab
Has been changed to:
Extent of ex posure to study medication in PS0011 will be summarized using descriptive statistics
by PS0011 treatment group . As with the primary summaries of TEAEs, extent of exposure 
will be presented with columns for bimekizumab 320mg Q4W, bimekizumab 160mg Q4W, 
and All bimekizumab.
Change # 104
Section 14.2.2 Other safety analyses (now Section 14.3.2)
Change from Baseline in laboratory  values, ECGs, and vital signs will be presented using 
descriptive statistics by  PS0010 randomized treatment group and overall. As the se variables are 
summarized over time and the initial values can be impacted by  the randomized treatment in 
PS0010, the presentation by  PS0010 randomized treatment group is intended to provide 
perspective on the change in these values starting with the ini tial PS0010 randomization through 
the 48- week Open- Label Treatment Period of PS0011. The table presentations will display  
descriptive statistics for the PS0010 Baseline and the observed and change from PS0010 
Baseline results by  scheduled visit for PS0011.
Has been changed to:
Change from Baseline in laboratory  values, ECGs, and vital signs will be presented using 
descriptive statistics by  PS0010/PS0011 randomized treatment group and overall .As these 
variables are summarized over time and the initial value s can be impacted by  the randomized 
treatment in PS0010, the presentation b y PS0010 /PS0011 randomized treatment group is 
intended to provide perspective on the change in these values starting with the initial PS0010 
randomization through the 48-week Open L abel Treatment Period of PS0011. The table 
presentations will display descriptive statistics for the PS0010 Baseline followed by descriptive 
statistics for the observed, change from PS0010 Baseline , and change from PS0011 results by  
scheduled visit for PS0011
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 120of 125Change # 105
Section 14.3 Planned PK analyses (now Section 14.4)
Bimekizumab plasma concentrations will be summarized for each treatment at each scheduled 
visit.
Has been changed to:
Bimekizumab plasma concentrations will be summarized for each treatment by 
PS0010/PS0011 treatment group at each scheduled visit. Descriptive statistics for the plasma 
concentrations at PS0010 Baseline will be presented followed by descriptive statistics f or 
the observed, change from PS0010 Baseline, and change from PS0011 Baseline results for 
scheduled visits in PS0011. Summarizing in this manner based on the PS0010/PS0011 
treatment group will allow for an evaluation of how changing doses (where applicable) 
impacted plasma concentrations relative to both the original (PS0010) Baseline as well as 
the new (PS0011) Baseline . For the descriptive statistics, geometric mean, geometric 
coefficient of variation, and 95% confidence interval for the geometric mean wi ll be used 
instead of the arithmetic mean and standard deviation.
Change # 10
6
Section 14.4 Planned immunological analyses (now Section 14.5)
Anti- bimekizumab antibody  data will be summarized for each treatment at each scheduled visit.
Has been changed to:
Anti- bimekizumab antibody  data will be summarized by PS0010/PS0011 treatment group for 
each treatment at each scheduled visit. The summary of anti -bimekizumab antibody levels 
will follow a similar approach to that used for the summary of bimekizumab plasm a 
concentrations. Additional analyses related to antibody positivity will be performed and 
will be described in greater detail in the SAP.
Change # 107
Section 14.5 Planned efficacy analyses (now Section 14.6)
Efficacy  variables will be summarized based on the FAS. The summaries described in this 
section will provide data on maintenance of effect of open -label bimekizumab over 48 weeks. 
Additionally , it will allow an assessment of the impact of dose adjustments on efficacy  results.
Has been changed to:
Efficacy  variables will be summarized based on the FAS. The summaries described in this 
section will provide data on maintenance of effect of open label bimekizumab study treatment
over 48 weeks. Additionally, it will allow an assessment of the impact of d ose adjustments 
on efficacy results.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 121of 125Change # 108
Section 14.5 Planned efficacy analyses (now Section 14.6)
Responder efficacy  variables (PASI 75, PASI90, PASI 100, IGA, and DLQI score of 0 or1) will 
be summarized descriptively  using counts and percentages by scheduled visit and PS0010 
randomized treatment group and overall. The PASI  responder variables are derived relative to 
the PS0010 Baseline. Missing data will be handled by  using nonresponder imputation (NRI ), 
meaning that subjects that discontinue earl y or who have missing data at a given time point are 
imputed as though they  did not achieve the given response. Supportive summaries will be based 
on observed case data.
Has been changed to:
Responder efficacy  variables (PASI 75, PASI90, PASI 100, IGA, and DLQI score of 0 or1) will 
be summarized descriptively  using counts and percentages b y scheduled visit and 
PS0010 /PS0011 randomized treatment group and overall .The PASI responder variables wi ll 
bederived relative to both the PS0010 Baseline and the PS0011 Baseline with responder rates 
being presented side -by-side in applicable summary tables .Missing data will be handled b y 
using nonresponder imputation (NRI), meaning that subjects that discontinue earl y or who have 
missing data at a given time point are imputed as though they did not achieve the given response. 
Supportive summaries will be ba sed on observed case data.
Change # 109
Section 14.5 Planned efficacy analyses (now Section 14.6)
Continuous efficacy  variables based on the change from Baseline (PASI, DLQI, BSA, mNAPSI , 
PSSI , PGADA, SF -36, and HADS) will be summarized using descriptive s tatistics by  scheduled 
visit and PS0010 randomized treatment group and overall. The table presentations will display  
descriptive statistics for the PS0010 Baseline and the observed and change from PS0010 
Baseline results by  scheduled visit for PS0011. Figures for selected variables will also be 
generated in order to demonstrate the kinetics of response over time. Missing data will be 
handled b y using multiple imputation (MI) via the Markov -Chain Monte Carlo (MCMC) 
method. Supportive summaries will be based on observed case data .
Has been changed to:
Continuous efficacy  variables based on the change from Baseline (PASI, DLQI, BSA, mNAPSI , 
PSSI , PGADA, SF -36, and HADS) will be summarized using descriptive statistics by  scheduled 
visit and PS0010 /PS0011 randomized treatment group and overall . The table presentations will 
display  descriptive statistics for the PS0010 Baseline , followed by descriptive statistics for the
and the observed ,and change from PS0010 Baseline , and change from PS0011 Baseline
resul ts by  scheduled visit for PS0011. Figures for selected variables will also be generated in 
order to demonstrate the kinetics of response over time. Missing data will be handled b y using 
multiple imputation (MI ) via the Markov- Chain Monte Carlo (MCMC) method. Supportive 
summaries will be based on observed case data.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 122of 125Change # 110
Section 14.5 Planned efficacy analyses (now Section 14.6)
The following text has been deleted
In addition to the summaries described above, the impact of dose adjustment on efficacy 
will be considered. This will be done primarily by summarizing efficacy variables by the 
3adjuster groups as defined in Section 14.3.2. Furthermore, a supportive analysis 
specifically for single adjusters will be performed in which PASI score will be summarized 
by visit, where Baseline is recalibrated for each individual subject and defined as the visit 
where the bimekizumab 160mg Q4W dose is initiated. The visits summarized will be in 
weeks relative to when the 160mg Q4W dose was started as opposed to the scheduled week 
of the PS0011 assessment. These summaries will be based on observed data only.
Change # 111
Section 14.6 Planned interim analysis and data monitoring (now Section 14.7)
A DMC will review the safety data on a recurring basis as outlined in the DMC charter. In 
addition to these ongoing reviews, an anal ysis combining safet y data from PS0010 and PS0011 
will be performed when the PS0010 study  database is locked. This review will account for data 
in PS0010 as well as the accrued safet y data in PS0011 available at the time of the PS0010 
database lock. The details of this combined safet y review of PS0010 and PS0011, including the 
events of interest to be considered, will be outlined in the DMC charter.
Has been changed to:
A DMC will review the s afety data on a recurring basis as outlined in the DMC charter. In 
addition to these ongoing reviews, an anal ysis combining safet y data from PS0010 and PS0011 
will be performed when the PS0010 study  database is locked. This review analysis will account 
fordata in PS0010 as well as the accrued safet y data in PS0011 available at the time of the 
PS0010 database lock. At the time of the interim analysis, the DMC will be unblinded; 
however, the Sponsor study team will remain blind. The details of this combined safet y 
review analysis of PS0010 and PS0011, including the events of interest to be considered, will be 
outlined in the DMC charter.
Change # 112
Section 15.1 Informed consent
Prior to participation in the study , the written In formed Consent Form should be signed and 
personall y dated b y the subject, or his/her legal representative, and b y the person who conducted 
the informed consent discussion (Investigator or designee). The subject or his/her legal 
representative must receive a cop y of the signed and dated Informed Consent Form. As part of 
the consent process, each subject must consent to direct access to his/her medical records for 
study -related monitoring, auditing, IRB/ IEC review, and regulatory  inspection.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 123of 125Has been changed to:
Prior to participation in the study , the written Informed Consent Form should be signed and 
personall y dated b y the subject , or his/her legal representative, and b y the person who 
conducted the informed consent discussion (I nvestigator or designee). The subject or his/her 
legal representative must receive a copy  of the signed and dated Informed Consent Form. As 
part of the consent process, each subject must co nsent to direct access to his/her medical records 
for study -related monitoring, auditing, IRB/IEC review, and regulatory  inspection.
Change # 113
Section 15.2 Subject identification cards
Upon signing the Informed Consent and Assent form (as applicable), t he subject or legal 
representative will be provided with a subject identification card in the language of the subject. 
The Investigator will fill in the subject identify ing information and medical emergency  contact 
information. The Investigator will instru ct the subject to keep the card with him/her at all times.
Has been changed to:
Upon signing the Informed Consent and Assent form (as applicable), the subject or legal 
representative will be provided with a subject identification card in the language of th e subject. 
The Investigator will fill in the subject identify ing information and medical emergency  contact 
information. The Investigator will instruct the subject to keep the card with him/her at all times.
Change # 114
Section 17 References
The following reference was added
Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. National 
Institutes of Health, National Cancer Institute, Division of Cancer Treatment and 
Diagnosis. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
Updated 26 Jul 2016.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 124of 12519 DECLA RATION AND SIGN ATURE OF INVESTIGA TOR
I confirm that I have carefully  read and understood this protocol and agree to conduct this 
clinical study  as outline d in this protocol, according to current Good Clinical Practice and local 
laws and requirements.
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol.
I have received and read all study -related in formation provided to me.
The objectives and content of this protocol as well as the results deriving from it will be treated 
confidentially , and will not be made available to third parties without prior authorization by  
UCB.
All rights of publication of the results reside with UCB, unless other agreements were made in a 
separate contract.
Investigator:
Printed name Date/Signature
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 12Aug 2016
Clinical Study Protocol Bimekizumab PS0011
Confidential Page 125of 12520 SPONSOR DECLARA TION
I confirm that I have carefully  read and understand this protocol and agree to conduct this 
clinical study  as outlined in this protocol and according to current Good Clinical Practice.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 